

Please type a plus sign (+) inside this box →  +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |    |                          |                    |
|--|---|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |   |    |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |   |    |    | Application Number       | 09/993,647         |
|  |   |    |    | Filing Date              | November 27, 2001  |
|  |   |    |    | First Named Inventor     | Bernd Riedl et al. |
|  |   |    |    | Group Art Unit           | 1624               |
|  |   |    |    | Examiner Name            | Deepak R. RAO      |
| Sheet  | 1 | of | 56 | Attorney Docket Number   | BAYER-0018-A       |

| U.S. PATENT DOCUMENTS |                       |                      |   |   |   |   |
|-----------------------|-----------------------|----------------------|---|---|---|---|
| Examiner Initials *   | Cite No. <sup>1</sup> | U.S. Patent Document |   | Name of Patentee or Applicant of Cited Document | Date of Publication of Cited Document<br>MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear |
|                       |                       | Number               | Kind Code <sup>2</sup><br><i>(if known)</i> |   |   |   |
|                       | A1                    | 502,504              |   | Thoms   | 08-01-1893  |   |
|                       | A2                    | 1,792,156            |   | Fitzky  | 02-10-1931  |   |
|                       | A3                    | 2,046,375            |   | Goldstein et al.                                | 07-07-1936  |   |
|                       | A4                    | 2,093,265            |   | Coffey et al.                                   | 09-14-1937  |   |
|                       | A5                    | 2,288,422            |   | Rohm  | 06-30-1942  |   |
|                       | A6                    | 2,649,476            |   | Martin  | 08-18-1953  |   |
|                       | A7                    | 2,683,082            |   | Hill et al.                                     | 07-06-1954  |   |
|                       | A8                    | 2,722,544            |   | Martin  | 11-01-1955  |   |
|                       | A9                    | 2,745,874            |   | Schetty et al.                                  | 05-15-1956  |   |
|                       | A10                   | 2,781,330            |   | Downey  | 02-12-1957  |   |
|                       | A11                   | 2,797,214            |   | Bossard   | 06-25-1957  |   |
|                       | A12                   | 2,867,659            |   | Model et al.                                    | 01-06-1959  |   |
|                       | A13                   | 2,877,268            |   | Applegath et al.                                | 03-10-1959  |   |
|                       | A14                   | 2,960,488            |   | Tamblyn et al.                                  | 11-15-1960  |   |
|                       | A15                   | 2,973,386            |   | Weldon  | 02-28-1961  |   |
|                       | A16                   | 3,151,023            |   | Martin  | 09-29-1964  |   |
|                       | A17                   | 3,200,035            |   | Martin et al.                                   | 08-10-1965  |   |
|                       | A18                   | 3,230,141            |   | Frick et al.                                    | 01-18-1966  |   |
|                       | A19                   | 3,284,433            |   | Becker et al.                                   | 11-08-1966  |   |
|                       | A20                   | 3,424,760            |   | Helsley et al.                                  | 01-28-1969  |   |
|                       | A21                   | 3,424,761            |   | Helsley et al.                                  | 01-28-1969  |   |
|                       | A22                   | 3,424,762            |   | Helsley   | 01-28-1969  |   |
|                       | A23                   | 3,547,940            |   | Brantley  | 12-15-1970  |   |
|                       | A24                   | 3,639,668            |   | Alles et al.                                    | 02-01-1972  |   |
|                       | A25                   | 3,646,059            |   | Brantley  | 02-29-1972  |   |
|                       | A26                   | 3,668,222            |   | Hauser  | 06-06-1972  |   |
|                       | A27                   | 3,689,550            |   | Schellenbaum et al.                             | 09-05-1972  |   |
|                       | A28                   | 3,743,498            |   | Brantley  | 07-03-1973  |   |
|                       | A29                   | 3,754,887            |   | Brantley  | 08-28-1973  |   |
|                       | A30                   | 3,823,161            |   | Lesser  | 07-09-1974  |   |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |                      |                    |                          |              |
|--|---|----------------------|--------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   |                      |                    | <b>Complete if Known</b> |              |
|  |   | Application Number   | 09/993,647         |                          |              |
|  |   | Filing Date          | November 27, 2001  |                          |              |
|  |   | First Named Inventor | Bernd Riedl et al. |                          |              |
|  |   | Group Art Unit       | 1624               |                          |              |
|  |   | Examiner Name        | Deepak R. RAO      |                          |              |
| Sheet  | 2 | of                   | 56                 | Attorney Docket Number   | BAYER-0018-A |

| U.S. PATENT DOCUMENTS |      |                      |  |                   |            |
|-----------------------|------|----------------------|--|-------------------|------------|
|                       |      | U.S. Patent Document |  |                   |            |
|                       | A31  | 3,828,001            |  | Broad et al.      | 08-06-1974 |
|                       | A32  | 3,860,645            |  | Nikawitz          | 01-14-1975 |
|                       | A33  | 3,990,879            |  | Soper             | 11-09-1976 |
|                       | A34  | 4,001,256            |  | Callahan et al.   | 01-04-1977 |
|                       | A35  | 4,009,847            |  | Aldrich et al.    | 03-01-1977 |
|                       | A36  | 4,042,372            |  | Harper            | 08-16-1977 |
|                       | A37  | 4,062,861            |  | Yukinaga et al.   | 12-13-1977 |
|                       | A37a | 4,063,928            |  | Johnston          | 12-20-1977 |
|                       | A38  | 4,071,524            |  | Banitt            | 01-31-1978 |
|                       | A39  | 4,103,022            |  | Sirrenberg et al. | 07-25-1978 |
|                       | A40  | 4,111,680            |  | Yukinaga et al.   | 09-05-1978 |
|                       | A41  | 4,111,683            |  | Singer            | 09-05-1978 |
|                       | A42  | 4,116,671            |  | Yukinaga et al.   | 09-26-1978 |
|                       | A43  | 4,173,637            |  | Nishiyama et al.  | 11-06-1979 |
|                       | A44  | 4,173,638            |  | Nishiyama et al.  | 11-06-1979 |
|                       | A45  | 4,183,854            |  | Crossley          | 01-15-1980 |
|                       | A46  | 4,212,981            |  | Yukinaga et al.   | 07-15-1980 |
|                       | A47  | 4,240,820            |  | Dickore et al.    | 12-23-1980 |
|                       | A48  | 4,279,639            |  | Okamoto et al.    | 07-21-1981 |
|                       | A48a | 4,293,328            |  | Yukinaga et al.   | 10-06-1981 |
|                       | A49  | 4,358,596            |  | Kröger            | 11-09-1982 |
|                       | A50  | 4,405,644            |  | Kabbe et al.      | 09-20-1983 |
|                       | A51  | 4,410,697            |  | Török et al.      | 10-18-1983 |
|                       | A52  | 4,437,878            |  | Acker et al.      | 03-20-1984 |
|                       | A53  | 4,468,380            |  | O'Doherty et al.  | 08-28-1984 |
|                       | A54  | 4,473,579            |  | Devries et al.    | 09-25-1984 |
|                       | A55  | 4,499,097            |  | Tomcufcik et al.  | 02-12-1985 |
|                       | A56  | 4,511,571            |  | Böger et al.      | 04-16-1985 |
|                       | A57  | 4,514,571            |  | Nakai et al.      | 04-30-1985 |
|                       | A58  | 4,526,997            |  | O'Doherty et al.  | 07-02-1985 |
|                       | A59  | 4,540,566            |  | Davis et al.      | 09-10-1985 |
|                       | A60  | 4,546,191            |  | Nishiyama et al.  | 10-08-1985 |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |                          |                        |              |
|---|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |   |    | <b>Complete if Known</b> |                        |              |
|   |   |    | Application Number       | 09/993,647             |              |
|   |   |    | Filing Date              | November 27, 2001      |              |
|   |   |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |   |    | Group Art Unit           | 1624                   |              |
|   |   |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 3 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| U.S. PATENT DOCUMENTS |                      |   |  |                   |            |
|-----------------------|----------------------|---|--|-------------------|------------|
|                       | U.S. Patent Document |   |  |                   |            |
| A61                   | 4,587,240            |   |  | Hider et al.      | 05-06-1986 |
| A62                   | 4,623,662            |   |  | DeVries           | 11-18-1986 |
| A63                   | 4,643,849            |   |  | Hirai et al.      | 02-17-1987 |
| A64                   | 4,740,520            |   |  | Hallenbach et al. | 04-26-1988 |
| A65                   | 4,760,063            |   |  | Hallenbach et al. | 07-26-1988 |
| A66                   | 4,775,763            |   |  | Dalton et al.     | 10-04-1988 |
| A67                   | 4,808,588            |   |  | King              | 02-28-1989 |
| A68                   | 4,820,871            |   |  | Kissener et al.   | 04-11-1989 |
| A69                   | 4,863,924            |   |  | Haga et al.       | 09-05-1989 |
| A69a                  | 4,921,525            |   |  | Grossman et al.   | 05-01-1990 |
| A70                   | 4,973,675            |   |  | Israel et al.     | 11-27-1990 |
| A70a                  | 4,977,169            |   |  | Häusermann et al. | 12-11-1990 |
| A71                   | 4,983,605            |   |  | Kondo et al.      | 01-08-1991 |
| A72                   | 4,985,449            |   |  | Haga et al.       | 01-15-1991 |
| A72a                  | 4,996,325            |   |  | Kristinsson       | 02-26-1991 |
| A73                   | 5,036,072            |   |  | Nakajima et al.   | 07-30-1991 |
| A74                   | 5,059,614            |   |  | Lepage et al.     | 10-22-1991 |
| A75                   | 5,063,247            |   |  | Sekiya et al.     | 11-05-1991 |
| A76                   | 5,098,907            | A |  | Kondo et al.      | 03-24-1992 |
| A77                   | 5,100,883            | A |  | Schiehser         | 03-31-1992 |
| A78                   | 5,118,677            | A |  | Caufield          | 06-02-1992 |
| A79                   | 5,118,678            | A |  | Kao et al.        | 06-02-1992 |
| A80                   | 5,120,842            | A |  | Failli et al.     | 06-09-1992 |
| A81                   | 5,130,331            | A |  | Pascual           | 07-14-1992 |
| A82                   | 5,151,344            | A |  | Abe et al.        | 09-29-1992 |
| A83                   | 5,151,413            | A |  | Caufield et al.   | 09-29-1992 |
| A84                   | 5,162,360            | A |  | Creswell et al.   | 11-10-1992 |
| A84a                  | 5,177,110            | A |  | Oechslein et al.  | 01-05-1993 |
| A85                   | 5,185,358            | A |  | Creswell et al.   | 02-09-1993 |
| A86                   | 5,256,790            | A |  | Nelson            | 10-26-1993 |
| A87                   | 5,258,389            | A |  | Goulet et al.     | 11-02-1993 |
| A88                   | 5,270,458            | A |  | Lemischka         | 12-14-1993 |

|                       |              |                 |            |
|-----------------------|--------------|-----------------|------------|
| Examiner<br>Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|-----------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |                          |                        |              |
|---|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>                 STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   |    | <b>Complete if Known</b> |                        |              |
|   |   |    | Application Number       | 09/993,647             |              |
|   |   |    | Filing Date              | November 27, 2001      |              |
|   |   |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |   |    | Group Art Unit           | 1624                   |              |
|   |   |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 4 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| U.S. PATENT DOCUMENTS |                      |           |   |                    |            |  |
|-----------------------|----------------------|-----------|---|--------------------|------------|--|
|                       | U.S. Patent Document |           |   |                    |            |  |
|                       | A89                  | 5,283,354 | A | Lemischka          | 02-01-1994 |  |
|                       | A90                  | 5,312,820 | A | Ashton et al.      | 05-17-1994 |  |
|                       | A91                  | 5,319,099 | A | Kamata et al.      | 06-07-1994 |  |
|                       | A92                  | 5,378,725 | A | Bonjouklian et al. | 01-03-1995 |  |
|                       | A93                  | 5,399,566 | A | Katano et al.      | 03-21-1995 |  |
|                       | A94                  | 5,423,905 | A | Fringeli           | 06-13-1995 |  |
|                       | A95                  | 5,429,918 | A | Seto et al.        | 07-04-1995 |  |
|                       | A96                  | 5,432,468 | A | Moriyama et al.    | 07-11-1995 |  |
|                       | A97                  | 5,441,947 | A | Dodge et al.       | 08-15-1995 |  |
|                       | A98                  | 5,447,957 | A | Adams et al.       | 09-05-1995 |  |
|                       | A99                  | 5,456,920 | A | Matoba et al.      | 10-10-1995 |  |
|                       | A100                 | 5,468,773 | A | Dodge et al.       | 11-21-1995 |  |
|                       | A101                 | 5,470,882 | A | Dixon et al.       | 11-28-1995 |  |
|                       | A102                 | 5,480,906 | A | Creemer et al.     | 01-02-1996 |  |
|                       | A103                 | 5,500,424 | A | Nagamine et al.    | 03-19-1996 |  |
|                       | A104                 | 5,508,288 | A | Forbes et al.      | 04-16-1996 |  |
|                       | A105                 | 5,547,966 | A | Atwal et al.       | 08-20-1996 |  |
|                       | A106                 | 5,559,137 | A | Adams et al.       | 09-24-1996 |  |
|                       | A107                 | 5,596,001 | A | Hamanaka           | 01-21-1997 |  |
|                       | A108                 | 5,597,719 | A | Freed et al.       | 01-28-1997 |  |
|                       | A109                 | 5,624,937 | A | Reel et al.        | 04-29-1997 |  |
|                       | A110                 | 5,656,612 | A | Monia              | 08-12-1997 |  |
|                       | A111                 | 5,658,903 | A | Adams et al.       | 08-19-1997 |  |
|                       | A111a                | 5,667,226 | A | Janich             | 09-16-1997 |  |
|                       | A112                 | 5,696,138 | A | Olesen et al.      | 12-09-1997 |  |
|                       | A113                 | 5,698,581 | A | Kleemann et al.    | 12-16-1997 |  |
|                       | A114                 | 5,710,094 | A | Minami et al.      | 01-20-1998 |  |
|                       | A115                 | 5,721,237 | A | Myers et al.       | 02-24-1998 |  |
|                       | A116                 | 5,726,167 | A | Dodge et al.       | 03-10-1998 |  |
|                       | A117                 | 5,747,498 | A | Schnur et al.      | 05-05-1998 |  |
|                       | A118                 | 5,773,459 | A | Tang et al.        | 06-30-1998 |  |
|                       | A119                 | 5,777,097 | A | Lee et al.         | 07-07-1998 |  |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |                      |                    |                          |              |
|---|---|----------------------|--------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |   |                      |                    | <i>Complete if Known</i> |              |
|   |   | Application Number   | 09/993,647         |                          |              |
|   |   | Filing Date          | November 27, 2001  |                          |              |
|   |   | First Named Inventor | Bernd Riedl et al. |                          |              |
|   |   | Group Art Unit       | 1624               |                          |              |
|   |   | Examiner Name        | Deepak R. RAO      |                          |              |
| Sheet   | 5 | of                   | 56                 | Attorney Docket Number   | BAYER-0018-A |

| U.S. PATENT DOCUMENTS |                      |           |   |                  |            |  |
|-----------------------|----------------------|-----------|---|------------------|------------|--|
|                       | U.S. Patent Document |           |   |                  |            |  |
|                       | A120                 | 5,780,262 | A | Brent et al.     | 07-14-1998 |  |
|                       | A121                 | 5,780,483 | A | Widdowson et al. | 07-14-1998 |  |
|                       | A122                 | 5,783,664 | A | Lee et al.       | 07-21-1998 |  |
|                       | A123                 | 5,786,362 | A | Krongrad         | 07-28-1998 |  |
|                       | A123a                | 5,801,794 | A | Lehureau et al.  | 09-01-1998 |  |
|                       | A124                 | 5,807,876 | A | Armistead et al. | 09-15-1998 |  |
|                       | A125                 | 5,807,891 | A | Bold et al.      | 09-15-1998 |  |
|                       | A126                 | 5,808,080 | A | Bell et al.      | 09-15-1998 |  |
|                       | A127                 | 5,814,646 | A | Heinz et al.     | 09-29-1998 |  |
|                       | A128                 | 5,869,043 | A | McDonnell et al. | 02-09-1999 |  |
|                       | A129                 | 5,871,934 | A | Lee et al.       | 02-16-1999 |  |
|                       | A130                 | 5,886,044 | A | Widdowson et al. | 03-23-1999 |  |
|                       | A131                 | 5,891,895 | A | Shiraishi et al. | 04-06-1999 |  |
|                       | A132                 | 5,908,865 | A | Doi et al.       | 06-01-1999 |  |
|                       | A133                 | 5,919,773 | A | Monia et al.     | 07-06-1999 |  |
|                       | A134                 | 5,929,250 | A | Widdowson et al. | 07-27-1999 |  |
|                       | A135                 | 5,955,366 | A | Lee et al.       | 09-21-1999 |  |
|                       | A136                 | 5,965,573 | A | Petrie et al.    | 10-12-1999 |  |
|                       | A137                 | 6,004,965 | A | Breu et al.      | 12-21-1999 |  |
|                       | A138                 | 6,005,008 | A | Widdowson et al. | 12-21-1999 |  |
|                       | A139                 | 6,015,908 | A | Widdowson et al. | 01-18-2000 |  |
|                       | A140                 | 6,017,692 | A | Brent et al.     | 01-25-2000 |  |
|                       | A141                 | 6,020,345 | A | Vacher et al.    | 02-01-2000 |  |
|                       | A142                 | 6,022,884 | A | Mantlo et al.    | 02-08-2000 |  |
|                       | A143                 | 6,025,151 | A | Peterson         | 02-15-2000 |  |
|                       | A144                 | 6,033,873 | A | McDonnell et al. | 03-07-2000 |  |
|                       | A145                 | 6,040,339 | A | Yoshida et al.   | 03-21-2000 |  |
|                       | A146                 | 6,043,374 | A | Widdowson et al. | 03-28-2000 |  |
|                       | A147                 | 6,080,763 | A | Regan et al.     | 06-27-2000 |  |
|                       | A148                 | 6,093,742 | A | Salituro et al.  | 07-25-2000 |  |
|                       | A149                 | 6,103,692 | A | Avruch et al.    | 08-15-2000 |  |
|                       | A150                 | 6,114,517 | A | Monia et al.     | 09-05-2000 |  |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |                      |                    |                          |              |
|---|---|----------------------|--------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |   |                      |                    | <b>Complete if Known</b> |              |
|   |   | Application Number   | 09/993,647         |                          |              |
|   |   | Filing Date          | November 27, 2001  |                          |              |
|   |   | First Named Inventor | Bernd Riedl et al. |                          |              |
|   |   | Group Art Unit       | 1624               |                          |              |
|   |   | Examiner Name        | Deepak R. RAO      |                          |              |
| Sheet   | 6 | of                   | 56                 | Attorney Docket Number   | BAYER-0018-A |

| U.S. PATENT DOCUMENTS |       |                      |    |                    |            |  |
|-----------------------|-------|----------------------|----|--------------------|------------|--|
|                       |       | U.S. Patent Document |    |                    |            |  |
|                       | A151  | 6,130,053            | A  | Thompson et al.    | 10-10-2000 |  |
|                       | A152  | 6,133,319            | A  | Widdowson          | 10-17-2000 |  |
|                       | A153  | 6,136,779            | A  | Foulkes et al.     | 10-24-2000 |  |
|                       | A154  | 6,143,764            | A  | Kubo et al.        | 11-07-2000 |  |
|                       | A155  | 6,147,107            | A  | Dent et al.        | 11-14-2000 |  |
|                       | A156  | 6,147,116            | A  | Barbachyn et al.   | 11-14-2000 |  |
|                       | A157  | 6,150,415            | A  | Hammock et al.     | 11-21-2000 |  |
|                       | A157a | 6,159,901            | A  | Kanno et al.       | 12-12-2000 |  |
|                       | A158  | 6,174,901            | B1 | Mantlo et al.      | 01-16-2001 |  |
|                       | A159  | 6,177,401            | B1 | Ullrich et al.     | 01-23-2001 |  |
|                       | A160  | 6,178,399            | B1 | Takebayashi et al. | 01-23-2001 |  |
|                       | A161  | 6,180,631            | B1 | McMahon et al.     | 01-30-2001 |  |
|                       | A162  | 6,180,675            | B1 | Widdowson et al.   | 01-30-2001 |  |
|                       | A163  | 6,187,799            | B1 | Wood et al.        | 02-13-2001 |  |
|                       | A164  | 6,193,965            | B1 | Karin et al.       | 02-27-2001 |  |
|                       | A165  | 6,204,267            | B1 | Tang et al.        | 03-20-2001 |  |
|                       | A166  | 6,210,710            | B1 | Skinner            | 04-03-2001 |  |
|                       | A167  | 6,211,373            | B1 | Widdowson et al.   | 04-03-2001 |  |
|                       | A168  | 6,218,539            | B1 | Widdowson          | 04-17-2001 |  |
|                       | A169  | 6,228,881            | B1 | Regan et al.       | 05-08-2001 |  |
|                       | A170  | 6,235,764            | B1 | Larson et al.      | 05-22-2001 |  |
|                       | A170a | 6,236,125            | B1 | Oudet et al.       | 05-22-2001 |  |
|                       | A171  | 6,242,601            | B1 | Breu et al.        | 06-05-2001 |  |
|                       | A172  | 6,262,113            | B1 | Widdowson et al.   | 07-17-2001 |  |
|                       | A173  | 6,271,261            | B1 | Widdowson          | 08-07-2001 |  |
|                       | A174  | 6,294,350            | B1 | Peterson           | 09-25-2001 |  |
|                       | A175  | 6,297,381            | B1 | Cirillo et al.     | 10-02-2001 |  |
|                       | A176  | 6,310,068            | B1 | Böttcher et al.    | 10-30-2001 |  |
|                       | A177  | 6,316,462            | B1 | Bishop et al.      | 11-13-2001 |  |
|                       | A178  | 6,319,921            | B1 | Cirillo et al.     | 11-20-2001 |  |
|                       | A179  | 6,329,415            | B1 | Cirillo et al.     | 12-11-2001 |  |
|                       | A180  | 6,333,341            | B1 | Mantlo et al.      | 12-25-2001 |  |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |                      |                    |                          |              |
|---|---|----------------------|--------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;"><i>(use as many sheets as necessary)</i></p> |   |                      |                    | <b>Complete if Known</b> |              |
|   |   | Application Number   | 09/993,647         |                          |              |
|   |   | Filing Date          | November 27, 2001  |                          |              |
|   |   | First Named Inventor | Bernd Riedl et al. |                          |              |
|   |   | Group Art Unit       | 1624               |                          |              |
|   |   | Examiner Name        | Deepak R. RAO      |                          |              |
| Sheet   | 7 | of                   | 56                 | Attorney Docket Number   | BAYER-0018-A |

| U.S. PATENT DOCUMENTS |                      |    |                    |            |  |  |
|-----------------------|----------------------|----|--------------------|------------|--|--|
|                       | U.S. Patent Document |    |                    |            |  |  |
| A181                  | 6,339,045            | B1 | Kanno et al.       | 01-15-2002 |  |  |
| A182                  | 6,344,476            | B1 | Ranges et al.      | 02-05-2002 |  |  |
| A183                  | 6,352,977            | B1 | Astles et al.      | 03-05-2002 |  |  |
| A184                  | 6,358,525            | B1 | Guo et al.         | 03-19-2002 |  |  |
| A185                  | 6,358,945            | B1 | Breitfelder et al. | 03-19-2002 |  |  |
| A186                  | 6,361,773            | B1 | Lee et al.         | 03-26-2002 |  |  |
| A187                  | 6,372,773            | B1 | Regan              | 04-16-2002 |  |  |
| A188                  | 6,372,933            | B1 | Baine et al.       | 04-16-2002 |  |  |
| A189                  | 6,380,218            | B1 | Marfat et al.      | 04-30-2002 |  |  |
| A190                  | 6,383,734            | B1 | Marshall et al.    | 05-07-2002 |  |  |
| A191                  | 6,387,900            | B1 | Pevarello et al.   | 05-14-2002 |  |  |
| A192                  | 6,391,917            | B1 | Petrie et al.      | 05-21-2002 |  |  |
| A193                  | 6,403,588            | B1 | Hayakawa et al.    | 06-11-2002 |  |  |
| A194                  | 6,414,011            | B1 | Hogenkamp et al.   | 07-02-2002 |  |  |
| A195                  | 6,444,691            | B1 | Oremus et al.      | 09-03-2002 |  |  |
| A196                  | 6,448,079            | B1 | Monia et al.       | 09-10-2002 |  |  |
| A197                  | 6,479,519            | B1 | Astles et al.      | 11-12-2002 |  |  |
| A198                  | 6,492,393            | B1 | Breitfelder et al. | 12-10-2002 |  |  |
| A199                  | 6,495,331            | B1 | Gelfand et al.     | 12-17-2002 |  |  |
| A200                  | 6,500,863            | B1 | Jin et al.         | 12-31-2002 |  |  |
| A201                  | 6,511,800            | B1 | Singh              | 01-28-2003 |  |  |
| A202                  | 6,511,997            | B1 | Minami et al.      | 01-28-2003 |  |  |
| A203                  | 6,521,407            | B1 | Warenus et al.     | 02-18-2003 |  |  |
| A204                  | 6,521,592            | B2 | Ko et al.          | 02-18-2003 |  |  |
| A205                  | 6,524,832            | B1 | Kufe et al.        | 02-25-2003 |  |  |
| A206                  | 6,525,046            | B1 | Cirillo et al.     | 02-25-2003 |  |  |
| A207                  | 6,525,065            | B1 | Caldwell et al.    | 02-25-2003 |  |  |
| A208                  | 6,525,091            | B2 | Robinson et al.    | 02-25-2003 |  |  |
| A209                  | 6,583,282            | B1 | Zhang et al.       | 06-24-2003 |  |  |
| A210                  | 6,608,052            | B2 | Breitfelder et al. | 08-19-2003 |  |  |
| A211                  | 6,617,324            | B1 | Naraian et al.     | 09-09-2003 |  |  |
| A212                  | 6,635,421            | B1 | Klagsbrun et al.   | 10-21-2003 |  |  |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |   |    |                          |                        |              |
|---|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |   |    | <b>Complete if Known</b> |                        |              |
|   |   |    | Application Number       | 09/993,647             |              |
|   |   |    | Filing Date              | November 27, 2001      |              |
|   |   |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |   |    | Group Art Unit           | 1624                   |              |
|   |   |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 8 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| U.S. PATENT DOCUMENTS |                      |              |    |                   |            |
|-----------------------|----------------------|--------------|----|-------------------|------------|
|                       | U.S. Patent Document |              |    |                   |            |
|                       | A213                 | 6,653,320    | B2 | Hayakawa et al.   | 11-25-2003 |
|                       | A214                 | 6,656,963    | B2 | Firestone et al.  | 12-02-2003 |
|                       | A215                 | 6,673,777    | B1 | Tracey et al.     | 01-06-2004 |
|                       | A216                 | 6,689,560    | B1 | Rapp et al.       | 02-10-2004 |
|                       | A217                 | 6,797,823    | B1 | Kubo et al.       | 09-28-2004 |
|                       | A217a                | 6,958,333    | B1 | Hayama et al.     | 10-25-2005 |
|                       | A218                 | 7,070,968    | B2 | Kufe et al.       | 07-04-2006 |
|                       | A219                 | 7,235,576    | B1 | Riedl et al.      | 06-26-2007 |
|                       | A220                 | 7,253,286    | B2 | Funahashi et al.  | 08-07-2007 |
|                       | A221                 | 7,307,071    | B2 | Lyons et al.      | 12-11-2007 |
|                       | A222                 | 7,329,670    | B1 | Dumas et al.      | 02-12-2008 |
|                       | A223                 | 7,351,834    | B1 | Riedl et al.      | 04-01-2008 |
|                       | A224                 | 7,371,763    | B2 | Dumas et al.      | 05-13-2008 |
|                       | A225                 | 7,517,880    | B2 | Miller et al.     | 04-14-2009 |
|                       | A226                 | 7,528,255    | B2 | Riedl et al.      | 05-05-2009 |
|                       | A226a                | 7,547,695    | B2 | Hoelzemann et al. | 06-16-2009 |
|                       | A227                 | 7,557,129    | B2 | Scott et al.      | 07-07-2009 |
|                       | A227a                | 7,605,261    | B2 | Deprez et al.     | 10-20-2009 |
|                       | A227b                | 7,612,092    | B2 | Funahashi et al.  | 11-03-2009 |
|                       | A228                 | 7,678,811    | B2 | Dumas et al.      | 03-16-2010 |
|                       | B1                   | 2001/0006975 | A1 | Wood et al.       | 07-05-2001 |
|                       | B2                   | 2001/0011135 | A1 | Riedl et al.      | 08-02-2001 |
|                       | B3                   | 2001/0011136 | A1 | Riedl et al.      | 08-02-2001 |
|                       | B4                   | 2001/0016659 | A1 | Riedl et al.      | 08-23-2001 |
|                       | B5                   | 2001/0027202 | A1 | Riedl et al.      | 10-04-2001 |
|                       | B6                   | 2001/0034447 | A1 | Riedl et al.      | 10-25-2001 |
|                       | B7                   | 2001/0038842 | A1 | Achen et al.      | 11-08-2001 |
|                       | B8                   | 2002/0037276 | A1 | Ptasznik et al.   | 03-28-2002 |
|                       | B9                   | 2002/0042517 | A1 | Uday et al.       | 04-11-2002 |
|                       | B10                  | 2002/0062763 | A1 | Macholdt et al.   | 05-30-2002 |
|                       | B11                  | 2002/0065283 | A1 | McMahon et al.    | 05-30-2002 |
|                       | B12                  | 2002/0065296 | A1 | Dumas et al.      | 05-30-2002 |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |   |    |                          |                        |              |
|--|---|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |   |    | <b>Complete if Known</b> |                        |              |
|  |   |    | Application Number       | 09/993,647             |              |
|  |   |    | Filing Date              | November 27, 2001      |              |
|  |   |    | First Named Inventor     | Bernd Riedl et al.     |              |
|  |   |    | Group Art Unit           | 1624                   |              |
|  |   |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet  | 9 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| U.S. PATENT DOCUMENTS |             |                      |    |                  |            |  |
|-----------------------|-------------|----------------------|----|------------------|------------|--|
|                       |             | U.S. Patent Document |    |                  |            |  |
|                       | <b>B13</b>  | 2002/0082255         | A1 | Eastwood         | 06-27-2002 |  |
|                       | <b>B14</b>  | 2002/0085857         | A1 | Kim et al.       | 07-04-2002 |  |
|                       | <b>B15</b>  | 2002/0085859         | A1 | Hashimoto et al. | 07-04-2002 |  |
|                       | <b>B16</b>  | 2002/0103253         | A1 | Ranges et al.    | 08-01-2002 |  |
|                       | <b>B16a</b> | 2002/0111495         | A1 | Magee et al.     | 08-15-2002 |  |
|                       | <b>B17</b>  | 2002/0128321         | A1 | Widdowson et al. | 09-12-2002 |  |
|                       | <b>B18</b>  | 2002/0137774         | A1 | Riedl et al.     | 09-26-2002 |  |
|                       | <b>B19</b>  | 2002/0161014         | A1 | Sadhu et al.     | 10-31-2002 |  |
|                       | <b>B20</b>  | 2002/0165275         | A1 | Wu et al.        | 11-07-2002 |  |
|                       | <b>B21</b>  | 2002/0165349         | A1 | Kirsch et al.    | 11-07-2002 |  |
|                       | <b>B22</b>  | 2002/0165394         | A1 | Dumas et al.     | 11-07-2002 |  |
|                       | <b>B23</b>  | 2002/0173507         | A1 | Santora et al.   | 11-21-2002 |  |
|                       | <b>B24</b>  | 2002/0188027         | A1 | Robinson et al.  | 12-12-2002 |  |
|                       | <b>B25</b>  | 2002/0197256         | A1 | Grewal           | 12-26-2002 |  |
|                       | <b>B26</b>  | 2003/0069284         | A1 | Keegan et al.    | 04-10-2003 |  |
|                       | <b>B26a</b> | 2003/0105091         | A1 | Riedl et al.     | 06-05-2003 |  |
|                       | <b>B27</b>  | 2003/0125359         | A1 | Lyons et al.     | 07-03-2003 |  |
|                       | <b>B28</b>  | 2003/0130309         | A1 | Moss et al.      | 07-10-2003 |  |
|                       | <b>B29</b>  | 2003/0144278         | A1 | Reidl et al.     | 07-31-2003 |  |
|                       | <b>B30</b>  | 2003/0157104         | A1 | Waksal           | 08-21-2003 |  |
|                       | <b>B30a</b> | 2003/0139605         | A1 | Riedl et al.     | 07-24-2003 |  |
|                       | <b>B31</b>  | 2003/0181442         | A1 | Riedl et al.     | 09-25-2003 |  |
|                       | <b>B32</b>  | 2003/0207870         | A1 | Dumas et al.     | 11-06-2003 |  |
|                       | <b>B33</b>  | 2003/0207872         | A1 | Reidl et al.     | 11-06-2003 |  |
|                       | <b>B34</b>  | 2003/0207914         | A1 | Dumas et al.     | 11-06-2003 |  |
|                       | <b>B34a</b> | 2003/0216396         | A1 | Dumas et al.     | 11-20-2003 |  |
|                       | <b>B35</b>  | 2003/0216446         | A1 | Dumas et al.     | 11-20-2003 |  |
|                       | <b>B36</b>  | 2003/0232400         | A1 | Radka et al.     | 12-18-2003 |  |
|                       | <b>B37</b>  | 2003/0232765         | A1 | Carter et al.    | 12-18-2003 |  |
|                       | <b>B37a</b> | 2004/0023961         | A1 | Dumas et al.     | 02-05-2004 |  |
|                       | <b>B38</b>  | 2004/0052880         | A1 | Kobayashi et al. | 03-18-2004 |  |
|                       | <b>B39</b>  | 2004/0096855         | A1 | Stratton et al.  | 05-20-2004 |  |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |    |                          |                    |
|--|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | Application Number       | 09/993,647         |
|  |    |    | Filing Date              | November 27, 2001  |
|  |    |    | First Named Inventor     | Bernd Riedl et al. |
|  |    |    | Group Art Unit           | 1624               |
|  |    |    | Examiner Name            | Deepak R. RAO      |
|  |    |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 10 | of | 56                       |                    |

| U.S. PATENT DOCUMENTS |                      |              |    |                   |            |
|-----------------------|----------------------|--------------|----|-------------------|------------|
|                       | U.S. Patent Document |              |    |                   |            |
|                       | <b>B40</b>           | 2004/0147541 | A1 | Lane et al.       | 07-29-2004 |
|                       | <b>B41</b>           | 2004/0192770 | A1 | Kozikowski et al. | 09-30-2004 |
|                       | <b>B42</b>           | 2004/0197256 | A1 | Rogers et al.     | 10-07-2004 |
|                       | <b>B43</b>           | 2004/0209905 | A1 | Kubo et al.       | 10-21-2004 |
|                       | <b>B43a</b>          | 2004/0224937 | A1 | Furness et al.    | 11-11-2004 |
|                       | <b>B44</b>           | 2004/0229937 | A1 | Dumas et al.      | 11-18-2004 |
|                       | <b>B45</b>           | 2004/0235829 | A1 | Scott et al.      | 11-25-2004 |
|                       | <b>B46</b>           | 2005/0032798 | A1 | Boyer et al.      | 02-10-2005 |
|                       | <b>B47</b>           | 2005/0038031 | A1 | Dumas et al.      | 02-17-2005 |
|                       | <b>B48</b>           | 2005/0038080 | A1 | Boyer et al.      | 02-17-2005 |
|                       | <b>B49</b>           | 2005/0059703 | A1 | Wilhelm et al.    | 03-17-2005 |
|                       | <b>B49a</b>          | 2005/0069963 | A1 | Lokshin et al.    | 03-31-2005 |
|                       | <b>B49b</b>          | 2005/0096344 | A1 | Fraleley et al.   | 05-05-2005 |
|                       | <b>B49c</b>          | 2005/0175737 | A1 | Knobel            | 08-11-2005 |
|                       | <b>B50</b>           | 2005/0256174 | A1 | Wood et al.       | 11-17-2005 |
|                       | <b>B51</b>           | 2005/0288286 | A1 | Flynn et al.      | 12-29-2005 |
|                       | <b>B52</b>           | 2006/0058358 | A1 | Dumas et al.      | 03-16-2006 |
|                       | <b>B52a</b>          | 2006/0241301 | A1 | Hoelzemann et al. | 10-26-2006 |
|                       | <b>B52b</b>          | 2006/0281762 | A1 | Staehele et al.   | 12-14-2006 |
|                       | <b>B53</b>           | 2006/0078617 | A1 | Schueckler        | 04-13-2006 |
|                       | <b>B54</b>           | 2006/0211738 | A1 | Mitchell et al.   | 09-21-2006 |
|                       | <b>B55</b>           | 2006/0234931 | A1 | Biggs, III et al. | 10-19-2006 |
|                       | <b>B56</b>           | 2006/0247186 | A1 | Carter et al.     | 11-02-2006 |
|                       | <b>B57</b>           | 2007/0020704 | A1 | Wilhelm et al.    | 01-25-2007 |
|                       | <b>B57a</b>          | 2007/0037224 | A1 | Hamer et al.      | 02-15-2007 |
|                       | <b>B57b</b>          | 2007/0066660 | A1 | Stahle et al.     | 03-22-2007 |
|                       | <b>B58</b>           | 2007/0105142 | A1 | Wilhelm           | 05-10-2007 |
|                       | <b>B58a</b>          | 2007/0149594 | A1 | Finsinger et al.  | 06-28-2007 |
|                       | <b>B59</b>           | 2007/0173514 | A1 | Moss et al.       | 07-26-2007 |
|                       | <b>B60</b>           | 2007/0178494 | A1 | Elting et al.     | 08-02-2007 |
|                       | <b>B61</b>           | 2007/0244120 | A1 | Dumas et al.      | 10-18-2007 |
|                       | <b>B61a</b>          | 2007/0254295 | A1 | Harvey et al.     | 03-16-2007 |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |                      |                    |                          |              |
|--|----|----------------------|--------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |    |                      |                    | <b>Complete if Known</b> |              |
|  |    | Application Number   | 09/993,647         |                          |              |
|  |    | Filing Date          | November 27, 2001  |                          |              |
|  |    | First Named Inventor | Bernd Riedl et al. |                          |              |
|  |    | Group Art Unit       | 1624               |                          |              |
|  |    | Examiner Name        | Deepak R. RAO      |                          |              |
| Sheet  | 11 | of                   | 56                 | Attorney Docket Number   | BAYER-0018-A |

| U.S. PATENT DOCUMENTS |                      |              |    |                   |            |  |
|-----------------------|----------------------|--------------|----|-------------------|------------|--|
|                       | U.S. Patent Document |              |    |                   |            |  |
|                       | <b>B62</b>           | 2007/0265315 | A1 | Dumas et al.      | 11-15-2007 |  |
|                       | <b>B63</b>           | 2008/0009527 | A1 | Dumas et al.      | 01-10-2008 |  |
|                       | <b>B64</b>           | 2008/0027061 | A1 | Riedl et al.      | 01-31-2008 |  |
|                       | <b>B65</b>           | 2008/0032979 | A1 | Riedl et al.      | 02-07-2008 |  |
|                       | <b>B66</b>           | 2008/0045546 | A1 | Bouchon et al.    | 02-21-2008 |  |
|                       | <b>B67</b>           | 2008/0045589 | A1 | Kelley            | 02-21-2008 |  |
|                       | <b>B68</b>           | 2008/0085902 | A1 | Bold et al.       | 04-10-2008 |  |
|                       | <b>B69</b>           | 2008/0108672 | A1 | Riedl et al.      | 05-08-2008 |  |
|                       | <b>B70</b>           | 2008/0153823 | A1 | Riedl et al.      | 06-26-2008 |  |
|                       | <b>B71</b>           | 2008/0194580 | A1 | Dumas et al.      | 08-14-2008 |  |
|                       | <b>B71a</b>          | 2008/0207699 | A1 | Hoelzemann et al. | 08-28-2008 |  |
|                       | <b>B72</b>           | 2008/0214545 | A1 | Lee et al.        | 09-04-2008 |  |
|                       | <b>B73</b>           | 2008/0227828 | A1 | Dumas et al.      | 09-18-2008 |  |
|                       | <b>B74</b>           | 2008/0242707 | A1 | Schuckler et al.  | 10-02-2008 |  |
|                       | <b>B75</b>           | 2008/0262236 | A1 | Logers et al.     | 10-23-2008 |  |
|                       | <b>B76</b>           | 2008/0269265 | A1 | Miller et al.     | 10-30-2008 |  |
|                       | <b>B77</b>           | 2008/0300281 | A1 | Dumas et al.      | 12-04-2008 |  |
|                       | <b>B77a</b>          | 2008/0311601 | A1 | Elting et al.     | 12-18-2008 |  |
|                       | <b>B77b</b>          | 2008/0311604 | A1 | Elting et al.     | 12-18-2008 |  |
|                       | <b>B78</b>           | 2009/0068146 | A1 | Wilhelm           | 03-12-2009 |  |
|                       | <b>B79</b>           | 2009/0093526 | A1 | Miller et al.     | 04-09-2009 |  |
|                       | <b>B80</b>           | 2009/0118268 | A1 | Riedl et al.      | 05-07-2009 |  |
|                       | <b>B81</b>           | 2009/0176791 | A1 | Sandner et al.    | 07-09-2009 |  |
|                       | <b>B82</b>           | 2009/0192127 | A1 | Scheuring et al.  | 07-30-2009 |  |
|                       | <b>B83</b>           | 2009/0215833 | A1 | Grunenberg et al. | 08-27-2009 |  |
|                       | <b>B84</b>           | 2009/0215835 | A1 | Wilhelm           | 08-27-2009 |  |
|                       | <b>B84a</b>          | 2009/0221010 | A1 | Elting et al.     | 09-03-2009 |  |
|                       | <b>B85</b>           | 2009/0227637 | A1 | Weber et al.      | 09-10-2009 |  |
|                       | <b>B86</b>           | 2009/0306020 | A1 | Scheuring et al.  | 12-10-2009 |  |
|                       | <b>B87</b>           | 2010/0035888 | A1 | Sandner et al.    | 02-11-2010 |  |
|                       | <b>B88</b>           | 2010/0063088 | A1 | Wood et al.       | 03-11-2010 |  |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |    |                          |  |                    |  |
|---|----|----|----|--------------------------|--|--------------------|--|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    |    | <i>Complete if Known</i> |  |                    |  |
|   |    |    |    | Application Number       |  | 09/993,647         |  |
|   |    |    |    | Filing Date              |  | November 27, 2001  |  |
|   |    |    |    | First Named Inventor     |  | Bernd Riedl et al. |  |
|   |    |    |    | Group Art Unit           |  | 1624               |  |
|   |    |    |    | Examiner Name            |  | Deepak R. RAO      |  |
| Sheet   | 12 | of | 56 | Attorney Docket Number   |  | BAYER-0018-A       |  |

| FOREIGN PATENT DOCUMENTS |                       |                         |                     |                                   |  |  |   |                |
|--------------------------|-----------------------|-------------------------|---------------------|-----------------------------------|--|--|---|----------------|
| Examiner Initials*       | Cite No. <sup>1</sup> | Foreign Patent Document |                     |                                   | Name of Patentee or Applicant of Cited Document  | Date of Publication of Cited Document MM-DD-YYYY | Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear | T <sup>6</sup> |
|                          |                       | Office <sup>2</sup>     | Number <sup>2</sup> | Kind Code <sup>5</sup> (if known) |  |  |   |                |
|                          | C1                    | WO                      | 90/02112            | A1                                | The Nutrasweet Company   | 03-08-1990                                       |   |                |
|                          | C2                    | WO                      | 92/03413            | A1                                | Rhone-Roulenc Rorer Limited et al.   | 03-05-1992                                       |   |                |
|                          | C3                    | WO                      | 92/05179            | A1                                | American Home Products Corporation   | 04-02-1992                                       |   |                |
|                          | C4                    | WO                      | 93/04170            | A1                                | The United States of America represented by The Secretary, Department Of Health And Human Services | 03-04-1993                                       |   |                |
|                          | C5                    | WO                      | 93/18028            | A1                                | SmithKline Beecham PLC et al.  | 09-16-1993                                       |   |                |
|                          | C6                    | WO                      | 93/24458            | A1                                | Pfizer Inc. et al.   | 12-09-1993                                       |   |                |
|                          | C7                    | WO                      | 94/02136            | A1                                | SmithKline Beecham Corp. et al.  | 02-03-1994                                       |   |                |
|                          | C8                    | WO                      | 94/02485            | A1                                | SmithKline Beecham Corp. et al.  | 02-03-1994                                       |   |                |
|                          | C9                    | WO                      | 94/04541            | A2                                | The UpJohn Co. et al.  | 03-03-1994                                       |   |                |
|                          | C10                   | WO                      | 94/14801            | A1                                | SmithKline Beecham PLC et al.  | 07-07-1994                                       |   |                |
|                          | C11                   | WO                      | 94/18170            | A1                                | SmithKline Beecham PLC et al.  | 08-18-1994                                       |   |                |
|                          | C12                   | WO                      | 94/22807            | A1                                | Neu-Rosearch, A/S et al.   | 10-13-1994                                       |   |                |
|                          | C13                   | WO                      | 94/23755            | A1                                | Board of Regents of the University of Nebraska   | 10-27-1994                                       |   |                |
|                          | C14                   | WO                      | 94/25012            | A2                                | SmithKline Beecham PLC et al.  | 11-10-1994                                       |   |                |
|                          | C15                   | WO                      | 95/02136            | A1                                | Mannesmann Akteingesellschaft  | 01-19-1995                                       |   | abs            |
|                          | C16                   | WO                      | 95/02591            | A1                                | SmithKline Beecham Corporation et al.  | 01-26-1995                                       |   |                |
|                          | C17                   | WO                      | 95/07922            | A1                                | SmithKline Beecham Corporation et al.  | 03-23-1995                                       |   |                |
|                          | C18                   | WO                      | 95/13067            | A1                                | SmithKline Beecham Corporation et al.  | 05-18-1995                                       |   |                |
|                          | C19                   | WO                      | 95/14023            | A1                                | Abbott Laboratories  | 05-26-1995                                       |   |                |
|                          | C20                   | WO                      | 95/16691            | A1                                | Sandoz Ltd. et al.   | 06-22-1995                                       |   |                |
|                          | C21                   | WO                      | 95/19169            | A2                                | Sugen, Inc.  | 07-20-1995                                       |   |                |
|                          | C22                   | WO                      | 95/31451            | A1                                | Smithkline Beecham Corporation et al.  | 11-23-1995                                       |   |                |
|                          | C23                   | WO                      | 95/33458            | A1                                | Smithkline Beecham Corporation et al.  | 12-14-1995                                       |   |                |
|                          | C24                   | WO                      | 95/33460            | A1                                | Smithkline Beecham Corporation et al.  | 12-14-1995                                       |   |                |
|                          | C25                   | WO                      | 96/02112            | A1                                | Thomson-CSF et al.   | 01-25-1996                                       |   | abs            |
|                          | C26                   | WO                      | 96/10559            | A1                                | Fujisawa Pharmaceutical Co., Ltd.  | 04-11-1996                                       |   |                |
|                          | C27                   | WO                      | 96/13632            | A1                                | Novo Nordisk A/S et al.  | 05-09-1996                                       |   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |    |                          |                    |  |
|---|----|----|----|--------------------------|--------------------|--|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    |    | <i>Complete if Known</i> |                    |  |
|   |    |    |    | Application Number       | 09/993,647         |  |
|   |    |    |    | Filing Date              | November 27, 2001  |  |
|   |    |    |    | First Named Inventor     | Bernd Riedl et al. |  |
|   |    |    |    | Group Art Unit           | 1624               |  |
|   |    |    |    | Examiner Name            | Deepak R. RAO      |  |
| Sheet   | 13 | of | 56 | Attorney Docket Number   | BAYER-0018-A       |  |

| FOREIGN PATENT DOCUMENTS |    |                         |    |  |            |  |     |
|--------------------------|----|-------------------------|----|--|------------|--|-----|
|                          |    | Foreign Patent Document |    |  |            |  |     |
| C28                      | WO | 96/25157                | A1 | Smith Kline Beecham Corporation et al.             | 08-22-1996 |  |     |
| C29                      | WO | 96/40673                | A1 | Sugen, Inc.  | 12-19-1996 |  |     |
| C30                      | WO | 96/40675                | A1 | Sugen, Inc.  | 12-19-1996 |  |     |
| C31                      | WO | 96/41807                | A1 | Sandoz Ltd. et al.                                 | 12-27-1996 |  |     |
| C32                      | WO | 97/03069                | A1 | Glaxo Group Limited et al.                         | 01-30-1997 |  |     |
| C33                      | WO | 97/09973                | A2 | The Regents of The University of California et al. | 03-20-1997 |  |     |
| C34                      | WO | 97/17267                | A1 | SCA Mölnlycke AB et al.                            | 05-15-1997 |  |     |
| C35                      | WO | 97/17329                | A1 | Kirin Beer Kabushiki Kaisha                        | 05-15-1997 |  | abs |
| C36                      | WO | 97/29743                | A1 | Smith Kline Beecham Corporation et al.             | 08-21-1997 |  |     |
| C37                      | WO | 97/30992                | A1 | Bristol-Myers Squibb Company                       | 08-28-1997 |  |     |
| C38                      | WO | 97/34146                | A1 | The General Hospital Corporation                   | 09-18-1997 |  |     |
| C39                      | WO | 97/40028                | A1 | Vertex Pharmaceuticals Incorporated                | 10-30-1997 |  |     |
| C40                      | WO | 97/40842                | A1 | Eli Lilly and Company et al.                       | 11-06-1997 |  |     |
| C41                      | WO | 97/45400                | A1 | Neu-Rosearch A/S et al.                            | 12-04-1997 |  |     |
| C42                      | WO | 97/49399                | A1 | SmithKline Beecham Corporation et al.              | 12-31-1997 |  |     |
| C43                      | WO | 97/49400                | A1 | SmithKline Beecham Corporation et al.              | 12-31-1997 |  |     |
| C44                      | WO | 98/17207                | A1 | Synthes AG Chur et al.                             | 04-30-1998 |  |     |
| C45                      | WO | 98/17267                | A1 | Zymogenetics, Inc. et al.                          | 04-30-1998 |  |     |
| C46                      | WO | 98/20868                | A1 | The Picower Institute for Medical Research         | 05-22-1998 |  |     |
| C47                      | WO | 98/22103                | A1 | Zeneca Limited et al.                              | 05-28-1998 |  |     |
| C48                      | WO | 98/22432                | A1 | Yamanouchi Pharmaceutical Co., Ltd.                | 05-28-1998 |  | abs |
| C49                      | WO | 98/32439                | A1 | SmithKline Beecham Corporation et al.              | 07-30-1998 |  |     |
| C50                      | WO | 98/34929                | A1 | SmithKline Beecham Corporation et al.              | 08-13-1998 |  |     |
| C51                      | WO | 98/45268                | A1 | Pfizer Products Inc. et al.                        | 10-15-1998 |  |     |
| C52                      | WO | 98/49150                | A1 | Takeda Chemical Industries, Ltd. et al.            | 11-05-1998 |  |     |
| C53                      | WO | 98/52558                | A1 | Bayer Corporation et al.                           | 11-26-1998 |  |     |
| C54                      | WO | 98/52559                | A1 | Bayer Corporation et al.                           | 11-26-1998 |  |     |
| C55                      | WO | 98/52937                | A2 | G.D. Searle and Co. et al.                         | 11-26-1998 |  |     |
| C56                      | WO | 98/52941                | A1 | G.D. Searle and Co. et al.                         | 11-26-1998 |  |     |
| C57                      | WO | 98/56377                | A1 | SmithKline Beecham Corporation et al.              | 12-17-1998 |  |     |
| C58                      | WO | 99/00357                | A1 | Vertex Pharmaceuticals Incorporated                | 01-07-1999 |  |     |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |    |                          |                    |  |
|---|----|----|----|--------------------------|--------------------|--|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    |    | <i>Complete if Known</i> |                    |  |
|   |    |    |    | Application Number       | 09/993,647         |  |
|   |    |    |    | Filing Date              | November 27, 2001  |  |
|   |    |    |    | First Named Inventor     | Bernd Riedl et al. |  |
|   |    |    |    | Group Art Unit           | 1624               |  |
|   |    |    |    | Examiner Name            | Deepak R. RAO      |  |
| Sheet   | 14 | of | 56 | Attorney Docket Number   | BAYER-0018-A       |  |

| FOREIGN PATENT DOCUMENTS |    |                         |    |   |            |  |     |
|--------------------------|----|-------------------------|----|---|------------|--|-----|
|                          |    | Foreign Patent Document |    |   |            |  |     |
| C59                      | WO | 99/00370                | A1 | Kureha Kagaku Kogyo Kabushiki Kaisha                    | 01-07-1999 |  | abs |
| C60                      | WO | 99/20617                | A1 | Pharmacia & UpJohn Company et al.                       | 04-29-1999 |  |     |
| C61                      | WO | 99/21835                | A1 | Fujisawa Pharmaceutical Co., Ltd. et al.                | 05-06-1999 |  |     |
| C62                      | WO | 99/23091                | A1 | Boehringer Ingelheim Pharmaceuticals, Inc.              | 05-14-1999 |  |     |
| C63                      | WO | 99/24035                | A1 | Bristol-Myers Squibb Company                            | 05-20-1999 |  |     |
| C64                      | WO | 99/24398                | A2 | Zeneca Limited et al.                                   | 05-20-1999 |  |     |
| C65                      | WO | 99/24635                | A1 | Advanced Technology Materials, Inc.                     | 05-20-1999 |  |     |
| C66                      | WO | 99/26657                | A1 | Medical University of South Carolina et al.             | 06-03-1999 |  |     |
| C67                      | WO | 99/28305                | A1 | E.I. Dupont De Nemours & Company et al.                 | 06-10-1999 |  |     |
| C68                      | WO | 99/32106                | A1 | Bayer Corporation                                       | 07-01-1999 |  |     |
| C69                      | WO | 99/32109                | A1 | Bristol-Myers Squibb Company                            | 07-01-1999 |  |     |
| C70                      | WO | 99/32110                | A1 | Bayer Corporation                                       | 07-01-1999 |  |     |
| C71                      | WO | 99/32111                | A1 | Bayer Corporation                                       | 07-01-1999 |  |     |
| C72                      | WO | 99/32436                | A1 | Bayer Corporation                                       | 07-01-1999 |  |     |
| C73                      | WO | 99/32437                | A1 | Slovak-Farma, A.S. et al.                               | 07-01-1999 |  |     |
| C74                      | WO | 99/32455                | A1 | Bayer Corporation                                       | 07-01-1999 |  |     |
| C75                      | WO | 99/32463                | A1 | Bayer Corporation                                       | 07-01-1999 |  |     |
| C76                      | WO | 99/33458                | A1 | Daiichi Pharmaceuticals Co., Ltd. et al.                | 07-08-1999 |  | abs |
| C77                      | WO | 99/35132                | A1 | Glaxo Group Limited et al.                              | 07-15-1999 |  |     |
| C78                      | WO | 99/40673                | A1 | Moving Magnet Technologies (S.A.) et al.                | 08-12-1999 |  | abs |
| C79                      | WO | 99/58502                | A1 | Vertex Pharmaceuticals Incorporated et al.              | 11-18-1999 |  |     |
| C80                      | WO | 99/62890                | A1 | Pfizer Products Inc. et al.                             | 12-09-1999 |  |     |
| C81                      | WO | 00/12497                | A2 | Scios Inc. et al.                                       | 03-09-2000 |  |     |
| C82                      | WO | 00/17175                | A1 | Vertex Pharmaceuticals Incorporated et al.              | 03-30-2000 |  |     |
| C83                      | WO | 00/19205                | A1 | Advanced Research and Technology Institute, Inc. et al. | 04-06-2000 |  |     |
| C84                      | WO | 00/26203                | A1 | Pharmacia & UpJohn S.P.A. et al.                        | 05-11-2000 |  |     |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |    |                          |                    |
|---|----|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    |    | <i>Complete if Known</i> |                    |
|   |    |    |    | Application Number       | 09/993,647         |
|   |    |    |    | Filing Date              | November 27, 2001  |
|   |    |    |    | First Named Inventor     | Bernd Riedl et al. |
|   |    |    |    | Group Art Unit           | 1624               |
|   |    |    |    | Examiner Name            | Deepak R. RAO      |
| Sheet   | 15 | of | 56 | Attorney Docket Number   | BAYER-0018-A       |

| FOREIGN PATENT DOCUMENTS |      |                         |          |    |   |            |     |
|--------------------------|------|-------------------------|----------|----|---|------------|-----|
|                          |      | Foreign Patent Document |          |    |   |            |     |
|                          | C85  | WO                      | 00/27414 | A2 | BASF Aktiengesellschaft et al.                    | 05-18-2000 |     |
|                          | C86  | WO                      | 00/31238 | A2 | Genetica, Inc. et al.                             | 06-02-2000 |     |
|                          | C87  | WO                      | 00/34303 | A1 | Isis Pharmaceuticals, Inc. et al.                 | 06-15-2000 |     |
|                          | C88  | WO                      | 00/35454 | A1 | Du Pont Pharmaceuticals Company                   | 06-22-2000 |     |
|                          | C89  | WO                      | 00/35455 | A1 | Telik, Inc.                                       | 06-22-2000 |     |
|                          | C90  | WO                      | 00/39101 | A1 | Astra Zeneca UK Limited et al.                    | 07-06-2000 |     |
|                          | C91  | WO                      | 00/39116 | A1 | Teikoku Hormone MFG. Co., Ltd.                    | 07-06-2000 | abs |
|                          | C92  | WO                      | 00/41698 | A1 | Bayer Corporation et al.                          | 07-20-2000 |     |
|                          | C93  | WO                      | 00/42012 | A1 | Bayer Corporation et al.                          | 07-20-2000 |     |
|                          | C94  | WO                      | 00/43366 | A1 | Kirin Beer Kabushiki Kaisha                       | 07-27-2000 | abs |
|                          | C95  | WO                      | 00/43384 | A1 | Boehringer Ingelheim Pharmaceuticals, Inc.        | 07-27-2000 |     |
|                          | C96  | WO                      | 00/47577 | A1 | SmithKline Beecham PLC et al.                     | 08-17-2000 |     |
|                          | C97  | WO                      | 00/50425 | A1 | Boehringer Ingelheim Pharmaceuticals, Inc.        | 08-31-2000 |     |
|                          | C98  | WO                      | 00/55139 | A2 | Boehringer Ingelheim Pharmaceuticals, Inc.        | 09-21-2000 |     |
|                          | C99  | WO                      | 00/55152 | A1 | Boehringer Ingelheim Pharmaceuticals, Inc.        | 09-21-2000 |     |
|                          | C100 | WO                      | 00/56331 | A1 | Vertex Pharmaceuticals Incorporated et al.        | 09-28-2000 |     |
|                          | C101 | WO                      | 00/71506 | A2 | Telik, Inc.                                       | 11-30-2000 |     |
|                          | C102 | WO                      | 00/71532 | A1 | Pfizer Products Inc. et al.                       | 11-30-2000 |     |
|                          | C103 | WO                      | 01/04115 | A2 | Boehringer Ingelheim Pharmaceuticals, Inc.        | 01-18-2001 |     |
|                          | C104 | WO                      | 01/07411 | A1 | Banyu Pharmaceutical Co., Ltd.                    | 02-01-2001 | abs |
|                          | C105 | WO                      | 01/09088 | A1 | Kirin Beer Kabushiki Kaisha et al.                | 02-08-2001 |     |
|                          | C106 | WO                      | 01/12188 | A1 | Pharmacia & UpJohn S.P.A. et al.                  | 02-22-2001 |     |
|                          | C107 | WO                      | 01/36403 | A1 | Boehringer Ingelheim Pharmaceuticals, Inc. et al. | 05-25-2001 |     |
|                          | C108 | WO                      | 01/47892 | A1 | American Home Products Corporation                | 07-05-2001 |     |
|                          | C109 | WO                      | 01/54723 | A1 | Sunnybrook Health Science Center et al.           | 08-02-2001 |     |
|                          | C110 | WO                      | 01/54727 | A1 | The Van Kampen Group, Inc. et al.                 | 08-02-2001 |     |
|                          | C111 | WO                      | 01/57008 | A1 | BASF Aktiengesellschaft et al.                    | 08-09-2001 |     |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |                      |                    |                          |              |
|---|----|----------------------|--------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |                      |                    | <b>Complete if Known</b> |              |
|   |    | Application Number   | 09/993,647         |                          |              |
|   |    | Filing Date          | November 27, 2001  |                          |              |
|   |    | First Named Inventor | Bernd Riedl et al. |                          |              |
|   |    | Group Art Unit       | 1624               |                          |              |
|   |    | Examiner Name        | Deepak R. RAO      |                          |              |
| Sheet   | 16 | of                   | 56                 | Attorney Docket Number   | BAYER-0018-A |

| FOREIGN PATENT DOCUMENTS |                         |    |           |    |  |            |     |
|--------------------------|-------------------------|----|-----------|----|--|------------|-----|
|                          | Foreign Patent Document |    |           |    |  |            |     |
|                          | C112                    | WO | 01/63403  | A2 | Sun Microsystems, Inc.                       | 08-30-2001 |     |
|                          | C113                    | WO | 01/66099  | A2 | Astra Zeneca AB et al.                       | 09-13-2001 |     |
|                          | C114                    | WO | 01/66540  | A1 | SmithKline Beecham P.L.C. et al.             | 09-13-2001 |     |
|                          | C114a                   | WO | 01/80843  | A2 | Supergen, Inc. et al.                        | 11-01-2001 |     |
|                          | C115                    | WO | 02/06382  | A1 | General Electric Company                     | 01-24-2002 |     |
|                          | C116                    | WO | 02/07747  | A1 | Joslin Diabetes Center, Inc. et al.          | 01-31-2002 |     |
|                          | C117                    | WO | 02/07772  | A2 | Boehringer Ingelheim Pharmaceuticals, Inc.   | 01-31-2002 |     |
|                          | C118                    | WO | 02/10141  | A1 | Pfizer Products Inc. et al.                  | 02-07-2002 |     |
|                          | C119                    | WO | 02/14281  | A1 | Cochran et al.                               | 02-21-2002 |     |
|                          | C120                    | WO | 02/14311  | A2 | Amgen Inc. et al.                            | 02-21-2002 |     |
|                          | C121                    | WO | 02/18346  | A1 | Pfizer Products Inc. et al.                  | 03-07-2002 |     |
|                          | C122                    | WO | 02/24635  | A2 | Fujisawa Pharmaceutical Co., Ltd. et al.     | 03-28-2002 |     |
|                          | C123                    | WO | 02/25286  | A2 | The President and Fellows of Harvard College | 03-28-2002 |     |
|                          | C124                    | WO | 02/32872  | A1 | Eisai Co., Ltd.                              | 04-25-2002 | abs |
|                          | C124-2                  | WO | 02/32872  | A1 | Eisai Co., Ltd.                              | 04-25-2002 |     |
|                          | C125                    | WO | 02/40445  | A1 | Novo Nordisk A/S                             | 05-23-2002 |     |
|                          | C126                    | WO | 02/42012  | A1 | Brill  | 05-30-2002 |     |
|                          | C127                    | WO | 02/44156  | A2 | Glaxo Group Limited et al.                   | 06-06-2002 |     |
|                          | C128                    | WO | 02/44158  | A1 | Pfizer Products Inc. et al.                  | 06-06-2002 |     |
|                          | C129                    | WO | 02/50091  | A1 | Glaxo Group Limited et al.                   | 06-27-2002 |     |
|                          | C130                    | WO | 02/059081 | A2 | Padia et al.                                 | 08-01-2002 |     |
|                          | C131                    | WO | 02/059102 | A2 | Aventis Pharma S.A. et al.                   | 08-01-2002 | abs |
|                          | C132                    | WO | 02/060900 | A2 | Telik, Inc. et al.                           | 08-08-2002 |     |
|                          | C133                    | WO | 02/062763 | A2 | Bayer Corporation et al.                     | 08-15-2002 |     |
|                          | C134                    | WO | 02/070008 | A1 | Imclone Systems Incorporated et al.          | 09-12-2002 |     |
|                          | C135                    | WO | 02/076930 | A2 | Telik, Inc.                                  | 10-03-2002 |     |
|                          | C136                    | WO | 02/076977 | A2 | Bayer Corporation et al.                     | 10-03-2002 |     |
|                          | C137                    | WO | 02/083628 | A1 | Boehringer Ingelheim Pharmaceuticals, Inc.   | 10-24-2002 |     |
|                          | C138                    | WO | 02/083642 | A1 | Boehringer Ingelheim Pharmaceuticals, Inc.   | 10-24-2002 |     |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**



Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |    |                          |                    |  |
|---|----|----|----|--------------------------|--------------------|--|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    |    | <i>Complete if Known</i> |                    |  |
|   |    |    |    | Application Number       | 09/993,647         |  |
|   |    |    |    | Filing Date              | November 27, 2001  |  |
|   |    |    |    | First Named Inventor     | Bernd Riedl et al. |  |
|   |    |    |    | Group Art Unit           | 1624               |  |
|   |    |    |    | Examiner Name            | Deepak R. RAO      |  |
| Sheet   | 17 | of | 56 | Attorney Docket Number   | BAYER-0018-A       |  |

| FOREIGN PATENT DOCUMENTS |       |                         |             |    |  |            |  |     |
|--------------------------|-------|-------------------------|-------------|----|--|------------|--|-----|
|                          |       | Foreign Patent Document |             |    |  |            |  |     |
|                          | C139  | WO                      | 02/085857   | A2 | Bayer Corporation et al.                   | 10-31-2002 |  |     |
|                          | C140  | WO                      | 02/085859   | A1 | Bayer Corporation et al.                   | 10-31-2002 |  |     |
|                          | C141  | WO                      | 02/088090   | A2 | Vertex Pharmaceuticals Incorporated et al. | 11-07-2002 |  |     |
|                          | C142  | WO                      | 02/092576   | A1 | Boehringer Ingelheim Pharmaceuticals, Inc. | 11-21-2002 |  |     |
|                          | C143  | WO                      | 03/004523   | A1 | Bayer Aktiengesellschaft et al.            | 01-16-2003 |  |     |
|                          | C144  | WO                      | 03/005999   | A2 | Boehringer Ingelheim Pharmaceuticals, Inc. | 01-23-2003 |  |     |
|                          | C145  | WO                      | 03/047523   | A2 | Onyx Pharmaceuticals, Inc.                 | 06-12-2003 |  |     |
|                          | C146  | WO                      | 03/047579   | A1 | Bayer Corporation et al.                   | 06-12-2003 |  |     |
|                          | C147  | WO                      | 03/056036   | A2 | Catalyst Biomedica Limited et al.          | 07-10-2003 |  |     |
|                          | C148  | WO                      | 03/059373   | A2 | Ramot at Tel Aviv University Ltd. et al.   | 07-24-2003 |  |     |
|                          | C149  | WO                      | 03/060111   | A2 | Catalyst Biomedica Limited et al.          | 07-24-2003 |  |     |
|                          | C150  | WO                      | 03/065995   | A2 | Supergen, Inc. et al.                      | 08-14-2003 |  |     |
|                          | C151  | WO                      | 03/068223   | A1 | Bayer Corporation et al.                   | 08-21-2003 |  |     |
|                          | C152  | WO                      | 03/068228   | A1 | Bayer Corporation et al.                   | 08-21-2003 |  |     |
|                          | C153  | WO                      | 03/068229   | A1 | Bayer Corporation et al.                   | 08-21-2003 |  |     |
|                          | C154  | WO                      | 03/068746   | A1 | Bayer Corporation et al.                   | 08-21-2003 |  |     |
|                          | C155  | WO                      | 03/082272   | A1 | Chiron Corporation et al.                  | 10-09-2003 |  |     |
|                          | C156  | WO                      | 03/094626   | A1 | KMB Produktions AG et al.                  | 11-20-2003 |  | abs |
|                          | C156a | WO                      | 03/097854   | A2 | Sugen, Inc. et al.                         | 11-27-2003 |  |     |
|                          | C157  | WO                      | 03/099771   | A2 | Novartis AG et al.                         | 12-04-2003 |  |     |
|                          | C158  | WO                      | 2004/004720 | A1 | Astex Technology Limited et al.            | 01-15-2004 |  |     |
|                          | C159  | WO                      | 2004/019941 | A1 | MERCK PATENT GMBH et al.                   | 03-11-2004 |  |     |
|                          | C160  | WO                      | 2004/037789 | A2 | MERCK PATENT GMBH et al.                   | 05-06-2004 |  |     |
|                          | C161  | WO                      | 2004/043374 | A2 | Dana-Farber Cancer Institute Inc. et al.   | 05-27-2004 |  |     |
|                          | C162  | WO                      | 2004/045578 | A2 | NOVARTIS AG et al.                         | 06-03-2004 |  |     |
|                          | C163  | WO                      | 2004/052880 | A1 | ASTRAZENECA AB et al.                      | 06-24-2004 |  |     |
|                          | C164  | WO                      | 2004/078128 | A2 | Bayer Pharmaceuticals Corporation et al.   | 09-16-2004 |  |     |
|                          | C165  | WO                      | 2004/078746 | A2 | Bayer Pharmaceuticals Corporation et al.   | 09-16-2004 |  |     |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |                      |                    |                          |              |
|--|----|----------------------|--------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |    |                      |                    | <b>Complete if Known</b> |              |
|  |    | Application Number   | 09/993,647         |                          |              |
|  |    | Filing Date          | November 27, 2001  |                          |              |
|  |    | First Named Inventor | Bernd Riedl et al. |                          |              |
|  |    | Group Art Unit       | 1624               |                          |              |
|  |    | Examiner Name        | Deepak R. RAO      |                          |              |
| Sheet  | 18 | of                   | 56                 | Attorney Docket Number   | BAYER-0018-A |

| FOREIGN PATENT DOCUMENTS |    |                         |    |  |            |  |     |
|--------------------------|----|-------------------------|----|--|------------|--|-----|
|                          |    | Foreign Patent Document |    |  |            |  |     |
| C166                     | WO | 2004/078747             | A1 | Bayer Pharmaceuticals Corporation et al. | 09-16-2004 |  |     |
| C167                     | WO | 2004/078748             | A2 | Bayer Pharmaceuticals Corporation et al. | 09-16-2004 |  |     |
| C168                     | WO | 2004/085399             | A1 | MERCK PATENT GMBH et al.                 | 10-07-2004 |  |     |
| C169                     | WO | 2004/085425             | A1 | AMGEN INC.                               | 10-07-2004 |  |     |
| C170                     | WO | 2004/108713             | A1 | Warner-Lambert Company LLC et al.        | 12-16-2004 |  |     |
| C171                     | WO | 2004/108715             | A1 | Warner-Lambert Company LLC et al.        | 12-16-2004 |  |     |
| C172                     | WO | 2004/113274             | A2 | Bayer Pharmaceuticals Corporation et al. | 12-29-2004 |  |     |
| C173                     | WO | 2005/000284             | A2 | Bayer Pharmaceuticals Corporation et al. | 01-06-2005 |  |     |
| C174                     | WO | 2005/002673             | A1 | Astex Technology Limited et al.          | 01-13-2005 |  |     |
| C175                     | WO | 2005/004863             | A1 | MERCK PATENT GMBH et al.                 | 01-20-2005 |  |     |
| C176                     | WO | 2005/004864             | A1 | MERCK PATENT GMBH et al.                 | 01-20-2005 |  |     |
| C177                     | WO | 2005/005389             | A2 | MERCK PATENT GMBH et al.                 | 01-20-2005 |  |     |
| C178                     | WO | 2005/005434             | A1 | NOVARTIS AG et al.                       | 01-20-2005 |  |     |
| C179                     | WO | 2005/009367             | A2 | AMBIT BIOSCIENCES CORPORATION et al.     | 02-03-2005 |  |     |
| C180                     | WO | 2005/009961             | A2 | Bayer Pharmaceuticals Corporation et al. | 02-03-2005 |  |     |
| C181                     | WO | 2005/011700             | A1 | SMITHKLINE BEECHAM CORPORATION et al.    | 02-10-2005 |  |     |
| C182                     | WO | 2005/016252             | A2 | Ariad Gene Therapeutics, Inc. et al.     | 02-24-2005 |  |     |
| C183                     | WO | 2005/019192             | A1 | MERCK PATENT GMBH et al.                 | 03-03-2005 |  | abs |
| C184                     | WO | 2005/032548             | A1 | CHIRON CORPORATION et al.                | 04-14-2005 |  |     |
| C185                     | WO | 2005/037273             | A1 | CHIRON CORPORATION et al.                | 04-28-2005 |  |     |
| C186                     | WO | 2005/037285             | A1 | CHIRON CORPORATION et al.                | 04-28-2005 |  |     |
| C187                     | WO | 2005/037829             | A1 | MERCK PATENT GMBH et al.                 | 04-28-2005 |  | abs |
| C188                     | WO | 2005/042520             | A1 | MERCK PATENT GMBH et al.                 | 05-12-2005 |  | abs |
| C189                     | WO | 2005/047283             | A1 | MERCK PATENT GMBH et al.                 | 05-26-2005 |  | abs |
| C190                     | WO | 2005/048948             | A2 | Ambit Biosciences Corporation et al.     | 06-02-2005 |  |     |
| C191                     | WO | 2005/049603             | A1 | MERCK PATENT GMBH et al.                 | 06-02-2005 |  | abs |
| C191a                    | WO | 2005/056764             | A2 | Compound Therapeutics, Inc. et al.       | 06-23-2005 |  |     |
| C192                     | WO | 2005/058832             | A1 | MERCK PATENT GMBH et al.                 | 06-30-2005 |  |     |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |                      |                    |                          |              |
|---|----|----------------------|--------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |                      |                    | <b>Complete if Known</b> |              |
|   |    | Application Number   | 09/993,647         |                          |              |
|   |    | Filing Date          | November 27, 2001  |                          |              |
|   |    | First Named Inventor | Bernd Riedl et al. |                          |              |
|   |    | Group Art Unit       | 1624               |                          |              |
|   |    | Examiner Name        | Deepak R. RAO      |                          |              |
| Sheet   | 19 | of                   | 56                 | Attorney Docket Number   | BAYER-0018-A |

| FOREIGN PATENT DOCUMENTS |              |                         |             |    |   |            |     |
|--------------------------|--------------|-------------------------|-------------|----|---|------------|-----|
|                          |              | Foreign Patent Document |             |    |   |            |     |
|                          | <b>C192a</b> | WO                      | 2005/059179 | A1 | Bayer Pharmaceutical Corporation et al.   | 06-30-2005 |     |
|                          | <b>C193</b>  | WO                      | 2005/075425 | A2 | MERCK PATENT GMBH et al.                  | 08-18-2005 |     |
|                          | <b>C194</b>  | WO                      | 2005/089443 | A2 | The Penn State Research Foundation et al. | 09-29-2005 |     |
|                          | <b>C195</b>  | WO                      | 2005/110994 | A2 | Bayer Pharmaceuticals Corporation et al.  | 11-24-2005 |     |
|                          | <b>C196</b>  | WO                      | 2006/026500 | A1 | Bayer Pharmaceuticals Corporation et al.  | 03-09-2006 |     |
|                          | <b>C197</b>  | WO                      | 2006/026501 | A1 | Bayer Pharmaceuticals Corporation et al.  | 03-09-2006 |     |
|                          | <b>C198</b>  | WO                      | 2006/027346 | A2 | ALTANA PHARMA AG et al.                   | 03-16-2006 |     |
|                          | <b>C199</b>  | WO                      | 2006/034797 | A1 | BAYER HEALTHCARE AG et al.                | 04-06-2006 |     |
|                          | <b>C200</b>  | WO                      | 2006/094626 | A1 | BAYER HEALTHCARE AG et al.                | 09-14-2006 |     |
|                          | <b>C201</b>  | WO                      | 2006/105844 | A1 | MERCK PATENT GMBH et al.                  | 10-12-2006 | abs |
|                          | <b>C202</b>  | WO                      | 2006/125540 | A1 | BAYER HEALTHCARE AG et al.                | 11-30-2006 |     |
|                          | <b>C203</b>  | WO                      | 2007/015947 | A2 | BAYER HEALTHCARE LLC et al.               | 02-08-2007 |     |
|                          | <b>C204</b>  | WO                      | 2007/039403 | A1 | ALTANA PHARMA AG et al.                   | 04-12-2007 |     |
|                          | <b>C205</b>  | WO                      | 2007/039404 | A1 | ALTANA PHARMA AG et al.                   | 04-12-2007 |     |
|                          | <b>C205a</b> | WO                      | 2007/047955 | A2 | BAYER HEALTHCARE LLC et al.               | 04-26-2007 |     |
|                          | <b>C206</b>  | WO                      | 2007/053573 | A2 | Bayer Pharmaceuticals Corporation et al.  | 05-10-2007 |     |
|                          | <b>C207</b>  | WO                      | 2007/054215 | A1 | BAYER HEALTHCARE AG et al.                | 05-18-2007 |     |
|                          | <b>C207a</b> | WO                      | 2007/056011 | A2 | BAYER HEALTHCARE LLC et al.               | 05-18-2007 |     |
|                          | <b>C207b</b> | WO                      | 2007/056012 | A2 | BAYER HEALTHCARE LLC et al.               | 05-18-2007 |     |
|                          | <b>C208</b>  | WO                      | 2007/059094 | A2 | Bayer Pharmaceuticals Corporation et al.  | 05-24-2007 |     |
|                          | <b>C209</b>  | WO                      | 2007/059154 | A2 | Bayer Pharmaceuticals Corporation et al.  | 05-24-2007 |     |
|                          | <b>C210</b>  | WO                      | 2007/059155 | A1 | Bayer Pharmaceuticals Corporation et al.  | 05-24-2007 |     |
|                          | <b>C211</b>  | WO                      | 2007/064872 | A2 | Bayer Pharmaceuticals Corporation et al.  | 06-07-2007 |     |
|                          | <b>C212</b>  | WO                      | 2007/087575 | A2 | UNIVERSITY OF CHICAGO et al.              | 08-02-2007 |     |
|                          | <b>C213</b>  | WO                      | 2007/096393 | A1 | NYCOMED GMBH et al.                       | 08-30-2007 |     |
|                          | <b>C214</b>  | WO                      | 2007/096395 | A1 | NYCOMED GMBH et al.                       | 08-30-2007 |     |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |                      |                    |                          |              |
|---|----|----------------------|--------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |                      |                    | <b>Complete if Known</b> |              |
|   |    | Application Number   | 09/993,647         |                          |              |
|   |    | Filing Date          | November 27, 2001  |                          |              |
|   |    | First Named Inventor | Bernd Riedl et al. |                          |              |
|   |    | Group Art Unit       | 1624               |                          |              |
|   |    | Examiner Name        | Deepak R. RAO      |                          |              |
| Sheet   | 20 | of                   | 56                 | Attorney Docket Number   | BAYER-0018-A |

| FOREIGN PATENT DOCUMENTS |                         |    |             |    |  |            |     |
|--------------------------|-------------------------|----|-------------|----|--|------------|-----|
|                          | Foreign Patent Document |    |             |    |  |            |     |
|                          | C215                    | WO | 2007/123722 | A2 | Bayer Pharmaceuticals Corporation et al.     | 11-01-2007 |     |
|                          | C216                    | WO | 2007/139930 | A2 | Bayer Pharmaceuticals Corporation et al.     | 12-06-2007 |     |
|                          | C217                    | WO | 2008/055966 | A1 | ABBOTT GMBH & CO. KG et al.                  | 05-15-2008 |     |
|                          | C218                    | WO | 2008/079968 | A1 | Bayer Pharmaceuticals Corporation et al.     | 07-03-2008 |     |
|                          | C219                    | WO | 2008/079972 | A2 | Bayer Pharmaceuticals Corporation et al.     | 07-03-2008 |     |
|                          | C220                    | WO | 2008/089389 | A2 | Bayer Pharmaceuticals Corporation et al.     | 07-24-2008 |     |
|                          | C221                    | WO | 2009/034308 | A2 | Cipla Limited et al.                         | 03-19-2009 |     |
|                          | C222                    | WO | 2009/054004 | A2 | Natco Pharma Limited et al.                  | 04-30-2009 |     |
|                          | D1                      | EP | 0016371     | A1 | F. Hoffman-La Roche & Co. Aktiengesellschaft | 10-01-1980 | abs |
|                          | D2                      | EP | 0107214     | A2 | Duphar International Research B.V.           | 05-02-1984 |     |
|                          | D3                      | EP | 0116932     | A1 | BASF Aktiengesellschaft                      | 08-29-1984 | abs |
|                          | D3a                     | EP | 0192263     | B1 | Ishihara Sangyo Kaisha Ltd. et al.           | 07-29-1992 |     |
|                          | D4                      | EP | 0192263     | A2 | Ishihara Sangyo Kaisha Ltd. et al.           | 08-27-1986 |     |
|                          | D5                      | EP | 0202538     | A1 | Bayer AG                                     | 11-26-1986 | abs |
|                          | D6                      | EP | 0230400     | A2 | CIBA-GEIGY AG                                | 07-29-1987 | abs |
|                          | D6a                     | EP | 0233559     | A1 | Ishihara Sangyo Kaisha Ltd. et al.           | 08-26-1987 |     |
|                          | D7                      | EP | 0233559     | B1 | Ishihara Sangyo Kaisha Ltd. et al.           | 05-06-1992 |     |
|                          | D8                      | EP | 0242666     | A1 | BASF Aktiengesellschaft                      | 10-28-1987 | abs |
|                          | D9                      | EP | 0264904     | A2 | Ishihara Sangyo Kaisha Ltd. et al.           | 04-27-1988 |     |
|                          | D10                     | EP | 0314615     | A2 | Ciba-Geigy AG                                | 05-03-1989 | abs |
|                          | D11                     | EP | 0335156     | A1 | Bayer AG                                     | 10-04-1989 | abs |
|                          | D12                     | EP | 0359148     | A1 | Ishihara Sangyo Kaisha, Ltd. et al.          | 03-21-1990 |     |
|                          | D13                     | EP | 0371876     | A1 | Novapharme                                   | 06-06-1990 | abs |
|                          | D14                     | EP | 0379915     | A1 | Bayer AG                                     | 08-01-1990 | abs |
|                          | D15                     | EP | 0380048     | A2 | Ishihara Sangyo Kaisha, Ltd.                 | 08-01-1990 |     |
|                          | D16                     | EP | 0381987     | A1 | Ishihara Sangyo Kaisha, Ltd. et al.          | 08-16-1990 |     |
|                          | D17                     | EP | 0405233     | A1 | Mitsubishi Kasei Corporation                 | 01-02-1991 |     |
|                          | D18                     | EP | 0425443     | A1 | Ciba-Geigy AG                                | 05-02-1991 | abs |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box →

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |    |                          |                    |  |
|---|----|----|----|--------------------------|--------------------|--|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    |    | <i>Complete if Known</i> |                    |  |
|   |    |    |    | Application Number       | 09/993,647         |  |
|   |    |    |    | Filing Date              | November 27, 2001  |  |
|   |    |    |    | First Named Inventor     | Bernd Riedl et al. |  |
|   |    |    |    | Group Art Unit           | 1624               |  |
|   |    |    |    | Examiner Name            | Deepak R. RAO      |  |
| Sheet   | 21 | of | 56 | Attorney Docket Number   | BAYER-0018-A       |  |

| FOREIGN PATENT DOCUMENTS |      |                         |           |    |   |            |     |
|--------------------------|------|-------------------------|-----------|----|---|------------|-----|
|                          |      | Foreign Patent Document |           |    |   |            |     |
|                          | D19  | EP                      | 0459887   | A1 | Novapharme  | 12-04-1991 | abs |
|                          | D20  | EP                      | 0502504   | A1 | Matsushita Electric Industrial Co., Ltd.                    | 09-09-1992 |     |
|                          | D21  | EP                      | 0509795   | A2 | American Home Products Corporation                          | 10-21-1992 |     |
|                          | D22  | EP                      | 0676395   | A2 | Hoechst Aktiengesellschaft                                  | 10-11-1995 | abs |
|                          | D23  | EP                      | 0690344   | A1 | Konica Corporation  | 01-03-1996 |     |
|                          | D24  | EP                      | 0709220   | A1 | Canon Kabushiki Kaisha                                      | 05-01-1996 |     |
|                          | D24a | EP                      | 0709225   | A1 | Nippon Paper Industries Co., Ltd.                           | 05-01-1996 |     |
|                          | D25  | EP                      | 0709225   | B1 | Nippon Paper Industries Co., Ltd.                           | 08-05-1998 |     |
|                          | D26  | EP                      | 0860433   | A1 | Kirin Beer Kabushiki Kaisha                                 | 08-26-1998 |     |
|                          | D27  | EP                      | 1056725   | A1 | Bayer Corporation   | 12-06-2000 |     |
|                          | D28  | EP                      | 1199306   | A1 | Banyu Pharmaceutical Co., Ltd.                              | 04-24-2002 |     |
|                          | D29  | EP                      | 1256587   | A1 | The Kitasato Institute                                      | 11-13-2002 |     |
|                          | D30  | EP                      | 1537075   | A0 | Neurosearch A/S et al.                                      | 06-08-2005 |     |
|                          | E1   | CH                      | 479557    |    | Dr. A. Wander AG  | 11-28-1969 | abs |
|                          | F1   | CL                      | 38688     |    | Ciba-Geigy AG   | 06-04-1993 |     |
|                          | G1   | CA                      | 2 146 707 | A1 | Hoechst Aktiengesellschaft                                  | 10-12-1995 |     |
|                          | G2   | CA                      | 2,028,536 | A1 | Ciba-Geigy AG   | 04-28-1991 |     |
|                          | H1   | DD                      | 253997    | A1 | Karl-Marx-Universität, Büro Für Neuerungen und Schutzrechte | 02-10-1988 | abs |
|                          | I1   | DE                      | 487014    | C1 | I.G. Farbenindustrie Akt.-Ges.                              | 11-14-1929 |     |
|                          | I2   | DE                      | 511468    | C1 | I.G. Farbenindustrie Akt.-Ges.                              | 10-16-1930 | abs |
|                          | I3   | DE                      | 523437    | C1 | I.G. Farbenindustrie Akt.-Ges.                              | 04-02-1931 |     |
|                          | I4   | DE                      | 2436179   | C2 | Shionogi & Co. Ltd.   | 04-10-1986 | abs |
|                          | I5   | DT                      | 2501648   | A1 | The Dow Chemical Co.  | 07-24-1975 | abs |
|                          | I6   | DT                      | 2436179   | A1 | Shionogi & Co., Ltd.  | 02-06-1975 | abs |
|                          | I7   | DE                      | 3305866   | A1 | BASF AG   | 08-23-1984 | abs |
|                          | I8   | DE                      | 3529247   | A1 | Bayer AG  | 11-20-1986 | abs |
|                          | I9   | DE                      | 3540377   | A1 | Bayer AG  | 05-21-1987 | abs |
|                          | J1   | FR                      | 1.457.172 | A  | Ferrania S.p.A.   | 09-19-1966 | abs |
|                          | K1   | GB                      | 771,333   |    | J.R. Geigy A.-G.  | 03-27-1957 |     |
|                          | K2   | GB                      | 828,231   |    | J.R. Geigy A.-G.  | 02-17-1960 |     |
|                          | K3   | GB                      | 921,682   |    | J.R. Geigy A.-G.  | 03-20-1963 |     |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |                      |                    |                          |              |
|---|----|----------------------|--------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |                      |                    | <b>Complete if Known</b> |              |
|   |    | Application Number   | 09/993,647         |                          |              |
|   |    | Filing Date          | November 27, 2001  |                          |              |
|   |    | First Named Inventor | Bernd Riedl et al. |                          |              |
|   |    | Group Art Unit       | 1624               |                          |              |
|   |    | Examiner Name        | Deepak R. RAO      |                          |              |
| Sheet   | 22 | of                   | 56                 | Attorney Docket Number   | BAYER-0018-A |

| FOREIGN PATENT DOCUMENTS |                      |                         |                  |    |  |            |                |
|--------------------------|----------------------|-------------------------|------------------|----|--|------------|----------------|
|                          |                      | Foreign Patent Document |                  |    |  |            |                |
|                          | <b>K4</b>            | GB                      | 1,110,099        |    | Rhone- Poulenc S.A.                            | 04-18-1968 |                |
|                          | <b>K4a</b>           | GB                      | 1,111,554        |    | Societa Per Azioni Ferrania                    | 05-01-1968 |                |
|                          | <b>K5</b>            | GB                      | 1 590 870        |    | Shionogi Seiyaku Kabushiki Kaisha.             | 06-10-1981 |                |
|                          | <b>L1</b>            | HU                      | P0004437         |    | Bayer Corporation                              | 06-28-2001 | abs            |
|                          | <del><b>M1</b></del> | <del>JP</del>           | <del>26555</del> |    | <del>Bayer Corporation</del>                   |            | <del>abs</del> |
|                          | <b>N1</b>            | JP                      | 44-2569          | B  | Sankyo Co., Ltd. and Asahi Chem. Ind. Co., Ltd | 02-03-1969 | abs            |
|                          | <b>N2</b>            | JP                      | 50-76072         | A  | Shionogi Seiyaku KK                            | 06-21-1975 | abs            |
|                          | <b>N3</b>            | JP                      | 50-77375         | A  | Shionogi Seiyaku KK                            | 06-24-1975 | abs            |
|                          | <b>N4</b>            | JP                      | 50-149668        | A  | unknown  | 11-29-1975 | abs            |
|                          | <b>N5</b>            | JP                      | 51-63170         | A  | Shionogi Shinzaburo                            | 06-01-1976 | abs            |
|                          | <b>N6</b>            | JP                      | 51-80862         | A  | Shionogi Seiyaku KK                            | 07-15-1976 | abs            |
|                          | <b>N7</b>            | JP                      | 53-86033         | A  | Shionogi Co. Ltd.                              | 07-29-1978 | abs            |
|                          | <b>N8</b>            | JP                      | 54-32468         | A  | Otsuka Pharmaceutical Co. Ltd.                 | 09-03-1979 | abs            |
|                          | <b>N9</b>            | JP                      | 55-98152         | A  | HOKKO CHEM. IND. CO.                           | 07-25-1980 | abs            |
|                          | <b>N10</b>           | JP                      | 55-124763        | A  | Ishihara Mining & Chemical Co.                 | 09-26-1980 | abs            |
|                          | <b>N11</b>           | JP                      | 55-162772        | A  | Shionogi & Co. Ltd.                            | 12-18-1980 | abs            |
|                          | <b>N13</b>           | JP                      | 57-53785         | B2 | Shionogi Seiyaku KK                            | 11-15-1982 | abs            |
|                          | <b>N14</b>           | JP                      | 58-21626         | B2 | Shionogi Seiyaku KK                            | 05-02-1983 | abs            |
|                          | <b>N16</b>           | JP                      | 61-20039         | A  | Konishiroku Photo Ind. Co., Ltd.               | 01-28-1986 | abs            |
|                          | <b>N15</b>           | JP                      | 63-214752        | A  | Fuji Photo Film Co. Ltd.                       | 09-07-1988 | abs            |
|                          | <b>N17</b>           | JP                      | 64-9455          | A  | Fuji Photo Film Co., Ltd.                      | 01-12-1989 | abs            |
|                          | <b>N18</b>           | JP                      | 1-102461         | A  | Konica Corp.                                   | 04-20-1989 | abs            |
|                          | <b>N19</b>           | JP                      | 1-132580         | A  | Ciba Geigy AG                                  | 05-25-1989 | abs            |
|                          | <b>N20</b>           | JP                      | 1-200254         | A  | Konica Corp.                                   | 08-11-1989 | abs            |
|                          | <b>N21</b>           | JP                      | 1-259360         | A  | Konica Corp.                                   | 10-17-1989 | abs            |
|                          | <b>N22</b>           | JP                      | 2-22650          | A  | Konica Corp.                                   | 01-25-1990 | abs            |
|                          | <b>N23</b>           | JP                      | 2-23337          | A  | Konica Corp.                                   | 01-25-1990 | abs            |
|                          | <b>N24</b>           | JP                      | 2-35450          | A  | Konica Corp.                                   | 02-06-1990 | abs            |
|                          | <b>N25</b>           | JP                      | 2-105146         | A  | Konica Corp.                                   | 04-17-1990 | abs            |
|                          | <b>N26</b>           | JP                      | 2-108048         | A  | Konica Corp.                                   | 04-19-1990 | abs            |
|                          | <b>N27</b>           | JP                      | 2-150840         | A  | Konica Corp.                                   | 06-11-1990 | abs            |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

<sup>1</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Unique citation designation number. <sup>3</sup> See attached Kinds of U.S. Patent Documents. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |                    |    |                          |  |
|--|----|--------------------|----|--------------------------|--|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |    |                    |    | <b>Complete if Known</b> |  |
| Application Number   |    | 09/993,647         |    |                          |  |
| Filing Date  |    | November 27, 2001  |    |                          |  |
| First Named Inventor   |    | Bernd Riedl et al. |    |                          |  |
| Group Art Unit   |    | 1624               |    |                          |  |
| Examiner Name  |    | Deepak R. RAO      |    |                          |  |
| Attorney Docket Number   |    | BAYER-0018-A       |    |                          |  |
| Sheet  | 23 | of                 | 56 |                          |  |

| FOREIGN PATENT DOCUMENTS |               |                         |                 |    |                              |                    |     |
|--------------------------|---------------|-------------------------|-----------------|----|------------------------------|--------------------|-----|
|                          |               | Foreign Patent Document |                 |    |                              |                    |     |
|                          | N28           | JP                      | 3-53247         | A  | Fuji Photo Film Co. Ltd.     | 03-07-1991         | abs |
|                          | N29           | JP                      | 3-144634        | A  | Konica Corp.                 | 06-20-1991         | abs |
|                          | N30           | JP                      | 3-198049        | A  | Fuji Photo Film Co. Ltd.     | 08-29-1991         | abs |
|                          | N31           | JP                      | 6-75172         | B2 | Fuji Photo Film Co. Ltd.     | 09-21-1994         | abs |
|                          | N32           | JP                      | 8-301841        | A  | Green Cross Corp. et al.     | 11-19-1996         | abs |
|                          | N33           | JP                      | 10-306078       | A  | Mitsubishi Chemical Corp.    | 11-17-1998         | abs |
|                          | <del>Q1</del> | <del>LB</del>           | <del>6124</del> |    | <del>Bayer Corporation</del> | <del>Unknown</del> |     |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>6</sup> |
|  | P1                    | Adjei et al., "A Phase I study of BAY 43-9006 and gefitinib in patients with refractory or recurrent non-small-cell lung cancer (NSCLC)," Abstract #3067, Meeting: 2005 ASCO Annual Meeting, Category: Developmental Therapeutics: Molecular Therapeutics, Subcategory: Antiangiogenic or Antimetastatic agents |                |
|  | P2                    | Ahmad et al., "Kinase Inhibition with BAY 43-9006 in Renal Cell Carcinoma," <i>Clinical Cancer Research</i> , September 15, 2004, Vol. 10(suppl.), pp. 6388s-6392s  |                |
|  | P3                    | Amornphimoltham et al., "Persistent Activation of the Akt Pathway in Head and Neck Squamous Cell Carcinoma: A Potential Target for UCN-01," <i>Clinical Cancer Research</i> , Vol. 10, June 15, 2004, pp. 4029-4037   |                |
|  | P3a                   | Arzneimitteltherapie, "Sorafenib" October 6, 2006, Auflage 18498, 7 pages   |                |
|  | P4                    | Arnone et al., "Selectivities in the Oxidation of Tertiary Amines and Pyridine Derivatives by Perfluoro <i>Cis</i> -2,3-dialkylloxaziridines," <i>Tetrahedron</i> , Vol. 54, 1998, pp. 7831-7842  |                |
|  | P4a                   | Arora et al., "Stromelysin 3, Ets-1, and Vascular Endothelial Growth Factor Expression in Oral Precancerous and Cancerous Lesions: Correlation with Microvessel Density, Progression, and Prognosis," <i>Clinical Cancer Research</i> , 11: 2272-2284 (March 15, 2005)  |                |
|  | P4b                   | Ascierto et al., "Prognostic Value of Serum VEGF in Melanoma Patients: a Pilot Study" <i>Anticancer Research</i> , 24: 4255-4258 (2004)   |                |
|  | P5                    | Auclair et al., "BAY 43-9006 (Sorafenib) is a potent inhibitor of FLT3 tyrosine kinase signaling and proliferation in AML cells," Abstract #5991, 96 <sup>th</sup> Annual Meeting, Anaheim/Orange County, CA, April 16-20, 2005   |                |
|  | P6                    | Audia et al., "Potent, Selective Tetrahydro- $\beta$ -carboline Antagonists of the Serotonin 2B (5HT <sub>2B</sub> ) Contractile Receptor in the Rat Stomach Fundus," <i>J. Med. Chem.</i> 1996, 39, pp. 2773-2780  |                |
|  | P7                    | Avruch et al., "Raf meets Ras: completing the framework of a signal transduction pathway," <i>TIBS</i> 19; July 1994; pp. 279-283   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |              |
|---|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |              |
|   |    |    | Application Number       | 09/993,647             |              |
|   |    |    | Filing Date              | November 27, 2001      |              |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |    |    | Group Art Unit           | 1624                   |              |
|   |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 24 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.           | † <sup>6</sup> |
|  | P8                    | Awada et al., "Phase I safety and pharmacokinetics of BAY 43-9006 administered for 21 days on/7 days off in patients with advanced, refractory solid tumours" British Journal of Cancer 92, pp.1855-1861 (2005).  |                |
|  | P8a                   | Bachelot et al., "Prognostic value of serum levels of interleukin 6 and of serum and plasma levels of vascular endothelial growth factor in hormone-refractory metastatic breast cancer patients," British Journal of Cancer, 88: 1721-1726 (2003)                        |                |
|  | P9                    | Badger et al., "Pharmacological Profile of SB 203580, a Selective Inhibitor of Cytokine Suppressive Binding Protein/p38 Kinase, in Animal Models of Arthritis, Bone Resorption, Endotoxin Shock and Immune Function," JPET 279: pp. 1453-1461 (1996)                      |                |
|  | P9a                   | Baka et al., "A review of the latest clinical compounds to inhibit VEGF in pathological angiogenesis," Expert Opinion Therapeutic Targets, 2006, Vol. 10, No.6, pp. 867-876   |                |
|  | P10                   | Balant et al., "Metabolic Considerations in Prodrug Design," Chapter Twenty-Three In: Burger's Medicinal Chemistry and Drug Discovery, 5 <sup>th</sup> ed. John Wiley & Sons, Inc., New York, 1995: Vol. 1, pp. 949-982   |                |
|  | P11                   | Bando et al., "Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer" British Journal of Cancer, 2005, Vol. 92, pp. 553-561   |                |
|  | P12                   | Banerjee et al., "Murine Coronavirus Replication-Induced p38 Mitogen-Activated Protein Kinase Activation Promotes Interleukin-6 Production and Virus Replication in Cultured Cells," Journal of Virology. American Society for Microbiology, 2002: Vol. 76, pp. 5937-5948 |                |
|  | P13                   | Bankston et al., "A Scalable Synthesis of BAY 43-9006: A Potent Raf Kinase Inhibitor for the Treatment of Cancer," Organic Process Research & Development, 2002, Vol. 6, pp. 777-781  |                |
|  | P14                   | Barnett et al., "Identification and characterization of pleckstrin-homology-domain-dependent and isoenzyme-specific Akt inhibitors," Biochem J., Vol. 385, 2005, pp. 399-408  |                |
|  | P14a                  | Baumann et al., "Raf induces NF-κB by membrane shuttle kinase MEKK1, a signaling pathway critical for transformation," Proc. Natl. Acad. Sci. USA, Vol. 97: No. 9: 4615-4620 (April 25, 2000)   |                |
|  | P15                   | Bayer Corporation et al., "Trial of BAY 43-9006 in Patients with Relapsed or Refractory Advanced Non-Small Cell Lung Carcinoma", NCT0010413, clinicaltrials.gov, 3 pages  |                |
|  | P16                   | Bellacosa et al., "Molecular Alterations Of The AKT2 Oncogene In Ovarian And Breast Carcinomas," Int. J. Cancer (Pred. Oncol.), Vol. 64, 1995, pp. 280-285  |                |
|  | P17                   | Berge et al., "Pharmaceutical Salts." Journal of Pharmaceutical Sciences. January 1977:1-19, Vol. 66, No. 1   |                |
|  | P18                   | Bergstrahl et al., "Microtubule stabilizing agents: Their molecular signaling consequences and the potential for enhancement by drug combination," Cancer Treatment Reviews, 2006, Vol. 32, pp. 166-179   |                |
|  | P19                   | Bertrand et al., "Inhibition of PI3K, mTOR and MEK signaling pathways promotes rapid apoptosis in B-Lineage ALL in the presence of stromal cell support", Leukemia, Vol. 19, pp. 98-102 (published online October 21, 2004)   |                |
|  | P20                   | Bhagwat et al., "The angiogenic regulator CD13/APN is a transcriptional target of Ras signaling pathways in endothelial morphogenesis," Blood, Vol. 101, No. 5, pp. 1818-1826, (March 1, 2003)  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |                          |                    |
|--|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    | Application Number       | 09/993,647         |
|  |    | Filing Date              | November 27, 2001  |
|  |    | First Named Inventor     | Bernd Riedl et al. |
|  |    | Group Art Unit           | 1624               |
|  |    | Examiner Name            | Deepak R. RAO      |
|  |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 25 | of                       | 56                 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | † <sup>6</sup> |
|  | P21                   | Bianchi et al., "A Phase II multi-center uncontrolled trial of sorafenib (BAY 43-9006) in patients with metastatic breast cancer" Journal of Clinical Oncology, Draft 33 pages (presented previously Oct. 30-Nov. 3, 2005).                                     |                |
|  | P22                   | Martín-Blanco, "p38 MAPK signalling cascades: ancient roles and new functions," BioEssays, 22:637-645, 2000   |                |
|  | P23                   | Foussard-Blanpin, Odette, "Comparative pharmacological study of substituted carboxamides upon central nervous system," Ann. Pharm. Fr. (1982), 40 (4), pp. 339-350  | abs            |
|  | P24                   | Board et al., "Platelet-derived growth factor receptor (PDGFR): A target for anticancer therapeutics," Drug Resistance Updates 8 (2005) 75-83.  |                |
|  | P24a                  | Bok et al., "Vascular Endothelial Growth Factor and Basic Fibroblast Growth Factor Urine Levels as Predictors of Outcome in Hormone-refractory Prostate Cancer Patients: A Cancer and Leukemia Group B Study," Cancer Research, 61: 2533-2536 (March 15, 2001)  |                |
|  | P25                   | Bollag et al., "Raf pathway inhibitors in oncology," Current Opinion in Investigational Drugs (2003) 4(12): pp. 1436-1441.  |                |
|  | P26                   | Bolton et al., "Chapter 17. Ras Oncogene Directed Approaches in Cancer Chemotherapy," Annual Reports In Medicinal Chemistry, Vol. 29, 1994, pp. 165-174   |                |
|  | P26a                  | Bono et al., "Serum KIT and KIT ligand levels in patients with gastrointestinal stromal tumors treated with imatinib," Blood 103:2929-2935 (2004)   |                |
|  | P27                   | Bos, J.L. "ras Oncogenes in Human Cancer: A Review," Cancer Research, Vol. 49, September 1, 1989, pp. 4682-4689   |                |
|  | P28                   | Boulton et al., "Heterocyclic Rearrangements. Part X. A Generalised Monocyclic Rearrangement," J. Chem. Soc. (C), 1967, pp. 2005-2007   |                |
|  | P28a                  | Boyer, S.J., "Small Molecule Inhibitors of KDR (VEGFR-2) Kinase: An Overview of Structure Activity Relationships," Current Topics in Medicinal Chemistry, 2002, Vol. 2, pp. 973-1000  |                |
|  | P29                   | Boyd, et al. "Arene Oxides Of Quinoline: Epoxidation, N-Oxidation And N-Methylation Reactions," J. Chem. Soc. Perkin Trans. 1, 1991: pp. 2189-2192  |                |
|  | P29a                  | Braybrooke et al., "A Phase II Study of Razoxane, an Antiangiogenic Topoisomerase II Inhibitor, in Renal Cell Cancer with Assessment of Potential Surrogate Markers of Angiogenesis," Clin. Canc. Res. 6:4697-4704 (2000)                                       |                |
|  | P29b                  | Broil et al., "Vascular endothelial growth factor (VEGF) – a valuable serum tumour marker in patients with colorectal cancer?" Eur. J. Surg. Oncol. 27:37-42 (2001)   |                |
|  | P30                   | Bruder et al., "Adenovirus Infection Stimulates The Raf/MAPK Signaling Pathway and Induces Interleukin-8 Expression" Journal of Virology, Vol. 71, pp. 398-404, 1997  |                |
|  | P31                   | Bundgaard, Hans. "Design of prodrugs: Bioreversible derivatives for various functional groups and chemical entities." pp. 1-92, in Design of Prodrugs, Elsevier Science Publishers B.V., Amsterdam, The Netherlands, 1985                                       |                |
|  | P32                   | Campbell et al., "Increasing complexity of Ras signaling," Oncogene, 1998, Vol. 17, pp. 1395-1413   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |              |
|---|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |              |
|   |    |    | Application Number       | 09/993,647             |              |
|   |    |    | Filing Date              | November 27, 2001      |              |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |    |    | Group Art Unit           | 1624                   |              |
|   |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 26 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                                 | T <sup>6</sup> |
|  | P33                   | Cancer Weekly, "Antisense Technology (Clinical Trial). Phase II Trial of Second Antisense Cancer Drug Begins," Cancer Weekly, p. 4 (December 8, 1997).  |                |
|  | P34                   | Canetta et al., "Carboplatin: current status and future prospects," Cancer Treatment Reviews, 1998, pp. 17-32, vol. 15(Supplement B)  |                |
|  | P34a                  | Caponigro et al., "Epidermal growth factor receptor as a major anticancer drug target," Exp. Opin. Thera. Targets, 2006, Vol. 10, No. 6, pp. 877-888  |                |
|  | P35                   | Carey et al., "Contents of Part A," pp. vii-xi and "Contents of Part B," pp. xiii-xviii, in Advanced Organic Chemistry, Second Edition, Part A: Structure and Mechanisms, Plenum Press, NY (1984)   |                |
|  | P36                   | Carling et al., "1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one: A Selective High-Affinity Antagonist for the Human Dopamine D <sub>4</sub> Receptor with Excellent Selectivity over Ion Channels," J. Med. Chem., 1999, 42, pp. 2706-2715                         |                |
|  | P37                   | Carlomagno et al., "BAY 43-9006 Inhibition of Oncogenic RET Mutants," Journal of the National Cancer Institute, 2006, Vol. 98, No. 5, pp. 326-334   |                |
|  | P37a                  | Carney et al., "Monitoring the Circulating Levels of the HER2/ <i>neu</i> Oncoprotein in Breast Cancer," Clin Breast Cancer 5(2): 105-116, (2004)   |                |
|  | P38                   | Carter et al., "Anti-Tumor Efficacy of the Orally Active <i>Raf</i> Kinase Inhibitor BAY 43-9006 in Human Tumor Xenograft Models," Proceedings of the American Association for Cancer Res., Vol. 42: p. 923, March 2001, Abstract #4954   |                |
|  | P39                   | Carter et al., "Drug-Tumor Interactions" pp. 362-365, in: Chemotherapy of Cancer, Second Edition, John Wiley & Sons, NY (1981)  |                |
|  | P40                   | Carter et al., "Sorafenib is efficacious and tolerated in combination with cytotoxic or cytostatic agents in preclinical models of human non-small cell lung carcinoma," Cancer Chemotherapy and Pharmacology, Springer Berlin/Heidelberg, Vol.59, No.2, pp. 183-195 (February 2007). Abstract. |                |
|  | P41                   | Chang et al., "BAY 43-9006 (Sorafenib) inhibits ectopic (s.c.) and orthotopic growth of a murine model of renal adenocarcinoma (Renca) predominantly through inhibition of tumor angiogenesis," 96 <sup>th</sup> Annual Meeting, Anaheim/Orange County, CA, April 16-20, 2005, 1 page.          |                |
|  | P42                   | Chang et al., "Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models," Cancer Chemother. Pharmacol., 2007, Vol. 59, pp. 561-574   |                |
|  | P43                   | Chen et al., "Role of Regulatory Elements and the MAPK/ERK OR p38 MAPK Pathways for Activation of Human Cytomegalovirus Gene Expression," Journal of Virology, 2002: Vol. 76, No. 10, pp. 4873-4885   |                |
|  | P44                   | Chen et al., "Suppression of Japanese encephalitis virus infection by non-steroidal, anti-inflammatory drugs," Journal of General Virology, 2002, Vol. 83, pp. 1897-1905  |                |
|  | P44a                  | Chen et al., "Expression of Proinflammatory and Proangiogenic Cytokines in Patients with Head and Neck Cancer," Clinical Cancer Research 5:1369-1379 (June 1999)  |                |
|  | P45                   | Chialda et al., "Inhibitors of mitogen-activated protein kinases differentially regulate costimulated T cell cytokine production and mouse airway eosinophilia," Respiratory Research 2005, 6:36, pp.1-19   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |    |                          |                    |
|--|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | Application Number       | 09/993,647         |
|  |    |    | Filing Date              | November 27, 2001  |
|  |    |    | First Named Inventor     | Bernd Riedl et al. |
|  |    |    | Group Art Unit           | 1624               |
|  |    |    | Examiner Name            | Deepak R. RAO      |
|  |    |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 27 | of | 56                       |                    |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                       | T <sup>6</sup> |
|  | P45a                  | Chin et al., "Vascular endothelial growth factor and soluble Tie-2 receptor in colorectal cancer: associations with disease recurrence," <i>European Journal of Surgical Oncology</i> , 29:497-505 (2003)   |                |
|  | P46                   | Choi et al., "Imatinib-Resistant Cell Lines Are Sensitive to the Raf Inhibitor BAY 43-9006," <i>Blood</i> , W.E.B. Saunders Company, Orlando, FL, US, Vol. 100, No. 11, Abstract # 1427 (December 10, 2002)   |                |
|  | P46a                  | Choong et al., "Forthcoming receptor tyrosine kinase inhibitors," <i>Exp. Opin. Ther. Targets</i> , 2006, Vol. 10, No. 6, pp. 793-797   |                |
|  | P47                   | Chow et al., "Measurement of MAP Kinase Activation by Flow Cytometry Using Phospho-Specific Antibodies to MEK and ERK: Potential for Pharmacodynamic Monitoring of Signal Transduction Inhibitors," <i>Cytometry (Communications in Clinical Cytometry)</i> 46:72-78 (2001)           |                |
|  | P47a                  | Christensen, et al., "Plasma vascular endothelial growth factor and interleukin-8 as biomarkers of antitumor efficacy of a prototypical erbB family tyrosine kinase inhibitor," <i>Mol. Cancer Ther.</i> , 4(6):938-947 (June 2005)   |                |
|  | P47b                  | Chu et al., "Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib," <i>Lancet</i> , 2007, Vol. 370, pp.2011-2019  |                |
|  | P48                   | Chustecka et al., "Bortezomib and Sorafenib Show Activity in Thyroid Cancer," <i>Medscape</i> , 2 pages (November 2, 2006)  |                |
|  | P49                   | Clark et al., "Safety and Pharmacokinetics of the Dual Action Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor, BAY 43-9006, in Patients with Advanced, Refractory Solid Tumors," <i>Clinical Cancer Res.</i> , August 1, 2005, Vol. 11, Number 15, pp. 5472-5480 |                |
|  | P49a                  | Garbe, "Auch ein Therapieplatz für Sorafenib?" <i>Medical Special</i> (2006) 2 pages  |                |
|  | P50                   | Copéret et al., "A Simple And Efficient Method for the Preparation of Pyridine-N-oxides II," <i>Tetrahedron Letters</i> , Elsevier Science Ltd., Pergamon Press, Oxford, UK 1998: Vol. 39, pp. 761-764  |                |
|  | P51                   | Cortes et al., "Targeting the Microtubules in Breast Cancer Beyond Taxanes: The Epothilones," <i>The Oncologist</i> , 2007, Vol. 12, pp. 271-280  |                |
|  | P52                   | Craig, "The mechanisms of drug release from solid dispersions in water-soluble polymers." <i>International Journal of Pharmaceutics</i> 231 (2002) 131-144, Elsevier Science B.V.   |                |
|  | P53                   | Le Cras et al., "Treatment of newborn rats with a VEGF receptor inhibitor causes pulmonary hypertension and abnormal lung structure." <i>Am. J. Physiol. Lung. Cell. Mol. Physiol.</i> Vol. 283, pp. L555-L562, 2002.   |                |
|  | P53a                  | Crump, Micheal, "Inhibition of raf kinase in the treatment of acute myeloid leukemia," <i>Medline Abstract</i> ISSN:1381-6128, <i>Current Pharmaceutical Design</i> , Vol. 8, Issue 25, 2002, pp. 2243-2248   |                |
|  | P54                   | Cunningham et al., "A Phase I Trial of H-ras Antisense Oligonucleotide ISIS 2503 Administered as a Continuous Intravenous Infusion in Patients with Advanced Carcinoma," <i>Cancer</i> , 2001, American Cancer Society, Vol. 92, Number 5, pp. 1265-1271                              |                |
|  | P55                   | Danson et al., "Improving Outcomes in Advanced Malignant Melanoma. Update on Systemic Therapy," <i>Drugs</i> , 2005, Vol. 65, Number 6, pp. 733-743   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |                      |                    |                          |                        |
|---|----------------------|--------------------|--------------------------|------------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |                      |                    | <b>Complete if Known</b> |                        |
|   | Application Number   | 09/993,647         |                          |                        |
|   | Filing Date          | November 27, 2001  |                          |                        |
|   | First Named Inventor | Bernd Riedl et al. |                          |                        |
|   | Group Art Unit       | 1624               |                          |                        |
|   | Examiner Name        | Deepak R. RAO      |                          |                        |
| Sheet   | 28                   | of                 | 56                       | Attorney Docket Number |
|   |                      |                    |                          | BAYER-0018-A           |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | † <sup>6</sup> |
|  | P56                   | Dasmahapatra et al., "In vitro Combination Treatment with Perifosine and UCN-01 Demonstrates Synergism against Prostate (PC-3) and Lung (A549) Epithelial Adenocarcinoma Cell Lines," <i>Clinical Cancer Research</i> , Vol. 10, August 1, 2004, pp. 5242-5252.   |                |
|  | P57                   | Daum et al., "The ins and outs of Raf kinases," <i>TIBS</i> 19, November 1994, pp. 474-480  |                |
|  | P58                   | Dayan et al., "Tertiary Amine Oxidation using HOF-CH <sub>3</sub> CN: A Novel Synthesis of N-Oxides," <i>Synthesis</i> , 1999, No. SI, pp. 1427-1430  |                |
|  | P59                   | DeGrendele, "Activity of the Raf Kinase Inhibitor BAY 43-9006 in Patients with Advanced Solid Tumors," <i>Clinical Colorectal Cancer</i> , May 2003, Vol. 3, pp. 16-18  |                |
|  | P59a                  | Dehtling, J. "Große Onkologie-Pipeline" <i>Medizinische Monatsschrift für Pharmazeuten</i> , 2006, Auflage 12914, 2 pages   |                |
|  | P60                   | Denny, "Prodrug strategies in cancer therapy," <i>European Journal Of Medicinal Chemistry</i> , 2001: Vol. 36, pp. 577-595  |                |
|  | P60a                  | DeVita et al., "Elevated Perioperative Serum Vascular Endothelial Growth Factor Levels in Patients with Colon Carcinoma," <i>Cancer</i> , 100 (2) pp. 270-278 (2004)  |                |
|  | P61                   | Devlin et al., "GATT and DISCOVERY: Significant Changes in U.S. Patent Law" <i>Screening Forum</i> , Vol. 3, No. 4, pp. 1, 3 and 6 (December 1995).   |                |
|  | P62                   | Doanes et al., "VEGF Stimulates MAPK through a Pathway That Is Unique for Receptor Tyrosine Kinases," <i>Biochem Biophys. Res. Commun.</i> 255: pp. 545-548, 1999.  |                |
|  | P63                   | Dörwald, "Preface," p. IX, in <i>Side Reactions in Organic Synthesis: A Guide to Successful Synthesis Design</i> , Wiley-VCH Verlag GmbH & Co. KGaA (2005)  |                |
|  | P64                   | Downward, J., "Mechanisms and consequence of activation of protein kinase B/Akt," <i>Current Opinion in Cell Biology</i> , Vol. 10, 1998, pp. 262-267.  |                |
|  | P64a                  | Dreys et al., "Soluble markers for the assessment of biological activity with PTK787/ZK 222584 (PTK/ZK), a vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor in patients with advanced colorectal cancer from two phase I trials," <i>Annals of Oncology</i> , 16: 558-565 (2005) |                |
|  | P64b                  | Dreys, J., "Soluble Markers for the Detection of Hypoxia under Antiangiogenic Treatment," <i>Anticancer Research</i> , 23: 1159-1162 (2003)   |                |
|  | P64c                  | Dreys, J., <i>Die Medizinische Welt</i> , 2006, pp. 3/5, 4/5, 5/5   |                |
|  | P65                   | "Doxorubicin HCl (ADR)," in <i>drugs: facts and comparisons</i> , 1994 Ed., pp. 2703-2705   |                |
|  | P65a                  | Dudek et al., "Circulating Angiogenic Cytokines in Patients with Advanced Non-Small Cell Lung Cancer: Correlation with Treatment Response and Survival," <i>Cancer Investigation</i> , 23: 193-200 (2005)   |                |
|  | P66                   | Dumas, J. "Protein kinase inhibitors from the urea class," <i>Curr. Opin. in Drug Discovery and Dev.</i> , 5(s):718-727, 2002   |                |
|  | P67                   | Dumas et al., "Discovery of a New Class of p38 Kinase Inhibitors," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> Vol. 10, (2000), pp. 2047-2050   |                |
|  | P68                   | Dumas et al., "1-Phenyl-5-pyrazolyl Ureas: Potent and Selective p38 Kinase Inhibitors," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 2000, Vol. 10, pp. 2051-2054  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |              |
|---|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |              |
|   |    |    | Application Number       | 09/993,647             |              |
|   |    |    | Filing Date              | November 27, 2001      |              |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |    |    | Group Art Unit           | 1624                   |              |
|   |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 29 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|--|-----------------------|--|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.          | T <sup>6</sup> |
|  | P68a                  | Dumas, J., "Growth factor receptor kinase inhibitors: Recent progress and clinical impact," <i>Current Opinion in Drug Discovery &amp; Development</i> , 2001, Vol. 4, No. 4, pp. 378-389  |                |
|  | P68b                  | Dumas, J., "Protein kinase inhibitors: emerging pharmacophores 1997-2000," <i>Expert Opinion on Therapeutic Patents</i> (2001) Vol. 11, No. 3, pp. 405-429   |                |
|  | P68c                  | Dumas et al., "Orally Active p38 Kinase Inhibitors from the Urea Class," Poster, 222nd American Cancer Society National Meeting 2001, Med I 256, 1 page  |                |
|  | P68d                  | Dumas, J., "Raf Kinase Inhibitors," <i>Expert Opinion on Therapeutic Patients</i> , Vol. 8, No. 12, pp. 1749-1750, 1998  |                |
|  | P69                   | Dumas et al., "Recent developments in the discovery of protein kinase inhibitors from the urea class," <i>Current Opinion in Drug Discovery &amp; Development</i> , 2004, Vol. 7, Number 5, pp. 600-616  |                |
|  | P70                   | Dumas et al., "Synthesis and Pharmacological Characterization of a Potent, Orally Active p38 Kinase Inhibitor," <i>Bioorganic &amp; Medicinal Chemistry Letters</i> , 2002, Vol. 12, pp. 1559-1562   |                |
|  | P70a                  | Dunst et al., "Tumor Hypoxia and Systemic Levels of Vascular Endothelial Growth Factor (VEGF) in Head and Neck Cancers," <i>Strahlentherapie und Onkologie</i> , 177(9): 469-473 (2001)  |                |
|  | P71                   | Ebos et al., "Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlated with antitumor efficacy" <i>PNAS</i> Vol. 104, No. 43, pp. 17069-17074 (October 23, 2007)  |                |
|  | P71a                  | Ebrahimi et al., "Cytokines in Pancreatic Carcinoma. Correlation with Phenotypic Characteristics and Prognosis," <i>Cancer</i> , 101(12): 2727-2736 (Published on-line Nov 3, 2004)  |                |
|  | P72                   | Eisen et al., "Phase I trial of BAY 43-9006 (Sorafenib) combined with dacarbazine (DTIC) in metastatic melanoma patients." Abstract #7508, Meeting: 2005 ASCO Annual Meeting, Category: Melanoma, Subcategory: Melanoma  |                |
|  | P73                   | Eisen et al., "Sorafenib in advanced melanoma: a Phase II randomised discontinuation trial analysis" <i>British Journal of Cancer</i> 95, 581-586 (2006)   |                |
|  | P74                   | Eisenhauer et al., "Impact of new non-cytotoxics in the treatment in ovarian cancer," <i>International J. Gynecol. Cancer</i> , 2001, Vol. 11, Supplement 1, pp. 68-72   |                |
|  | P75                   | El-Deiry, Wafik S., "Meeting Report: The International Conference on Tumor Progression and Therapeutic Resistance", <i>Cancer Research</i> , 2005; Vol. 65, No. 11, pp. 4475-4484  |                |
|  | P76                   | Elting et al., "Biomarkers associated with clinical outcomes in TARGETs, a Phase III single-agent, placebo-controlled study of sorafenib in advanced renal cell carcinoma," <i>Proc. Amer. Assoc. Cancer Res.</i> Vol. 47, Abstract # 2909, 2006, pp. 683-684            |                |
|  | P77                   | Escudier et al., "Randomized Phase III trial of the Raf kinase and VEGFR inhibitor sorafenib (BAY 43-9006) in patients with advanced renal cell carcinoma (RCC)," Meeting: 2005 ASCO Annual Meeting, Category: Genitourinary Cancer, Subcategory: Kidney Cancer, 1 page. |                |
|  | P78                   | Escudier et al., "Sorafenib in Advanced Clear-Cell Renal-Cell Carcinoma" <i>New England Journal of Medicine</i> Vol. 356: 125-134 (January 11, 2007).  |                |
|  | P79                   | European Medicines Agency, "CHMP Assessment Report for Nexavar" Doc Ref: EMEA/CHMP/140610/2006, 63 pages.  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |              |
|---|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |              |
|   |    |    | Application Number       | 09/993,647             |              |
|   |    |    | Filing Date              | November 27, 2001      |              |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |    |    | Group Art Unit           | 1624                   |              |
|   |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 30 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|--|-----------------------|--|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | T <sup>6</sup> |
|  | P79a                  | Fabian et al., "A small molecule-kinase interaction map for clinical kinase inhibitors," Nature Biotechnology, 2005, Vol. 23, No. 3, pp 329-336, 4 supplementary pages   |                |
|  | P79b                  | Faderl et al., "Angiogenic factors may have a different prognostic role in adult acute lymphoblastic leukemia," Blood, 2005 Vol. 106 No. 13, pp. 4303-4307   |                |
|  | P80                   | Faivre et al., "Molecular basis for sunitinib efficacy and future clinical development" Nature Reviews Drug Discovery, Nature Publishing Group, pp. 734-745, Vol. 6 (September 2007)   |                |
|  | P80a                  | Fakhari et al., "Upregulation of Vascular Endothelial Growth Factor Receptors is Associated with Advanced Neuroblastoma," Journal of Pediatric Surgery, 37(4): 582-587 (April 2002)  |                |
|  | P81                   | Favaro et al., "Targeted therapy in renal cell carcinoma," Expert Opin. Investig. Drugs 14(10):1251-1258 (2005)  |                |
|  | P81a                  | Fiedler et al. "A phase 2 clinical study of SU5416 in patients with refractory acute myeloid leukemia," Blood, 102(8): 2763-2767(prepublished online Jul. 3, 2003)   |                |
|  | P82                   | Feldmann, "Pathogenesis of arthritis: recent research progress," Nature Immunology 2001, Vol. 2, No. 9, pp. 771-773.   |                |
|  | P83                   | Fields Virology Second Editon, "Contents," Vol.1, pp. ix-xiv, Raven Press, NY (1990)   |                |
|  | P84                   | Flaherty et al., "A Phase I Trial of the Oral, Multikinase Inhibitor Sorafenib in Combination with Carboplatin and Paclitaxel" Clin Cancer Res 41(15):4836-4842 (August 1, 2008).  |                |
|  | P85                   | Flaherty et al., "Phase III trial of Bay 43-9006 carboplatin (C) and paclitaxel (P) demonstrates preliminary antitumor activity in the expansion cohort of patients with metastatic melanoma." Journal of Clinical Oncology, 2004 ASCO annual meeting proceedings, Vol. 22, No. 14S (2004) Supplement: 7507, 4 pages |                |
|  | P85a                  | Flaherty et al., "Antisense therapeutics: lessons from early clinical trials," Current Opin. in Oncol. 13: 499-505 (2001)  |                |
|  | P86                   | Foekens et al., "High Tumor Levels of Vascular Endothelial Growth Factor Predict Poor Response to Systemic Therapy in Advanced Breast Cancer," Cancer Research, 2001, Vol. 61, pp. 5407-5414   |                |
|  | P87                   | Forbes et al., "N-(1-Methyl-5-indolyl)-N'-(3-methyl-5-isothiazolyl)urea: A Novel, High-Affinity 5-HT <sub>2B</sub> Receptor Antagonist," Journal of Medicinal Chemistry, 1995, Vol. 38, No. 6, pp. 855-857   |                |
|  | P88                   | Franco et al., "Dissolution properties and anticonvulsant activity of phenytoin-polyethylene glycol 6000 and -polyvinylpyrrolidone K-30 solid dispersions," International Journal of Pharmaceutics 225 (2001) pp. 63-73  |                |
|  | P89                   | Fridman et al., "The Minimal Fragments of c-Raf-1 and NF1 That Can Suppress v-Ha-Ras-Induced Malignant Phenotype," The Journal of Biological Chemistry, Vol. 269, no. 48, 1994, pp. 30105-30108  |                |
|  | P90                   | Garcia-López et al., "New Routes for the Synthesis of Pyrrolo[3,2-d]- and [2,3-d]-pyrimidine Systems starting from a Common Pyrrole Derivative." Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-Organic Chemistry (1972-1999), 1978, pp. 483-487  |                |
|  | P91                   | Gatzemeier et al., "Phase II trial of single-agent sorafenib in patients with advanced non-small cell lung carcinoma," Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings Part 1, Vol. 24, No. 18S (June 20 Supplement) 2006, abstract no. 7002, 4 pages.  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |                          |                    |
|---|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    | <b>Complete if Known</b> |                    |
|   |    | Application Number       | 09/993,647         |
|   |    | Filing Date              | November 27, 2001  |
|   |    | First Named Inventor     | Bernd Riedl et al. |
|   |    | Group Art Unit           | 1624               |
|   |    | Examiner Name            | Deepak R. RAO      |
| Sheet   | 31 | of                       | 56                 |
|   |    | Attorney Docket Number   | BAYER-0018-A       |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.     | T <sup>6</sup> |
|  | P92                   | Geiger et al., "Antitumor Activity of a C-raf Antisense Oligonucleotide in Combination with Standard Chemotherapeutic Agents against Various Human Tumors Transplanted Subcutaneously into Nude Mice," <i>Clinical Cancer Research</i> Vol. 3, 1179-1185, July 1997 |                |
|  | P93                   | Geng et al., "A Specific Antagonist of the p110δ Catalytic Component of Phosphatidylinositol 3'-Kinase, IC486068, Enhances Radiation-Induced Tumor Vascular Destruction," <i>Cancer Research</i> , 64, July 2004, pp. 4893-4899                                     |                |
|  | P94                   | Gennaro, Alfonso R. "Table of Contents," pp. xiv-xv, in Remington: The Science and Practice of Pharmacy, 20TH Ed. Remington. Lippincott Williams & Wilkins, 2000  |                |
|  | P94a                  | George et al., "VEGF-A, VEGF-C and VEGF-D in Colorectal Cancer Progression," <i>Neoplasia</i> , 3(5): 420-427 (2001)  |                |
|  | P94b                  | George et al., "Prognostic Significance of Plasma Vascular Endothelial Growth Factor Levels in Patients with Hormone-refractory Prostate Cancer Treated on Cancer and Leukemia Group B 9480," <i>Clinical Cancer Research</i> , 7: 1932-1936 (July 2001)            |                |
|  | P95                   | Abou-Alfa et al., "Phase II Study of Sorafenib in Patients with Advanced Hepatocellular Carcinoma" <i>Journal of Clinical Oncology</i> , Vol. 24, No. 26, pp. 4293-4300 (September 10, 2006).   |                |
|  | P96                   | Giambartolomei et al., "Sustained activation of the Raf/MEK/Erk pathway in response to EGF in stable cell lines expressing the Hepatitis C Virus (HCV) core protein," <i>Oncogene</i> , Nature Publishing Group, 2001: Vol 20, pp. 2606-2610                        |                |
|  | P97                   | Gills et al., "The development of phosphatidylinositol ether lipid analogues as inhibitors of the serine/threonine kinase, Akt," <i>Expert Opin. Investig. Drugs</i> , Vol. 13, No. 7, 2004, pp. 787-797  |                |
|  | P98                   | Gollob, "Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma" Pub Med PMID: 16425993, <i>Clin. Genitourin. Cancer</i> 4(3):167-174 (2005) abstract.  |                |
|  | P99                   | Gómez-Esquer et al., "mRNA expression of the angiogenesis markers VEGF and CD105 (endoglin) in human breast cancer," <i>Anticancer Res.</i> , 2004, Vol. 24, No. 3a, pp. 1581-1585, XP-002455577, abstract.   |                |
|  | P100                  | Grant et al., "Some Hypotensive Thiadiazoles," <i>J. Med. Chem.</i> (1972), 15(10), pp. 1082-1084   |                |
|  | P101                  | Greene et al., "Contents," pp. xi-xii, in: <i>Protective Groups in Organic Synthesis</i> , 3rd Ed. John Wiley & Sons, Inc., New York, 1999  |                |
|  | P102                  | Gelasser, "The Importance of Solvates," in: <i>Polymorphism in the Pharmaceutical Industry</i> , Chapter 8, p. 211, 2006, Wiley-VCH Verlag GmbH & Co., KGaA, Weinheim   |                |
|  | P103                  | Gridelli et al., "Sorafenib and Sunitinib in the Treatment of Advanced Non-Small Cell Lung Cancer" <i>The Oncologist</i> (2007) 12:191-200  |                |
|  | P104                  | Guan et al., "H5N1 influenza: A protean pandemic threat," <i>Proc. Natl. Acad. Sci. USA</i> , 25-05-2004; Vol. 101, pp. 8156-8161   |                |
|  | P106                  | Gupta et al., "Sorafenib targets BRAF and VEGFR in metastatic thyroid carcinoma" <i>Journal of Clinical Oncology</i> , 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol. 25, No. 18S (June 20 Supplement), 2007: 6019 abstract                       |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |    |                          |                        |              |
|--|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |    |    | <b>Complete if Known</b> |                        |              |
|  |    |    | Application Number       | 09/993,647             |              |
|  |    |    | Filing Date              | November 27, 2001      |              |
|  |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|  |    |    | Group Art Unit           | 1624                   |              |
|  |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet  | 32 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                       | T <sup>6</sup> |
|  | P107                  | Gura, "Systems for identifying new drugs are often faulty." <i>Science</i> , 1997, Vol. 278, (5340), pp. 1041-1042, MEDLINE with Full text  |                |
|  | P108                  | Hahn et al., "Sorafenib," <i>Curr. Opin. Oncol.</i> 18:615-621 (2006)   |                |
|  | P108a                 | Hall-Jackson et al., "Paradoxical activation of Raf by a novel Raf inhibitor," <i>Chemistry &amp; Biology</i> , 6: 559-568 (July 1999)  |                |
|  | P109                  | Han et al., "Targeted Prodrug Design To Optimize Drug Delivery." <i>AAPS Pharmsci.</i> 2000: Vol. 2, No. 1, Article 6, 1-11   |                |
|  | P110                  | Hanna, "Second-Line Treatment of Non-small Cell Lung Cancer: Big Targets, Small Progress; Small Targets, Big Progress?" <i>Journal of Thoracic Oncology</i> Vol. 1, No. 9, pp. 927-928 (November 2006).   |                |
|  | P111                  | Hansch et al., "Contents," 21 pages, in: <i>Comprehensive Medicinal Chemistry. The Rational Design, Mechanistic Study &amp; Therapeutic Application of Chemical Compounds</i> , Pergamon Press, Oxford, Uk, 1990.   |                |
|  | P113                  | Hanson, "Pulmonary-Allergy, Dermatological, Gastrointestinal & Arthritis, Inhibitors of p38 kinase," <i>Exp. Opin. Ther. Patents</i> , 1997, Vol. 7, Number 7, pp. 729-733  |                |
|  | P114                  | Hardmann et al., excerpts from chapter 3. Principles of Therapeutics, in: Goodman & Gilman's <i>The Pharmacological Basis of Therapeutics</i> , 9th ed., 1996, pp. 51 and 57-58   |                |
|  | P114a                 | Harris et al., "Soluble Tie2 and Flt1 Extracellular Domains in Serum of Patients with Renal Cancer and Response to Antiangiogenic Therapy," <i>Clin. Cancer Res.</i> 7:1992-1997 (2001)   |                |
|  | P114b                 | Hayes et al., "Serum vascular endothelial growth factor as a tumour marker in soft tissue sarcoma," <i>British Journal of Surgery</i> , 91:242-247 (Published on-line Nov. 24, 2003)  |                |
|  | P115                  | Hegedus, L.S. "Contents," 4 pages in: <i>Transition Metals In The Synthesis Of Complex Organic Molecules</i> , University Science Books, Mill Valley, California, 1994  |                |
|  | P116                  | Heim et al., "Antitumor effect and potentiation or reduction in cytotoxic drug activity in human colon carcinoma cells by the Raf kinase inhibitor (RKI) BAY 43-9006," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, Vol. 41, Number 12, pp. 616-617 |                |
|  | P117                  | Heim et al., "The Raf kinase inhibitor BAY 43-9006 reduces cellular uptake of platinum compounds and cytotoxicity in human colorectal carcinoma cell lines," <i>Anti-Cancer Drugs</i> , 2005, Vol. 16, pp. 129-136  |                |
|  | P118                  | Herlaar et al., "p38 MAPK signalling cascades in inflammatory disease," <i>Molecular Medicine Today</i> , Vol. 5, pp. 439-447 (October 1999)  |                |
|  | P118a                 | Herrera et al., "Unraveling the complexities of the Raf/MAP kinase pathway for pharmacological intervention," <i>Trends in Molecular Medicine</i> , 2002, Vol. 8, No. 4 (Suppl.), pp. S27-S31   |                |
|  | P119                  | Higuchi T. et al., "Contents," in: <i>Prodrugs as Novel Drug Delivery Systems</i> , ACS Symposium Series 14, American Chemical Society, Washington, DC, 1975, p. vii  |                |
|  | P119a                 | Higuchi et al., "Mitochondrial DNA determines androgen dependence in prostate cancer cell lines," <i>Oncogene</i> , 2006, Vol. 25, pp. 1437-1445  |                |
|  | P120                  | Hilger et al., "Correlation of ERK-phosphorylation and toxicities in patients treated with the Raf kinase inhibitor BAY 43-9006" <i>International Journal of Clinical Pharmacology and Therapeutics</i> , Vol. 42, No. 11, pp. 648-649 (2004)   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |              |
|---|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |              |
|   |    |    | Application Number       | 09/993,647             |              |
|   |    |    | Filing Date              | November 27, 2001      |              |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |    |    | Group Art Unit           | 1624                   |              |
|   |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 33 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|  | P121                  | Hilger et al., "ERK1/2 phosphorylation: a biomarker analysis within a phase I study with the new Raf kinase inhibitor Bay 43-9006" International Journal of Clinical Pharmacology and Therapeutics, Vol. 40, No. 12, pp. 567-568 (2002)                         |                |
|  | P122                  | Hilger et al., "Inhibition of ERK phosphorylation and clinical outcome in patients treated with the Raf kinase inhibitor BAY 43-9006" Proc Am Soc Clin Oncol 21: 2002 (abstr 1916), 3 pages   |                |
|  | P123                  | Hirasawa et al., "Effect of p38 Mitogen-Activated Protein Kinase on the Replication of Encephalomyocarditis Virus." Journal of Virology, 05/2003: Vol. 77, No. 10, pp. 5649-5656  |                |
|  | P124                  | Holmlund et al., "Phase I Trial of C-raf Antisense Oligonucleotide ISIS 5132 (CGP 69846A) By 21-Day Continuous Intravenous Infusion (CIV) In Patients With Advanced Cancer," (Meeting abstract), 1998 ASCO Annual Meeting, Abstract no. 811, 2 pages            |                |
|  | P125                  | Hotte et al., "Bay 43-9006: Early clinical data in patients with advanced solid malignancies," Current Pharmaceutical Design, 8: 2249-2253, 2002  |                |
|  | P125a                 | Hu et al., "Soluble Vascular Endothelial Growth Factor Receptor 1, and Not Receptor 2, Is an Independent Prognostic Factor in Acute Myeloid Leukemia and Myelodysplastic Syndromes," Cancer, 100(9): 1884-1891 (Published on-line March 29, 2004)               |                |
|  | P126                  | Hubbard, "Oncogenic Mutations in B-Raf: Some Losses Yield Gains," Cell Volume 116, Issue 6, 764-766 (2004)  |                |
|  | P126a                 | Hyodo et al., "Clinical Significance of Plasma Vascular Endothelial Growth Factor in Gastrointestinal Cancer," European Journal of Cancer, 34(13): 2041-2045 (1998)   |                |
|  | P127                  | Ihle et al., "Molecular pharmacology and antitumor activity of PX-866, a novel inhibitor of phosphoinositide-3-kinase signaling," Molecular Cancer Therapy, Vol. 3, No. 7, 2004, pp. 763-772  |                |
|  | P127a                 | Ishigami et al., "Predictive value of vascular endothelial growth factor (VEGF) in metastasis and prognosis of human colorectal cancer," British Journal of Cancer, 78(10): 1379-1384 (1998)  |                |
|  | P127b                 | Jacobsen et al., "Vascular Endothelial Growth Factor as Prognostic Factor in Renal Cell Carcinoma," Journal of Urology, 163(1): 343-347 (Jan. 2000)   |                |
|  | P127c                 | Jacobsen et al., "Prognostic importance of serum vascular endothelial growth factor in relation to platelet and leukocyte counts in human renal cell carcinoma," European Journal of Cancer Prevention, 2002, 11(3) pp. 245-252                                 |                |
|  | P128                  | Jain et al., "Randomized Discontinuation Trial of Sorafenib (BAY 43-9006)," Cancer Biology & Therapy, Vol. 5, Issue 10, pp. 1270-1272 (2006).   |                |
|  | P129                  | Jeffcoat et al., "The Metabolism and Toxicity of Halogenated Carbanilides," Drug Metabolism and Disposition, Vol. 5, Number 2, pp. 157-166 (1977)   |                |
|  | P129a                 | Jimeno et al., "Analysis of Biologic Surrogate Markers from a Children's Oncology Group Phase I Trial of Gefitinib in Pediatric Patients with Solid Tumors," Pediatr. Blood Cancer, 49(3): 352-357 (2007)   |                |
|  | P130                  | Jin et al., "Inhibition of AKT survival pathway by a small molecule inhibitor in human endometrial cancer cells," British Journal Of Cancer, Vol. 91, 2004, pp. 1808-1812   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box



PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |    |    |                          |                    |
|--|----|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    |    |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    |    | Application Number       | 09/993,647         |
|  |    |    |    | Filing Date              | November 27, 2001  |
|  |    |    |    | First Named Inventor     | Bernd Riedl et al. |
|  |    |    |    | Group Art Unit           | 1624               |
|  |    |    |    | Examiner Name            | Deepak R. RAO      |
| Sheet  | 34 | of | 56 | Attorney Docket Number   | BAYER-0018-A       |

| <b>OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS</b> |                       |   |                |
|---|-----------------------|---|----------------|
| Examiner Initials *                                       | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                 | T <sup>6</sup> |
|   | P131                  | Johnson et al., "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials," British Journal of Cancer, 2001, Vol. 84, No. 10, pp. 1424-1431   |                |
|   | P132                  | Johnston, D, et al., "Elevation of the Epidermal Growth Factor Receptor and Dependent Signaling in Human Papillomavirus-infected Laryngeal Papillomas." Cancer Research, 1999: Vol. 59, pp. 968-974   |                |
|   | P132b                 | Jungmayr, P., "Aktueller Stand der Krebstherapie," Deutsche Apotheker Zeitung, Sept 30, 2004, Auflage ca. 36.000  |                |
|   | P133                  | Kapoun et al., "TGFβR1 kinase activity, but not p38 activation is required for TGFβR1-induced myofibroblast differentiation and pro-fibrotic gene expression," Molecular Pharmacology Fast Forward, abstract, 2006, www.molpharmaspetsjournals.org, 2 pages                     |                |
|   | P133a                 | Karayiannakis et al., "Circulating VEGF Levels in the Serum of Gastric Cancer Patients," Annals of Surgery, 236(1): 37-42 (July 2002)   |                |
|   | P133b                 | Karayiannakis et al., "Clinical significance of preoperative serum vascular endothelial growth factor levels in patients with colorectal cancer and the effect of tumor surgery," Surgery, 131(5): 548-555 (May 2002)   |                |
|   | P133c                 | Karp et al., "Targeting Vascular Endothelial Growth Factor for Relapsed and Refractory Adult Acute Myelogenous Leukemias: Therapy with Sequential 1-β-D Arabinofuranosylcytosine, Mitoxantrone, and Bevacizumab," Clinical Cancer Research, 10: 3577-3585 (June 1, 2004)        |                |
|   | P134                  | Katritzky et al., "1.18. Azetidines, Azetines, and Azetes: Monocyclic" pp. 507-508 in: Comprehensive Heterocyclic Chemistry II, A Review of the Literature 1982-1995: The Structure, Reactions, Synthesis, and Uses of Heterocyclic Compounds. Pergamon Press, Oxford, UK, 1996 |                |
|   | P135                  | Katritzky, Alan R., Tables of Content, in: Comprehensive Organic Functional Group Transformations. Pergamon Press, Oxford, UK, 1995, 25 pages   |                |
|   | P136                  | Katritzky et al., "Contents," 2 pages, in: Comprehensive Heterocyclic Chemistry, The Structure, Reactions, Synthesis, and Uses of Heterocyclic Compounds. Pergamon Press, Oxford, UK, 1984  |                |
|   | P137                  | Keller et al., "The role of Raf kinase inhibitor protein (RKIP) in health and disease." Biochemical Pharmacology 68: pp. 1049-1053 (2004)   |                |
|   | P139                  | Kempter et al., "Synthese potentieller Pflanzenschutz- und Schädlingsbekämpfungsmittel aus substituierten Anilinen." Pädagogische Hochschule, Eingegangen am 1.7.1982, Vol. 27, Issue 1, 101-120 (1983)   | abs            |
|   | P140                  | Kessler et al., "Use of the DNA Flow-Thru Chip, a Three-Dimensional Biochip, for Typing and Subtyping of Influenza Viruses." Journal of Clinical Microbiology. 05-2004; Vol. 42, pp. 2173-2185  |                |
|   | P141                  | Khire et al., "Omega-carboxypyridyl substituted ureas as Raf kinase inhibitors: SAR of the amide substituent," Bioorg. Med. Chem. Lett., 2004, Vol. 14, pp. 783-786   |                |
|   | P141a                 | Kido, Y., "Vascular Endothelial Growth Factor (VEGF) Serum Concentration Changes during Chemotherapy in Patients with Lung Cancer," Kurume Medical Journal, 48(1): 43-47 (2001)   |                |
|   | P142                  | Klemm et al., "Chemistry of Thienopyridines. XXXVII. Syntheses in the Cyclopenta, Cyclohexa-, and Cycloheptathieno[2,3-b]pyridine Series. Three Analogs of 9-Amino-1,2,3,4-tetrahydroacridine [1]," J. Heterocyclic Chem., 27, 1990, pp.1537-1541                               |                |
|   | P143                  | van Muijlwijk-Koezen et al., "Isoquinoline and Quinazoline Urea Analogues as Antagonists for the Human Adenosine A <sub>3</sub> Receptor," J. Med. Chem. 2000, 43, pp. 2227-2238  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |              |
|---|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |              |
|   |    |    | Application Number       | 09/993,647             |              |
|   |    |    | Filing Date              | November 27, 2001      |              |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |    |    | Group Art Unit           | 1624                   |              |
|   |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 35 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|--|-----------------------|--|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                                    | T <sup>6</sup> |
|  | P144                  | Kolch et al., "Raf-1 protein kinase is required for growth of induced NIH/3T3 cells," Nature, Vol. 349, January 31, 1991, pp. 426-428  |                |
|  | P145                  | Kolch et al., "The role of Raf kinases in malignant transformation" Expert reviews in molecular medicine (April 25, 2002) ISSN: 1462-3994 © Cambridge University Press, 18 pages   |                |
|  | P145a                 | Konecny et al., "Association between HER-2/ <i>neu</i> and Vascular Endothelial Growth Factor Expression Predicts Clinical Outcome in Primary Breast Cancer Patients," Clinical Cancer Research, 10: 1706-1716 (March 1, 2004)   |                |
|  | P145b                 | Korfee et al., "New targeted treatments in lung cancer-overview of clinical trials," Lung Cancer, 45 (Suppl. 2): S199-S208 (2004)  |                |
|  | P145c                 | Kraft et al., "Vascular Endothelial Growth Factor in the Sera and Effusions of Patients with Malignant and Nonmalignant Disease," Cancer, 85(1): 178-187 (Jan 1, 1999)   |                |
|  | P146                  | Kubo et al., "Herbicidal Activity of 1,3,4-Thiadiazole Derivatives," J. Agr. Food Chem. (1970), 18(1), pp. 60-65   |                |
|  | P147                  | Kubo et al., "Synthesis and structure-activity relationship of quinazoline-urea derivatives as novel orally active VEGF receptor tyrosine kinase selective inhibitors," Proceedings of the American Association of Cancer Res., 2002, Vol. 43, p. 182, abstract no. 913                            |                |
|  | P148                  | Kuefer et al., "Translational research in renal cell cancer. Illustrated by the example of the vascular endothelial growth factor pathway," Der Urologe, 2006, Vol. 45, No. 3, pp. 328, 330-335  | abs            |
|  | P149                  | Kumar et al., "Drugs targeted against protein kinases" Expert Opin. Emerging Drugs 6(2):303-315 (2001)   |                |
|  | P150                  | Kupsch et al., "Results of a Phase I Trial of Sorafenib (BAY 43-9006) in Combination with Oxaliplatin in Patients with Refractory Solid Tumors, Including Colorectal Cancer," Clinical Colorectal Cancer, Cancer Information Group Journal, Vol. 5 Issue 3, pp. 188-196, abstract (September 2005) |                |
|  | P151                  | Kurik et al., "Optical Properties of Segmented Oligourethane with Azomethine Terminal Fragments," Polymer Science, series B, 1996, Vol. 38 pp. 2038-2041   | abs            |
|  | P152                  | Kyriakis et al., "Raf-1 activates MAP kinase-kinase" Nature, 358, 6385, pp. 417-421 (July 30, 1992).   |                |
|  | P152a                 | Laack et al., "Pretreatment serum levels of matrix metalloproteinase-9 and vascular endothelial growth factor in non-small-cell lung cancer," Annals of Oncology, 13(10): 1550-1557 (Oct 2002)   |                |
|  | P153                  | Dal Lago et al., "Selected Combination Therapy with Sorafenib: A Review of Clinical Data and Perspectives in Advanced Solid Tumors" The Oncologist, Vol. 13, No. 8, pp. 845-858 (Aug 11, 2008)   |                |
|  | P153a                 | Lau et al., "Abrogation of c-Raf expression induces apoptosis in tumor cells," Oncogene 16, 1899-1902 (1998)   |                |
|  | P154                  | Lee et al., "BAY-43-9006 Bayer/Onyx," Current Opinion in Investigational Drugs, 2003, Vol. 4, Number 6, pp. 757-763  |                |
|  | P155                  | Lee et al., "Bicyclic Imidazoles as a Novel Class of Cytokine Biosynthesis Inhibitors," Annals N.Y. Academy of Science, 1993, Vol. 696, pp. 149-170  |                |
|  | P156                  | Lee et al.: "FTY720 induces apoptosis of human hepatoma cell lines through PI3-K-mediated Akt dephosphorylation," Carcinogenesis, Vol. 25, No. 12, 2004, pp. 2397-2405   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |    |                          |                        |              |
|--|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center;">(use as many sheets as necessary)</p> |    |    | <b>Complete if Known</b> |                        |              |
|  |    |    | Application Number       | 09/993,647             |              |
|  |    |    | Filing Date              | November 27, 2001      |              |
|  |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|  |    |    | Group Art Unit           | 1624                   |              |
|  |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet  | 36 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | † <sup>6</sup> |
|  | P156a                 | Lee et al., "Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients," <i>European Journal of Cancer</i> , 36(6): 748-753 (April 2000)  |                |
|  | P156b                 | Lee and Heymach, "Emerging Antiangiogenic Agents in Lung Cancer," <i>Clinical Lung Cancer</i> , 7(5): 304-308 (March 2006)  |                |
|  | P156c                 | Legros et al., "Imatinib mesylate (STI571) decreases the vascular endothelial growth factor plasma concentration in patients with chronic myeloid leukemia," <i>Blood</i> , 104(2): 495-501 (Prepublished on-line Feb 19, 2004)   |                |
|  | P157                  | Lemoine, "Overview of <i>ras</i> oncogenes and their clinical potential," Chapter 10, In: <i>Mutant Oncogenes: Targets for Therapy?</i> (eds. Lemoine NR & Epenetos A), Chapman & Hall, London. pp. 85-91   |                |
|  | P158                  | Lepage et al., "New N-aryl isoxazolecarboxamides and N-isoxazolybenzamides as anticonvulsant agents," <i>Eur. J. Med. Chem.</i> , Vol. 27, 1992, pp. 581-593  |                |
|  | P159                  | Leuner et al., "Improving drug solubility for oral delivery using solid dispersions," <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 50, 2000, pp. 47-60   |                |
|  | P159a                 | Liang et al., "Differential Expression of VEGF and Its Receptors in the Primary Cells of Various Risk Classified Acute Lymphoblastic Leukemia Patients," <i>Blood</i> 104: Abstract 4446 (2004)   |                |
|  | P159b                 | Li et al. "Correlation of Serum VEGF Levels with Clinical Stage, Therapy Efficacy, Tumor Metastasis and Patient Survival in Ovarian Cancer," <i>Anticancer Research</i> , 24: 1973-1980 (2004)  |                |
|  | P160                  | Lin, "Synthesis of 1-(2-Pyridine-1-oxide)-2-(1-Methyl-2-Pyridinium)-Ethane Chloride," <i>OPPI Briefs</i> , Vol. 23, No.1, 1991, pp. 114-115   |                |
|  | P160a                 | Linderholm et al., "Correlation of Vascular Endothelial Growth Factor Content with Recurrences, Survival, and First Relapse Site in Primary Node-Positive Breast Carcinoma After Adjuvant Treatment," <i>Journal of Clinical Oncology</i> , 18(7): 1423-1431 (April 2000)                                     |                |
|  | P160b                 | Linderholm et al., "p53 and Vascular-Endothelial-Growth-Factor (VEGF) Expression Predicts Outcome in 833 Patients with Primary Breast Carcinoma," <i>Int. J. Cancer (Pred. Oncol.)</i> : 89(1): 51-62 (2000)  |                |
|  | P160c                 | Lissoni et al., "Anti-angiogenic activity of melatonin in advanced cancer patients," <i>Neuroendocrinology Letters</i> , 2001, 22:45-47   |                |
|  | P160d                 | Lissoni et al., "Chemotherapy and angiogenesis in advanced cancer: vascular endothelial growth factor (VEGF) decline as predictor of disease control during taxol therapy in metastatic breast cancer," <i>International Journal of Biological Markers</i> , 15(4): 308-311 (Oct. 1, 2000)                    |                |
|  | P160e                 | Lissoni et al., "Abnormally enhanced blood concentrations of vascular endothelial growth factor (VEGF) in metastatic cancer patients and their relation to circulating dendritic cells, IL-12 and endothelin-1," <i>Journal of Biological Regulators and Homeostatic Agents</i> , 15(2): 140-144 (April 2001) |                |
|  | P160f                 | Lissoni et al., "Changes in circulating VEGF levels in relation to clinical response during chemotherapy for metastatic cancer," <i>International Journal of Biological Markers</i> , 18(2): 152-155 (2003)   |                |
|  | P160g                 | Llovet et al., "Molecular Targeted Therapies in Hepatocellular Carcinoma," <i>Hepatology</i> , Vol. 48, No. 4, pp. 1312-1327, 2008  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |              |
|---|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |              |
|   |    |    | Application Number       | 09/993,647             |              |
|   |    |    | Filing Date              | November 27, 2001      |              |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |    |    | Group Art Unit           | 1624                   |              |
|   |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 37 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|  | P160h                 | Lockhart et al., "Phase I/Pilot Study of SU5416 (Semaxinib) in Combination With Irinotecan/Bolus 5-FU/LV (IFL) in Patients With Metastatic Colorectal Cancer," American Journal of Clinical Oncology, 29(2):109-115 (April 2006)                                |                |
|  | P161                  | Lorigan et al., "Phase II trial of sorafenib combined with dacarbazine in metastatic melanoma patients" ASCO 2006 DTIC abstract, 2 pages (January 11, 2006)   |                |
|  | P162                  | Lowinger et al., "Design and Discovery of Small Molecules Targeting Raf-1 Kinase," Current Pharmaceutical Design, 2002, Vol. 8, pp. 2269-2278   |                |
|  | P163                  | Lowinger et al., "Discovery of novel class of potent Raf kinase inhibitors: structure activity relationships," Clinical Cancer Research, November 2000, Vol. 6 (Suppl.), p. 4533s, abstract no. 335   |                |
|  | P163a                 | Lowy et al., "Function and Regulation of RAS" Annual Review of Biochemistry, Vol. 62, pp. 851-891, 1993   |                |
|  | P164                  | Ludwig et al., "MEK inhibition impairs influenza B virus propagation without emergence of resistant variants," FEBS Letters, 2004, Vol. 561, pp. 37-43  |                |
|  | P165                  | Luo et al., "Enhancement of radiation effects by pXLG-mENDO in a lung carcinoma model," Int. J. Radiation Oncology Biol. Phys., 2005, Vol. 63, No. 2, pp. 553-564   |                |
|  | P166                  | Lyons et al., "Discovery of a novel Raf kinase inhibitor," <i>Endocrine-Related Cancer</i> , 2001, Vol. 8, pp. 219-225  |                |
|  | P167                  | Madwed et al., "Pharmacological evaluation of BIRB 796, a selective inhibitor of p38 MAP kinase (MAPK), in animal models of endotoxic shock, inflammation and arthritis," <i>Inflammation Res.</i> , 50:S184, abstract no. W22/03, 2001                         |                |
|  | P168                  | Magnuson et al., "The Raf-1 serine/threonine protein kinase," <i>Cancer Biology</i> , Vol. 5, 1994, pp. 247-253   |                |
|  | P168a                 | Manenti et al., "Circulating plasma vascular endothelial growth factor in mice bearing human ovarian carcinoma xenograft correlates with tumor progression and response to therapy," <i>Molecular Cancer Therapeutics</i> , 4(5): 715-725 (May 2005)            |                |
|  | P169                  | Mannová et al., "Activation of the N-Ras-PI3K-Akt-mTOR Pathway by Hepatitis C Virus: Control of Cell Survival and Viral Replication," <i>Journal of Virology</i> , July 2005, Vol. 79, No.14, pp. 8742-8749   |                |
|  | P170                  | Markgraf et al., "Strained Heterocyclic Systems. 19. 1-Azatriptycene and Derivatives," <i>Tetrahedron</i> , Vol. 47, No. 2, 1991, pp. 183-188   |                |
|  | P171                  | Marshall, "MAP kinase kinase kinase, MAP kinase kinase, and MAP kinase," <i>Curr. Opin. Genet. Dev.</i> 4: 82-89, 1994  |                |
|  | P171a                 | Marx, J., "Why a New Cancer Drug Works Well. In Some Patients." <i>Science</i> , Vol. 304, pp. 658-659, 2004  |                |
|  | P172                  | McGoon et al., "Screening, Early Detection, and Diagnosis of Pulmonary Arterial Hypertension," <i>CHEST</i> , 2004: 126, pp. 14S-34S  |                |
|  | P172a                 | Medinger et al., "Hemmung der Tumorangiogenese Neue Therapieoptionen in der Onkologie." <i>Med Welt</i> , 2006, 57, pp. 437-441   | abs            |
|  | P172b                 | Med Report Deutschland, "Sorafenib zur Therapie des fortgeschrittenen Nierenzellkarzinoms zugelassen," (2006), 1 page   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |    |                          |                    |
|--|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | Application Number       | 09/993,647         |
|  |    |    | Filing Date              | November 27, 2001  |
|  |    |    | First Named Inventor     | Bernd Riedl et al. |
|  |    |    | Group Art Unit           | 1624               |
|  |    |    | Examiner Name            | Deepak R. RAO      |
|  |    |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 38 | of | 56                       |                    |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|--|-----------------------|--|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | T <sup>6</sup> |
|  | P173                  | Meuillet et al., "In Vivo Molecular Pharmacology and Antitumor Activity of the Targeted Akt Inhibitor PX-316," Oncology Research, Vol. 14, 2004, pp. 513-527   |                |
|  | P174                  | Michaelis, "Phenylharnstoff des 1-Phenyl-3-methyl-5-aminopyrazols," Justus Liebigs Ann. Chem. (JLACBF) 397, 1913, p. 143   |                |
|  | P174a                 | Milanini et al., "p42/p44 MAP Kinase Module Plays a Key Role in the Transcriptional Regulation of the Vascular Endothelial Growth Factor Gene in Fibroblasts," Journal of Biological Chemistry, 273(29): 18165-18172 (July 17, 1998)   |                |
|  | P175                  | Milano et al., "New molecular targeted therapies in thyroid cancer" Anti-Cancer Drugs (2006) © Lippincott Williams & Wilkins., Vol. 17:869-879   |                |
|  | P175a                 | Mills et al., "The Effects of Standard Anthracycline-Based Chemotherapy on Soluble ICAM-1 and Vascular Endothelial Growth Factor Levels in Breast Cancer," Clinical Cancer Research, 10: 4998-5003 (August 1, 2004)  |                |
|  | P175b                 | Milojkovic et al., "Immunohistochemical Characterisation of Vascular Endothelial Growth Factor (VEGF) and its Receptors Flt-1 and KDR in Chronic Myeloid Leukaemia (CML) Patients Treated with Imatinib Mesylate," Blood, 104 Abstract 1999 (2004)   |                |
|  | P175c                 | Minna et al., "A Bull's Eye For Targeted Lung Cancer Therapy," Science, Vol. 304, pp. 1458-1460, 2004  |                |
|  | P176                  | Mita et al., "The Molecular Target of Rapamycin (mTOR) as a Therapeutic Target Against Cancer." Cancer Biology & Therapy 2:4 Suppl. 1, S169-S177 (July/August 2003)  |                |
|  | P177                  | Moelling et al., "Signal Transduction as Target of Gene Therapy," Institute of Medical Virology, University of Zürich, Recent Results in Cancer Research, Vol. 142, pp. 63-71 (1996)   |                |
|  | P178                  | Molhoek et al., "Synergistic inhibition of human melanoma proliferation by combination treatment with B-Raf inhibitor BAY 43-9006 and mTOR inhibitor rapamycin," Journal of Translational Medicine (2005) 3: 39, pp.1-11   |                |
|  | P179                  | Monia, "First-and second-generation antisense oligonucleotide inhibitors targeted against human c-raf kinase," (1997) Oligonucleotides as therapeutic agents Wiley, Chichester (Ciba Foundation Symposium 209) pp. 107-123   |                |
|  | P180                  | Monia et al., "Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinase," Nature Medicine, Vol. 2, No. 6, June 1996, pp. 668-675  |                |
|  | P180a                 | Monia et al., "Sequence-specific antitumor activity of a phosphorothioate oligodeoxyribonucleotide targeted to human C-raf kinase supports and antisense mechanism of action <i>in vivo</i> ," Proc. Natl. Acad. Sci USA, Vol. 93, 15481-15484 (Dec. 1996)   |                |
|  | P180b                 | Morabito et al., Tyrosine Kinase Inhibitors of Vascular Endothelial Growth Factor Receptors I Clinical Trials: Current Status and Future Directions," The Oncologist, 11: 753-764 (2006)   |                |
|  | P181                  | Mori et al., "Differential activation of the c-Jun N-terminal kinase/stress-activated protein kinase and p38 mitogen-activated protein kinase signal transduction pathways in the mouse brain upon infection with neurovirulent influenza A virus," Journal of General Virology, 2003, 84, pp. 2401-2408 |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |                          |                    |
|--|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    | Application Number       | 09/993,647         |
|  |    | Filing Date              | November 27, 2001  |
|  |    | First Named Inventor     | Bernd Riedl et al. |
|  |    | Group Art Unit           | 1624               |
|  |    | Examiner Name            | Deepak R. RAO      |
|  |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 39 | of                       | 56                 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|--|-----------------------|--|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | † <sup>6</sup> |
|  | P182                  | Moore et al., "Phase I study to determine the safety and pharmacokinetics of the novel Raf kinase and VEGFR inhibitor BAY 43-9006, administered for 28 days on/7 days off in patients with advanced, refractory solid tumors," <i>Annals of Oncology</i> , 2005, Vol. 16, pp.1688-1694                         |                |
|  | P183                  | Motzer et al., "Survival And Prognostic Stratification Of 670 Patients With Advanced Renal Cell Carcinoma", <i>J. Clin. Oncol.</i> , 17(8):pp. 2530-2540 (1999).   |                |
|  | P184                  | Mross et al., "Drug-drug interaction pharmacokinetic study with the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with irinotecan (CPT-11) in patients with solid tumors," <i>International Journal of Clinical Pharmacology and Therapeutics</i> , 2003, Vol. 41, Number 12, pp. 618-619 |                |
|  | P185                  | Mross et al., "Results from an <i>in vitro</i> and a clinical/pharmacological phase I study with the combination irinotecan and sorafenib" <i>European Journal of Cancer</i> 43, pp. 55-63 (2007).   |                |
|  | P186                  | Murata et al., "Facile Synthesis of New Pyrrolo[3,4- <i>d</i> ]pyrimidine-2,4-diones," <i>Chemical and Pharmaceutical Bulletin</i> , Vol. 22, Number 5, 1974, pp. 1212-1213  |                |
|  | P187                  | Murphy et al., "BAY 43-9006 controls tumor growth through inhibition of vascular development," 96 <sup>th</sup> Annual Meeting, Anaheim/Orange County, CA, April 16-20, 2005, abstract no. 2985  |                |
|  | P188                  | Muthumani et al., "Suppression of HIV-1 viral replication and cellular pathogenesis by a novel p38/JNK kinase inhibitor," <i>AIDS</i> , Lippincott Williams & Wilkins, 2004: Vol. 18, pp. 739-748.   |                |
|  | P189                  | National Cancer Institute, "Carboplatin and Paclitaxel With or Without Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Melanoma", 7 pages, NCT00110019, <a href="http://clinicaltrials.gov">clinicaltrials.gov</a> . (2005)   |                |
|  | P190                  | National Cancer Institute, "Paclitaxel, Carboplatin, and Radiation Therapy in Treating Patients Who Are Undergoing Surgery for Stage III Non-Small Cell Lung Cancer," 5 pages, NCT00096226, (2005)   |                |
|  | P191                  | National Cancer Institute, "Sorafenib With or Without Paclitaxel and Carboplatin in Treating Patients With Recurrent Ovarian Cancer, Primary Peritoneal Cancer, or Fallopian Tube Cancer," 5 pages, NCT00096200, (2005)  |                |
|  | P192                  | National Cancer Institute, Clinical Trials (PDQ®), "Phase II Randomized Study of ISIS 5132 or ISIS 3521 in Women with Previously Treated Metastatic Breast Cancer," 3 pages, <a href="http://www.cancer.gov">www.cancer.gov</a> website (1998).  |                |
|  | P193                  | National Cancer Institute, Clinical Trials (PDQ®), "Phase II Randomized Study of ISIS 3521 and ISIS 5132 for Locally Advanced or Metastatic Colorectal Cancer," 3 pages, <a href="http://www.cancer.gov">www.cancer.gov</a> website (1998).  |                |
|  | P194                  | National Cancer Institute, Clinical Trials (PDQ®), "Phase II Randomized Study of ISIS 3521 and ISIS 5132 in Patients with Hormone Refractory Prostate Cancer," 3 pages, <a href="http://www.cancer.gov">www.cancer.gov</a> website (1998).   |                |
|  | P195                  | National Cancer Institute, Clinical Trials (PDQ®), "Phase II Study of ISIS 5132 in Patients with Advanced Pancreatic Cancer," 3 pages, <a href="http://www.cancer.gov">www.cancer.gov</a> website (1999).  |                |
|  | P196                  | National Institutes Of Health Clinical Center, "BAY 43-9006 (Sorafenib) to Treat Relapsed Non-Small Cell Lung Cancer". 4 pages, NCT00098254, <a href="http://clinicaltrials.gov">clinicaltrials.gov</a> (2005).  |                |
|  | P197                  | Naumann et al., "Raf protein serine/threonine kinases" in: <i>Protein Phosphorylation</i> , VCH Verlagsgesellschaft mbH Chapter 7, pp. 203-236 (1996).   |                |
|  | P198                  | Naumann et al., "The Role of Raf Kinases in Development and Growth of Tumors" <i>Recent Results in Cancer Research</i> , Vol. 143, pp. 237-244 (1997).   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |              |
|---|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |              |
|   |    |    | Application Number       | 09/993,647             |              |
|   |    |    | Filing Date              | November 27, 2001      |              |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |    |    | Group Art Unit           | 1624                   |              |
|   |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 40 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | † <sup>6</sup> |
|  | P199                  | Nemunaitis et al., "Phase I Evaluation of ISIS 3521, an Antisense Oligodeoxynucleotide to Protein Kinase C-Alpha, in Patients with Advanced Cancer" Journal of Clinical Oncology, Vol. 17, No. 11, pp 3586-3595 (November 1999).                                |                |
|  | P199a                 | Neufeld et al., "Vascular endothelial growth factor (VEGF) and its receptors," The FASEB Journal, 13: 9-22 (Jan. 1999)  |                |
|  | P200                  | "Nexavar Receives FDA Fast Track Designation for Skin Cancer" 4 pages, (July 21, 2006) <a href="http://www.medicalnewstoday.com/articles/47793.php">http://www.medicalnewstoday.com/articles/47793.php</a> (last visited on 6/16/2008).                         |                |
|  | P201                  | Nicholson, K. M. et al.: "The protein kinase B/Akt signalling pathway in human malignancy," Cellular Signalling 14, 2004, pp. 381-395   |                |
|  | P202                  | Nickel et al., "Carboxylic acid analogues of suramin, potential filaricides," Indian Journal of Chemistry, February 1991, Vol. 30B, pp. 182-187   |                |
|  | P202a                 | Nilsson et al., "Vascular Endothelial Growth Factor (VEGF) Pathway," Journal of Thoracic Oncology, 1(8): 768-770 (Oct. 2006)  |                |
|  | P202b                 | Noble et al., "Protein Kinase Inhibitors: Insights into Drug Design From Structure," Science, (2004), Vol. 303, pp 1800-1805  |                |
|  | P203                  | O'Dwyer et al., "c-raf-1 Depletion and Tumor Responses in Patients Treated with the c-raf-1 Antisense Oligodeoxynucleotide ISIS 5132 (CGP 69846A)," Clinical Cancer Research Vol. 5, pp. 3977-3982 (December 1999)  |                |
|  | P204                  | Oka et al., "Constitutive Activation of Mitogen-activated Protein (MAP) Kinases in Human Renal Cell Carcinoma," Cancer Research 55, pp. 4182-4187, (September 15, 1995)   |                |
|  | P205                  | Gollob et al., "Phase II trial of sorafenib (BAY 43-9006) in combination with interferon alpha 2b in patients with metastatic renal cell carcinoma," European Journal of Cancer, 2005, Vol. 3, No. 2, pp. 226-227, abstract no. 795                             |                |
|  | P205a                 | Osella-Abate et al., "VEGF-165 serum levels and tyrosinase expression in melanoma patients: correlation with the clinical course," Melanoma Research, 12: 325-334 (Aug. 2002)   |                |
|  | P205b                 | Oza et al., "Phase II study of CGP 69846A (ISIS 5132) in recurrent epithelial ovarian cancer: an NCIC clinical trials group study (NCIC IND 116)," PubMed Abstract 12694666, Gynecol. Oncol. 2003 Apr; 89(1):129-133  |                |
|  | P206                  | Ozols, "New Developments With Carboplatin in the Treatment of Ovarian Cancer," <i>Seminars in Oncology</i> , Vol. 19, Number 1, Supplement 2, February 1992, pp. 85-89  |                |
|  | P207                  | Panka et al., "BAY 43-9006 induces apoptosis in melanoma cell lines," 96 <sup>th</sup> Annual Meeting, Anaheim/Orange County, CA, April 16-20, 2005, abstract no. 5328  |                |
|  | P208                  | Panteva et al., "Hepatitis viruses and the MAPK pathway: is this a survival strategy?" <i>Virus Research</i> , 2003, Vol 92: 131-140.   |                |
|  | P209                  | Paquette, Table of Contents for The Encyclopedia of Reagents for Organic Synthesis, John Wiley, New York, 1994 Table of Contents  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |                          |                    |
|---|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    | <b>Complete if Known</b> |                    |
|   |    | Application Number       | 09/993,647         |
|   |    | Filing Date              | November 27, 2001  |
|   |    | First Named Inventor     | Bernd Riedl et al. |
|   |    | Group Art Unit           | 1624               |
|   |    | Examiner Name            | Deepak R. RAO      |
| Sheet   | 41 | of                       | 56                 |
|   |    | Attorney Docket Number   | BAYER-0018-A       |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|--|-----------------------|--|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.      | T <sup>6</sup> |
|  | P210                  | Pavlović-Lažetić et al., "Bioinformatics analysis of SARS coronavirus genome polymorphism," 25-05-2004, BMC Bioinformatics, Vol. 5:65, 14 pages  |                |
|  | P210a                 | Pederson et al., "Early changes in serum IL-6 and VEGF levels predict clinical outcome following first-line therapy in aggressive non-Hodgkin's lymphoma," Ann. Hematol., 84:510-516 (2005)  |                |
|  | P210b                 | Peters, H.D., "Sorafenib bei soliden Tumoren," Focus Onkologie, 2007, Auflage 12000, 6 pages   |                |
|  | P211                  | Robert et al., "Phase I trial of sorafenib (BAY 43-9006) in combination with interferon alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma and malignant melanoma," European Journal of Cancer, 2005, Vol. 3, No. 2, p. 254, Abstract 883 |                |
|  | P212                  | Hu et al., "Soluble Vascular Endothelial Growth Factor Receptor 1, and Not Receptor 2, Is an Independent Prognostic Factor in Acute Myeloid Leukemia and Myelodysplastic Syndromes," Cancer 2004, Vol. 100, no. 9, pp. 1884-1891                                     |                |
|  | P213                  | Raez et al., "New developments in chemotherapy for advanced non-small cell lung cancer," Current Opin. Oncol., Vol. 18, 2006, pp. 156-161  |                |
|  | P214                  | Rahmani et al., "Apoptosis Induced by the Kinase Inhibitor BAY 43-9006 in Human Leukemia Cells Involves Down-regulation of Mcl-1 through Inhibition of Translation," J. Biol. Chem. 280(42):35217-35227 (2005)   |                |
|  | P215                  | Rak et al., "Oncogenes and Angiogenesis: Signaling Three-Dimensional Tumor Growth," Journal of Investigative Dermatology Symposium Proceedings (2000) 5, 24-33   |                |
|  | P216                  | Rak et al., "Oncogenes and Tumor Angiogenesis: Differential Modes of Vascular Endothelial Growth Factor Up-Regulation in <i>ras</i> -transformed Epithelial Cells and Fibroblasts," Cancer Research 60, pp. 490-498, (January 15, 2000)                              |                |
|  | P217                  | Rak et al., "Oncogenes as inducers of tumor angiogenesis," Cancer and Metastasis Reviews 14: 263-277, 1995   |                |
|  | P218                  | Sturm-Ramirez et al., "Reemerging H5N1 Influenza Viruses in Hong Kong in 2002 Are Highly Pathogenic to Ducks," Journal of Virology, 2004-05, 78(9):4892-4901   |                |
|  | P219                  | Raposo et al., "Catalysis of Nucleophilic Addition of Pyrrolidine to 2-(5H)-Furanone through Chromenone Cleft-Type Receptors," Tetrahedron Letters Vol. 37, No. 38, pp. 6947-6950, 1996  |                |
|  | P220                  | Ratain et al., "Phase II Placebo-Controlled Randomized Discontinuation Trial of Sorafenib in Patients with Metastatic Renal Cell Carcinoma," Journal of Clinical Oncology Vol. 24 No. 16, pp. 2505-2512 (June 1, 2006)   |                |
|  | P221                  | Ravi et al., "Activated Raf-1 Causes Growth Arrest in Human Small Cell Lung Cancer Cells," J. Clin. Invest., Vol. 101, no. 1, pp. 153-159 (1998)   |                |
|  | P222                  | Reddy et al., "Sorafenib: recent update on activity as a single agent and in combination with interferon-alpha2 in patients with advanced-stage renal cell carcinoma," Clin. Genitourin. Cancer 4:246-248 (2006) abstract  |                |
|  | P223                  | Redman et al., "p38 Kinase Inhibitors for the Treatment of Arthritis and Osteoporosis: Thienyl, Furyl, and Pyrrolyl Ureas," Bioorganic & Medicinal Chemistry Letters 11 (2001) 9-12  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |              |
|---|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |              |
|   |    |    | Application Number       | 09/993,647             |              |
|   |    |    | Filing Date              | November 27, 2001      |              |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |    |    | Group Art Unit           | 1624                   |              |
|   |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 42 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|--|-----------------------|--|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                                | † <sup>6</sup> |
|  | P224                  | Regan et al., "Pyrazole Urea-Based Inhibitors of p38 MAP kinase: From Lead Compound to Clinical Candidate," J. Med. Chem. 45:2994-3008, 2002   |                |
|  | P225                  | Richly et al., "A phase I clinical and pharmacokinetic study of the Raf kinase inhibitor (RKI) BAY 43-9006 administered in combination with doxorubicin in patients with solid tumors," International Journal of Clinical Pharmacology and Therapeutics, 2003, Vol. 41, Number 12, pp. 620-621 |                |
|  | P226                  | Richly et al., "Results of a Phase I trial of sorafenib (BAY 43-9006) in combination with doxorubicin in patients with refractory solid tumors," Annals of Oncology, 2006, 17, pp. 866-873   |                |
|  | P227                  | Richly et al., "Results of a phase I trial of BAY 43-9006 in combination with doxorubicin in patients with primary hepatic cancer," International Journal of Clinical Pharmacology and Therapeutics, 2004, Vol. 42, Number 11, pp. 650-651   |                |
|  | P228                  | Ridley et al., "Actions of IL-1 are Selectively Controlled by p38 Mitogen-Activated Protein Kinase, Regulation of Prostaglandin H Synthase-2, Metalloproteinases, and IL-6 at Different Levels," The American Association of Immunologists, 1997, J. Immunol. Vol. 158, pp. 3165-3173          |                |
|  | P228a                 | Rini and Small, "Biology and Clinical Development of Vascular Endothelial Growth Factor-Targeted Therapy in Renal Cell Carcinoma," Journal of Clinical Oncology, 23(5): 1028-1043 (Feb. 10, 2005)  |                |
|  | P228b                 | Robak et al., "Vascular endothelial growth factor and its soluble receptors VEGFR-1 and VEGFR-2 in the serum of patients with systemic lupus erythematosus," Mediators of Inflammation 12(5):293-298 (October 2003)  |                |
|  | P229                  | Robertson et al. "HIV-1 Nomenclature Proposal," Science, April 7, 2000, pp. 55-57, Vol. 288  |                |
|  | P230                  | Robinson et al., "Enhanced Radiosensitization with Gemcitabine in Mismatch Repair-Deficient HCT116 Cells," Cancer Research 63, 6935-6941 (October 15, 2003)  |                |
|  | P231                  | Robke et al., "Conversion of Aminopyridines into N-Oxides by Caro's Acid Anion (Peroxymonosulfate)," J. Chem. Research (S), 1993, pp. 412-413  |                |
|  | P232                  | Roche, E. B., "Structural Aspects of Selective Distribution," Chapter 3, in: Design of Biopharmaceutical Properties Through Prodrugs and Analogs, American Pharmaceutical Association, Washington, D.C., 1977, pp. 27-46   |                |
|  | P232a                 | Rodriguez et al., "A sensitive fluorometric enzyme-linked immunosorbent assay that measures vascular endothelial growth factor <sub>165</sub> in human plasma," Journal of Immunological Methods, 219(1-2): 45-55 (Oct. 1998)  |                |
|  | P233                  | Roman et al., "Human Papillomaviruses: Are We Ready to Type?" Clinical Microbiology Reviews. 04-1989: Vol. 2, pp.166-190   |                |
|  | P234                  | Rowinsky et al., "Sequences of Taxol and Cisplatin: A Phase I and Pharmacologic Study," Journal of Clinical Oncology, Vol. 9, Number 9, September 1991, pp. 1692-1703  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |              |
|---|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |              |
|   |    |    | Application Number       | 09/993,647             |              |
|   |    |    | Filing Date              | November 27, 2001      |              |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |    |    | Group Art Unit           | 1624                   |              |
|   |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 43 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | † <sup>6</sup> |
|  | P235                  | Rowinsky et al., "Taxol: The First of the Taxanes, an Important New Class of Antitumor Agents," <i>Seminars in Oncology</i> , Vol. 19, Number 6, December 1992, pp. 646-662   |                |
|  | P236                  | Rubin, Lewis J., "Primary Pulmonary Hypertension," <i>New England Journal of Medicine</i> , Vol. 336, No 2, pp. 111-117 (1997)  |                |
|  | P237                  | Rudin et al., "Phase I Trial of ISIS 5132, an Antisense Oligonucleotide Inhibitor of <i>c-rpf-1</i> , Administered by 24-hour Weekly Infusion to Patients with Advanced Cancer" <i>Clinical Cancer Research</i> Vol. 7, pp. 1214-1220 (May 2001).               |                |
|  | P238                  | Russo et al., "Sintesi Di Derivati 2,6-Sostituiti Del 5H-1,3,4-Tiadiazolo[3,2-a]-s-Triazina-5,7-Dione," <i>Il Farmaco</i> , Ed.Sci. (1978), 33(12), 972-983   |                |
|  | P238a                 | Rydén et al., "Tumor specific VEGF-A and VEGFR2/KDR protein are co-expressed in breast cancer," <i>Breast Cancer Research and Treatment</i> , 82(3):147-154 (Dec. 2003)   |                |
|  | P239                  | Salvatore et al., "BRAF Is a Therapeutic Target in Aggressive Thyroid Carcinoma," <i>Clin. Cancer Res.</i> pp. 1623-1629; 12(5) (March 1, 2006).  |                |
|  | P240                  | Sarkar et al., "Indole-3-Carbinol And Prostate Cancer," <i>Journal of Nutrition</i> 134, 2004, pp. 3493S-3498S  |                |
|  | P241                  | Serajuddin, "Solid Dispersion of Poorly Water-Soluble Drugs: Early Promises Subsequent Problems, and Recent Breakthroughs," <i>Journal of Pharmaceutical Sciences</i> Vol 88, No. 10, pp. 1058-1066 (October 1999)  |                |
|  | P241a                 | Shaked et al., "Cellular and Molecular Surrogate Markers to Monitor Targeted and Non-Targeted Antiangiogenic Drug Activity and Determine Optimal Biologic Dose," <i>Current Cancer Drug Targets</i> , 5: 551-559 (Nov. 2005)                                    |                |
|  | P242                  | Shelton et al., "Effects of the RAF/MEK/ERK and PI3K/AKT signal transduction pathways on the abrogation of cytokine-dependence and prevention of apoptosis in hematopoietic cells," <i>Oncogene</i> , Vol. 22, No. 16, 04/2003; pp. 2478-2492                   |                |
|  | P243                  | Shi et al., "Constitutive and Inducible Interleukin 8 Expression by Hypoxia and Acidosis Renders Human Pancreatic Cancer Cells More Tumorigenic and Metastatic," <i>Clinical Cancer Research</i> , 1999, Vol. 5, pp. 3711-3721                                  |                |
|  | P243a                 | Shimanuki et al., "Role of Serum Vascular Endothelial Growth Factor in the Prediction of Angiogenesis and Prognosis for Non-small Cell Lung Cancer," <i>Lung</i> , 183: 29-42 (2005)  |                |
|  | P244                  | Simone, Joseph, V., "Part XIV. Oncology," in: <i>Cecil Textbook of Medicine</i> , 20th Edition, Vol. 1, 2-3-1997. W.B. Saunders Company, pp. 1004-1010  |                |
|  | P245                  | Sinkula et al., "Rationale for Design of Biologically Reversible Drug Derivatives: Prodrugs," <i>Journal of Pharmaceutical Sciences</i> , Vol. 64, No. 2, February 1975, pp. 181-210  |                |
|  | P246                  | Siu et al., "Phase I study of oral raf-1 kinase inhibitor BAY 43-9006 with gemcitabine in patients with advanced solid tumors," Abstract no. 828, <i>Proc. Am. Soc. Clin. Oncol.</i> , 2003, Vol. 22, p. 207  |                |
|  | P247                  | Siu et al., "Phase I Trial of Sorafenib and Gemcitabine in Advanced Solid Tumors with an Expanded Cohort in Advanced Pancreatic Cancer," <i>Clin. Cancer Res.</i> 12(1):144-151 (2006)  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |    |                          |                    |
|--|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE<br/>STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | Application Number       | 09/993,647         |
|  |    |    | Filing Date              | November 27, 2001  |
|  |    |    | First Named Inventor     | Bernd Riedl et al. |
|  |    |    | Group Art Unit           | 1624               |
|  |    |    | Examiner Name            | Deepak R. RAO      |
|  |    |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 44 | of | 56                       |                    |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | † <sup>6</sup> |
|  | P248                  | Smith et al., "Discovery of Heterocyclic Ureas as a New Class of Raf Kinase Inhibitors: Identification of a Second Generation Lead by a Combinatorial Chemistry Approach," Bioorganic & Medicinal Chemistry Letters, 2001, Vol. 11, pp. 2775-2778               |                |
|  | P249                  | Smith et al., (Abstract) "Recent Advances in the Research and Development of RAF Kinase Inhibitors," Current Topics in Medicinal Chemistry 6(11):1071-1089 (2006)   |                |
|  | P250                  | Smyth, R.M. et al., "Anchimeric Assistance in the Specific Acid-catalysed Hydration of Benzonitriles" J. Chem. Soc. Perkin Trans. 2 1993 pp. 2171-2174  |                |
|  | P251                  | Song, Huai-Dong et al., "Cross-host evolution of severe acute respiratory syndrome coronavirus in palm civet and human," Proc. Natl. Acad. Sci. USA 102(7):2430-2435 (2005)   |                |
|  | P252                  | Sorbara et al., "BAY-43-9006," Drugs of the Future, 2002, Vol. 27, Number 12, pp. 1141-1147   |                |
|  | P253                  | van Spronsen et al., "Novel treatment strategies in clear-cell metastatic renal cell carcinoma," Anti-Cancer Drugs, 2005, Vol. 16, pp. 709-717  |                |
|  | P253a                 | Stadler et al., "A Randomized Phase II Trial of the Antiangiogenic Agent SU5416 in Hormone-Refractory Prostate Cancer," Clinical Cancer Research, 10: 3365-3370 (May 15, 2004)  |                |
|  | P254                  | Stahl et al., "Deregulated Akt3 Activity Promotes Development of Malignant Melanoma," Cancer Research, Vol. 64, No. 19; 10/2004; pp. 7002-7010  |                |
|  | P255                  | Stavchansky et al., "Evaluation of the Bioavailability of a Solid Dispersion of Phenytoin in Polyethylene Glycol 6000 and a Commercial Phenytoin Sodium Capsule in the Dog," Journal of Pharmaceutical Sciences, Vol. 73, No. 6, June 1984, pp. 733-736         |                |
|  | P256                  | Krontiris, "Chapter 71. Molecular and Cellular Biology of Cancer," and Capizzi, "Chapter 72, Principles of Treatment of Cancer," in: Internal Medicine, 4th Edition, Stein, Jay H., MD, Ed., Mosby, 1994, pp. 699-715   |                |
|  | P257                  | Sternberg et al., "Conspiracy Theory: RAS and RAF Do Not Act Alone" Cell, Vol. 95, pp. 447-450 (November 13, 1998).   |                |
|  | P258                  | Stella et al., "Prodrugs and Site-Specific Drug Delivery," Journal of Medicinal Chemistry, Vol. 23, No. 12, December 1980, pp. 1275-1282  |                |
|  | P259                  | Stella et al., "Prodrugs as therapeutics," Exp. Opin. Ther. Patents 14(3): 277-280 (2004)   |                |
|  | P260                  | Stella et al., "Prodrugs. Do They Have Advantages in Clinical Practice?" Drugs, Vol. 29, 1985, pp. 455-473  |                |
|  | P260a                 | Stevenson et al., "Phase I Clinical/Pharmacokinetic and Pharmacodynamic Trial of the c-raf-1 Antisense Oligonucleotide ISIS 5132 (CGP 69846A)," The Journal of Clinical Oncology, Vol. 17, No7: pp. 2227-2236 (July 1999)                                       |                |
|  | P261                  | Stöckl et al., "Integrity of c-Raf-1/MEK signal transduction cascade is essential for hepatitis B virus gene expression," Oncogene. Nature Publishing Group, 2003: Vol. 22, pp. 2604-2610   |                |
|  | P262                  | Stokoe et al., "Activation of c-Raf-1 by Ras and Src through different mechanisms: activation <i>in vivo</i> and <i>in vitro</i> ," The Embo Journal, Vol. 16 No. 9 pp. 2384-2396 (1997)  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |              |
|---|----|----|--------------------------|------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |              |
|   |    |    | Application Number       | 09/993,647             |              |
|   |    |    | Filing Date              | November 27, 2001      |              |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |              |
|   |    |    | Group Art Unit           | 1624                   |              |
|   |    |    | Examiner Name            | Deepak R. RAO          |              |
| Sheet   | 45 | of | 56                       | Attorney Docket Number | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|--|-----------------------|--|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                                | † <sup>6</sup> |
|  | P263                  | Storm et al., "raf Oncogenes in Carcinogenesis" Critical Reviews in Oncogenesis, Vol. 2, Issue 1, pp. 1-8 (1990)   |                |
|  | P263a                 | Strumberg, D., "Preclinical and Clinical Development of the Oral Multikinase Inhibitor Sorafenib in Cancer Treatment," Drugs of Today, 41(12): 773-784 (2005)  |                |
|  | P264                  | Strumberg et al., "Phase I Clinical and Pharmacokinetic Study of the Novel Raf Kinase and Vascular Endothelial Growth Factor Receptor Inhibitor BAY 43-9006 in Patients With Advanced Refractory Solid Tumors," Journal of Clinical Oncology, February 10, 2005, Vol 23, Number 5, pp. 965-972 |                |
|  | P265                  | Strumberg et al., "Phase I Clinical, Pharmacokinetic and Pharmacodynamic Study of the Raf Kinase Inhibitor BAY 43-9006 in Patients with Locally Advanced or Metastatic Cancer," Proc. Am. Soc. Clin. Oncol. 20: 2001 (abstr 330)   |                |
|  | P266                  | Strumberg et al., "Results of phase I pharmacokinetic and pharmacodynamic studies of the Raf kinase inhibitor BAY 43-9006 in patients with solid tumors," International Journal of Clinical Pharmacology and Therapeutics, 2002, Vol 40, Number 12, pp. 580-581                                |                |
|  | P266a                 | Strumberg et al., "Sorafenib Neue Therapieoption in der Onkologie," Krankenhauspharmazie, 2007, Vol. 28, pp. 93-97, pages 1/5, 2/5, 3/5 and 4/5  |                |
|  | P267                  | Suzuki et al., "The role of p38 mitogen-activated protein kinase in IL-6 and IL-8 production from the TNF- $\alpha$ - or IL-1 $\beta$ -stimulated rheumatoid synovial fibroblasts," FEBS Letters (2000), Vol. 465, pp. 23-27   |                |
|  | P268                  | Swarbrick et al., "Contents," pp. xvii-xviii in: Encyclopedia of Pharmaceutical Technology." 2nd Edition, Marcel Dekker, Inc. 2002   |                |
|  | P269                  | Swart, Guido W.M., "International Melanoma Research Congress – Foundation for Melanoma Research," IDRUGS: The Investigational Drugs Journal, 08/2003; Vol. 6, no. 8, pp. 752-754   |                |
|  | P270                  | Tabellini et al., "Novel 2'-substituted, 3'-deoxy-phosphatidyl-myo-inositol analogues reduce drug resistance in human leukaemia cell lines with an activated phosphoinositide 3-kinase/Akt pathway," British Journal Of Haematology, 126, 2004, pp. 574-582                                    |                |
|  | P271                  | Takimoto et al., "Safety and anti-tumor activity of sorafenib (Nexavar®) in combination with other anti-cancer agents: a review of clinical trials," Cancer Chemotherapy and Pharmacology (2008) 61:535-548  |                |
|  | P272                  | Tamm et al., "Hypoxia-Induced Interleukin-6 and Interleukin-8 Production Is Mediated by Platelet Activation Factor and Platelet-Derived Factor in Primary Human Lung Cells," Am. J. Respir. Cell Mol. Biol. Vol. 19, pp. 653-661, (1998)   |                |
|  | P273                  | Tanaka et al., "Current status and perspective of antiangiogenic therapy for cancer: hepatocellular carcinoma," Int. J. Clin. Oncol. (2006) 11:82-89 (2006)  |                |
|  | P274                  | Tang et al., "Inhaled nitric oxide attenuates pulmonary hypertension and improves lung growth in infant rats after neonatal treatment with a VEGF receptor inhibitor." Am. J. Physiol. Lung Cell. Mol. Physiol. 287:L344-L351 (2004)   |                |
|  | P275                  | Tarzia et al., "Synthesis and anti-inflammatory properties of some pyrrolo(1H,3H) [3,4-d]pyrimidin-2-ones and pyrrolo=(1H,6H)[3,4-d]pyrimidin-2-ones," Chemical Abstracts, Vol. 91, 1979, 91:74558p  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |                          |                    |
|--|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    | Application Number       | 09/993,647         |
|  |    | Filing Date              | November 27, 2001  |
|  |    | First Named Inventor     | Bernd Riedl et al. |
|  |    | Group Art Unit           | 1624               |
|  |    | Examiner Name            | Deepak R. RAO      |
|  |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 46 | of                       | 56                 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.                                       | † <sup>6</sup> |
|  | P275a                 | Teknos et al., "Elevated Serum Vascular Endothelial Growth Factor and Decreased Survival in Advanced Laryngeal Carcinoma," <i>Head &amp; Neck</i> , 24: 1004-1011 (November 2002)   |                |
|  | P276                  | Thaimattam et al., "3D-QSAR CoMFA, CoMSIA studies on substituted ureas as Raf-1 kinase inhibitors and its confirmation with structure-based studies," <i>Bioorganic &amp; Medicinal Chemistry</i> , 2004, Vol. 12, pp. 6415-6425  |                |
|  | P277                  | Thelen et al., "VEGF-D promotes tumor growth and lymphatic spread in a mouse model of hepatocellular carcinoma" <i>Int. J. Cancer</i> 122, 2471-2481 (2008) © 2008 Wiley-Liss, Inc.   |                |
|  | P278                  | Thompson et al., "Recent progress in targeting the Raf/MEK/ERK pathway with inhibitors in cancer drug discovery," <i>Curr. Opin. Pharmacol.</i> , August 2005, Vol. 5, Number 4, pp. 350-356  |                |
|  | P279                  | Tong et al., "Pharmacodynamic Monitoring of BAY 43-9006 (Sorafenib) in Phase I Clinical Trials Involving Solid Tumor and AML/MDS Patients, Using Flow Cytometry to Monitor Activation of the ERK Pathway in Peripheral Blood Cells," <i>Cytometry Part B (Clinical Cytometry)</i> 70B: 107-114 (2006) |                |
|  | P280                  | Trost et al., "Contents," Vols. 1-9, 36 pages in: <i>Comprehensive Organic Synthesis: Selectivity, Strategy &amp; Efficiency in Modern Organic Chemistry</i> , Pergamon Press, Oxford, UK, 1991.  |                |
|  | P281                  | Gupta-Abramson et al., "Phase II Trial of Sorafenib in Advanced Thyroid Cancer" <i>Journal of Clinical Oncology</i> Vol. 26, No. 29, pp. 4714-4719 (October 10, 2008).  |                |
|  | P282                  | Veronese et al., "Mechanisms of Hypertension Associated with BAY 43-9006," <i>Journal of Clinical Oncology</i> , 2006, Vol. 24, No. 9, pp. 1363-1369  |                |
|  | P283                  | Vivanco et al., "The Phosphatidylinositol 3-Kinase-AKT Pathway in Human Cancer," <i>Nature Reviews Cancer</i> , Vol. 2, July 2002, pp. 489-501  |                |
|  | P284                  | Vlahos et al., "A Specific Inhibitor of Phosphatidylinositol 3-Kinase, 2-(4-Morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002)," <i>The Journal of Biological Chemistry</i> , Vol. 269, No.7, 1994, pp. 5241-5248   |                |
|  | P284a                 | Wakelee et al., "Targeting Angiogenesis with Vascular Endothelial Growth Factor Receptor Small-Molecular Inhibitors: Novel Agents with Potential in Lung Cancer," <i>Clinical Lung Cancer</i> , 7(Suppl 1): S31-S38 (Sept 2005)   |                |
|  | P285                  | Wald et al., "Involvement of the CXCL12/CXCR4 pathway in the advanced liver disease that is associated with hepatitis C virus or hepatitis B virus," <i>Eur. J. Immunol.</i> , Vol. 34, p. 1164-1174 (2004)   |                |
|  | P286                  | Wan et al., "Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF," <i>Cell</i> , March 19, 2004, Vol. 116, pp. 855-867   |                |
|  | P287                  | Weekly Epidemiological Record, "Influenza," World Health Organization. 04-1999; Vol. 14, pp. 111-112.   |                |
|  | P288                  | Wernuth, C. G., "Designing Prodrugs and Bioprecursors II: Bioprecursor Prodrugs," in: <i>The Practice of Medicinal Chemistry</i> , Academic Press Limited 1996, pp. 697-715   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |                      |                    |                          |              |
|---|----|----------------------|--------------------|--------------------------|--------------|
| Substitute for form 1449A/PTO<br><br><h2 style="text-align: center;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2><br><i>(use as many sheets as necessary)</i> |    |                      |                    | <b>Complete if Known</b> |              |
|   |    | Application Number   | 09/993,647         |                          |              |
|   |    | Filing Date          | November 27, 2001  |                          |              |
|   |    | First Named Inventor | Bernd Riedl et al. |                          |              |
|   |    | Group Art Unit       | 1624               |                          |              |
|   |    | Examiner Name        | Deepak R. RAO      |                          |              |
| Sheet   | 47 | of                   | 56                 | Attorney Docket Number   | BAYER-0018-A |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|--|-----------------------|--|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | † <sup>6</sup> |
|  | P289                  | White et al., "Heterocyclic Ureas: Inhibitors of Acyl-CoA:Cholesterol O-Acyltransferase as Hypocholesterolemic Agents." <i>J. Med. Chem.</i> 1996, 39, pp. 4382-4395   |                |
|  | P289a                 | Wierzbowska et al., "Circulating VEGF and its soluble receptors sVEGFR-1 and sVEGFR-2 in patients with acute leukemia," <i>Eur. Cytokine Netw.</i> , 14(3): 149-153 (Sept. 2003)   |                |
|  | P289b                 | Wilhelm et al., "A Novel RAF Kinase Inhibitor Blocks the RAF/MEK/ERK Pathway in Tumor Cells," Poster, 92nd Annual Meeting of the American Association for Cancer Research, March 24-28, 2001, New Orleans, LA USA, 1 page  |                |
|  | P290                  | Wilhelm et al., "BAY 43-9006 Exhibits Broad Spectrum Oral Antitumor Activity and Targets the RAF/MEK/ERK Pathway and Receptor Tyrosine Kinases Involved in Tumor Progression and Angiogenesis," <i>Cancer Research</i> , October 1, 2004, Vol. 64, pp. 7099-7109 |                |
|  | P291                  | Wilhelm et al., "BAY 43-9006: Preclinical Data," <i>Curr Pharm Des.</i> 2002, Vol. 8, Number 25, pp. 2255-2257   |                |
|  | P291a                 | Wilhelm et al., "Discovery and development of sorafenib: a multikinase inhibitor for treating cancer," <i>Nature Reviews, Drug Discovery</i> , 2006, Vol. 5, pp. 835-844   |                |
|  | P291b                 | Wilhelm et al., "Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling," <i>Mol. Cancer Ther.</i> 2008, Vol. 7, No. 10, pp. 3129-3140  |                |
|  | P293                  | Wilkinson Geoffrey, "Contents," 7 pages in: <i>Comprehensive Organometallic Chemistry. The Synthesis, Reactions, and Structures of Organometallic Compounds</i> , Pergamon Press, Oxford, U.K. 1982: Vol. 1-3  |                |
|  | P294                  | Wilson et al., "The structural basis for the specificity of pyridinylimidazole inhibitors of p38 MAP kinase," <i>Chemistry &amp; Biology</i> , 1997, Vol. 4, Number 6, pp. 423-431.  |                |
|  | P294a                 | Stollorz, "Die Krebsformel, die der Zufall fand," <i>Frankfurter Allgemeine Sonntagszeitung</i> , July 2, 2006, NR 26, pp. 68-69   |                |
|  | P295                  | Wissner et al., "Analogues of Platelet Activating Factor. 7. Bis-Aryl Amide and Bis-Aryl Urea Receptor Antagonists of PAF," <i>J. Med. Chem.</i> , 1992, Vol. 35, pp. 4779-4789  |                |
|  | P296                  | Wojnowski et al., "Endothelial apoptosis in Braf-deficient mice," <i>Nature Genetics</i> Vol. 16, pp. 293-297 (July 1997)  |                |
|  | P297                  | Onyx Pharmaceuticals, Inc., "Novel RAF Kinase Inhibitor Bay 43-9006 Shows Early Signs of Tolerability and Activity in Phase 1B Combination Trials Reported at ASCO," 1 page, (Press Release: June 2, 2003)   |                |
|  | P298                  | Wright et al., "Bovine Immunodeficiency Virus Expression <i>in Vitro</i> is Reduced in the Presence of $\beta$ -Chemokines, MIP-1 $\alpha$ , MIP-1 $\beta$ and RANTES." <i>Veterinary Research Communications</i> . 2002: Vol. 26, pp. 239-250.                  |                |
|  | P299                  | Wright et al., "Clinical Trials Referral Resource. Current Clinical Trials of BAY 43-9006, Part 1," <i>Oncology</i> , April 2005, Vol. 19, No. 4: pp. 499-502  |                |
|  | P299a                 | Wu et al., "Plasma vascular endothelial growth factor is useful in assessing progression of breast cancer post surgery and during adjuvant treatment," <i>International Journal of Oncology</i> , 20: 509-516 (2002)   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |
|---|----|----|--------------------------|------------------------|
| Substitute for form 1449A/PTO<br><br><h2 style="text-align: center; margin: 0;">INFORMATION DISCLOSURE STATEMENT BY APPLICANT</h2> <p style="text-align: center; margin: 0;"><i>(use as many sheets as necessary)</i></p> |    |    | <b>Complete if Known</b> |                        |
|   |    |    | Application Number       | 09/993,647             |
|   |    |    | Filing Date              | November 27, 2001      |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |
|   |    |    | Group Art Unit           | 1624                   |
|   |    |    | Examiner Name            | Deepak R. RAO          |
| Sheet   | 48 | of | 56                       | Attorney Docket Number |
|   |    |    |                          | BAYER-0018-A           |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |  |                |
|--|-----------------------|--|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.  | † <sup>6</sup> |
|  | P300                  | Xu et al., "Hypoxia-induced Elevation in Interleukin-8 Expression by Human Ovarian Carcinoma Cells," Cancer Research, 1999, Vol. 59, pp. 5822-5829   |                |
|  | P301                  | He et al., "Oral Formulation of a Novel Antiviral Agent, PG301029, in a Mixture of Gelucire 44/14 and DMA (2:1, wt/wt)," AAPS PharmSciTech 2005; Vol.6 (1) Article 1, 5 pages, ( <a href="http://www.aapsharmscitech.org">http://www.aapsharmscitech.org</a> )   |                |
|  | P301a                 | Yamaguchi et al., "Expression of Vascular Endothelial Growth Factor in Human Hepatocellular Carcinoma," Hepatology, 28(1) pp. 68-77 (1998)   |                |
|  | P302                  | Yang et al. "Akt/Protein Kinase B Signaling Inhibitor-2, a Selective Small Molecule Inhibitor of a Akt Signaling with Antitumor Activity in Cancer Cells Overexpressing Akt," Cancer Research, 64, July 1, 2004, pp. 4394-4399   |                |
|  | P303                  | Yang et al., "Antiviral chemotherapy control of poxvirus infections through inhibition of cellular signal transduction," The Journal of Clinical Investigation, 2005; 115(2):pp. 379-387   |                |
|  | P304                  | Yeh et al., "Characterization of severe acute respiratory syndrome coronavirus genomes in Taiwan: Molecular epidemiology and genome evolution," Proc. Natl. Acad. Sci. USA 2004-02-24, 101(8):2542-2547  |                |
|  | P305                  | Yu et al., "The role of Mcl-1 downregulation in the proapoptotic activity of the multikinase inhibitor BAY 43-9006," Oncogene 24:6861-6869 (2005)  |                |
|  | P306                  | Zachos et al., "Herpes Simplex Virus Type 1 Infection Stimulates p38/c-Jun N-terminal Mitogen-activated Protein Kinase Pathways and activates Transcription Factor AP-1," Journal of Biological Chemistry, The American Society for Biochemistry and Molecular Biology, Inc. 1999; Vol. 274, pp. 5097-5103 |                |
|  | P306a                 | Zangari et al., "Phase II Study of SU5416, a Small Molecule Vascular Endothelial Growth Factor Tyrosine Kinase Receptor Inhibitor, in Patients with Refractory Multiple Myeloma," Clinical Cancer Research, 10: 88-95 (Jan 1, 2004)  |                |
|  | P307                  | Norden-Zfoni, Anat. "Blood-Based Biomarkers of SU11248 Activity and Clinical Outcome in Patients with Metastatic Imatinib-Resistant Gastrointestinal Stromal Tumor," Clin. Cancer. Res. 2007; 13(9):2643-2650 May 1, 2007  |                |
|  | P308                  | Zhao et al., "Moderate mutation rate in the SARS coronavirus genome and its implications," BMC Evolutionary Biology, 2004, 4:21, 9 pages   |                |
|  | P309                  | Zhu et al., "From the Cyclooxygenase-2 Inhibitor Celecoxib to a Novel Class of 3- Phosphoinositide-Dependent Protein Kinase-1 Inhibitors," Cancer Research 64, June 15, 2004, pp. 4309-4318  |                |
|  | P310                  | Carter et al., "Anti-tumor Efficacy of the Orally Active RAF Kinase Inhibitor Bay 43-90006 in Human Tumor Xenograft Model," #4954, Proceedings of the American Association for Cancer Res., 2001, Vol. 42, p. 923  |                |
|  | P311                  | Iwadate et al., MEDLINE/NLM, NLM8336809 "Intra-arterial ACNU, CDDP chemotherapy for brain metastases from lung cancer: comparison of cases with and without intra-arterial mannitol infusion," 1 page, abstract, <b>June 1993</b>  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**



Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |    |                          |                    |
|--|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | Application Number       | 09/993,647         |
|  |    |    | Filing Date              | November 27, 2001  |
|  |    |    | First Named Inventor     | Bernd Riedl et al. |
|  |    |    | Group Art Unit           | 1624               |
|  |    |    | Examiner Name            | Deepak R. RAO      |
|  |    |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 49 | of | 56                       |                    |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.   | T <sup>6</sup> |
|  | P312                  | Kubo et al., "Synthesis and Structure-Activity Relationship of Quinazoline-Urea Derivatives as Novel Orally Active VEGF Receptor Tyrosine Kinase Selective Inhibitors," Proceedings of the American Association of Cancer Res., 2002, Vol. 43, p. 182, abstract no. 913   |                |
|  | P313                  | Riedl et al., # 4956 "Potent Raf Kinase Inhibitors from the Diphenylurea Class: Structure Activity Relationships," Proceedings of the American Association for Cancer Research, Vol. 42, March 2001 (2001-03), page 923, 92nd Annual Meeting of the American Association for Cancer Research; New Orleans, LA, USA; March 24-28, 2001   |                |
|  | P314                  | Strumberg et al., abstract no. #2921 "Phase I and Pharmacokinetic Study of the Raf Kinase Inhibitor Bay 43-9006 in Patients with Locally Advanced or Metastatic Cancer," Proceedings of the American Association for Cancer Research, vol. 42, March 2001 (2001-03), page 543, 92nd Annual Meeting of the American Association for Cancer Research; New Orleans, LA, USA; March 24-28, 2001 |                |
|  | P315                  | Abstract of DE 3305866 A1, August 23, 1984, BASF AG et al.  |                |
|  | P316                  | Abstract of EP 4931 A (Equivalent 4,240,820), Bayer AG, 1 page, <b>1980</b>   |                |
|  | P317                  | Abstract of EP 16371 (1980), 1 page, Hoffmann-La Roche AG   |                |
|  | P318                  | Abstract of EP 16371, October 1, 1980, 1 page   |                |
|  | P319                  | Abstract of EP 116932, August 29, 1984, 2 pages.  |                |
|  | P320                  | Abstract of EP 116932, (1984), 2 pages, BASF AG   |                |
|  | P321                  | Abstract of EP 0202538, (1986), 3 pages   |                |
|  | P322                  | Abstract of EP 0202538 A1, "Growth Promoting Agents, November 26, 1986, 4 pages, Bayer AG   |                |
|  | P323                  | Abstract of EP 0405233A1, Mitsubishi Kasei Corp., 2 pages, <b>1991</b>  |                |
|  | P324                  | Abstract of EP 0405233A1, Tetsuo Sekiya et al., 1 page, <b>1991</b>   |                |
|  | P325                  | Abstract of EP 0676395A2, (1995), 3 pages, Hoechst AG   |                |
|  | P326                  | Abstract of EP 676395, (U.S. equivalent 5,698,581), December 16, 1997, 1 page   |                |
|  | P327                  | Patent Abstracts of Japan 02-022650, 01-25-1990, 2 pages, Konica Corp.  |                |
|  | P328                  | esp@cenet Abstracts of Japan 02-022650, 01-25-1990, 1 page  |                |
|  | P329                  | Patent Abstracts of Japan 02-023337, 01-25-1990, 2 pages, Konica Corp.  |                |
|  | P329a                 | Patent Abstracts of Japan 63-214752, 09-07-1988, 2 pages, family member of JP 6-07512 B4, Fuji Photo Film Co. Ltd.  |                |
|  | P330                  | esp@cenet Abstract of Japan 02-023337, 1 page, <b>1990</b>  |                |
|  | P331                  | Abstract of JP 55162772 A2, Preparation of Substituted Acetic Acid Derivatives, Shiongi & Co., Ltd. December 1980, 1 page   |                |
|  | P332                  | Esp@cenet Abstract of WO 9822103, 28 May 1998, Philip Hedge et al.  |                |
|  | P332a                 | Abstract of WO 9822098 A2, QLT Phototherapeutics Inc. et al., 05-28-1998, 1 page  |                |
|  | P333a                 | Abstract of WO 9822103 A1, Zeneca Limited, published 05-28-1998, 1 page   |                |
|  | P333b                 | Abstract of WO 9852559 A1, Bayer Corp. et al., published 11-26-1998, 1 page   |                |
|  | P333c                 | Abstract of WO 9852562 A1, Verkaik, MSE, et al., published 11-26-1998, 1 page   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |                          |                    |
|--|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    | Application Number       | 09/993,647         |
|  |    | Filing Date              | November 27, 2001  |
|  |    | First Named Inventor     | Bernd Riedl et al. |
|  |    | Group Art Unit           | 1624               |
|  |    | Examiner Name            | Deepak R. RAO      |
|  |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 50 | of                       | 56                 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.       | T <sup>6</sup> |
|  | P333d                 | Abstract of WO 9900357 A1, Vertex Pharm. Inc., published 01-07-1999, 1 page   |                |
|  | P333e                 | Abstract of WO 9900364 A1, Pharmacia & Upjohn S.P.A. et al., published 01-07-1999, 1 page   |                |
|  | P333f                 | Abstract of WO 9932098 A2, Janssen Pharm NV, published 07-01-1999, 1 page   |                |
|  | P333g                 | Abstract of WO 9932106 A1, Bayer Corp., published 07-01-1999, 1 page  |                |
|  | P333h                 | Abstract of WO 9932148 A1, Beth Israel Deaconess Medical Center et al., pub. 07-01-1999, 1 page   |                |
|  | P333i                 | Abstract of WO 9932436 A1, Bayer Corp., published 07-01-1999, 1 page  |                |
|  | P333j                 | Abstract of WO 9932455 A1, Bayer Corp., published 07-01-1999, 1 page  |                |
|  | P333k                 | Abstract of WO 9932457 A1, Hoechst Marion Roussel Deutschland GmbH et al., published 07-01-1999, 1 page   |                |
|  | P334                  | Caplus 72:79046, Abstract of CH 479557, "Tuberculostatic and cancerostatic polybasic ureas," Dr. A. Wander, October 15, 1969, 6 pages   |                |
|  | P335                  | Caplus 84:180049, Abstract JP 56029871, "Substituted acetic acid derivatives," Hamada, Yoshinori et al., July 10, 1981, 1 page  |                |
|  | P336                  | Caplus 84:43857, Abstract JP 58021626, "Alkanoic acid derivatives containing a pyridine ring," Maeda, Ryoze et al., May 2, 1983, 1 page   |                |
|  | P337                  | Caplus 86:72448, Abstract JP 57053785, "Pyridine derivatives," Maeda, Ryoze et al., November 15, 1982, 1 page   |                |
|  | P338                  | Caplus 87:62295, "The metabolism and toxicity of halogenated carbanilides. Biliary metabolites of 3,4,4'-trichlorocarbanilide and 3-trifluoromethyl-4,4'-dichlorocarbanilide in the rat," Chemical Life Science, pp. 157-66, 1977, 1 page                             |                |
|  | P339                  | Caplus 98:78152, Abstract of JP 57185219, "Antitumor benzophenone derivatives," November 15, 1982, 1 page, Chugai Pharmaceutical Co., Ltd.  |                |
|  | P340                  | Caplus 113:106314, Abstract of JP 2022650, "Silver halide color photographic material containing a cyan coupler of 2-ureido-phenol type to improve dye developability and remove lecuo cyan dye," Noboru Mizukura et al. January 25, 1990, 1 page                     |                |
|  | P341                  | Caplus 113:142130, Abstract of JP 2023337, "Silver halide photographic material containing phenolic cyan coupler a colorless cyan coupler," Toshihiko Yagi et al., January 25, 1990, 1 page   |                |
|  | P342                  | Caplus 125:245169, "Production of murine monoclonal antibodies against sulcofuron and flucofuron by in vitro immunization," G. A. Bonwick et al., J. Immunol. Methods, 196(2), pp. 163-173, 1996, 1 page  |                |
|  | P343                  | Caplus 126:166148, "Inhibitors of coenzyme A-independent transacylase induce apoptosis in human HL-60 cells," James D. Winkler et al., J. Pharmacol. Exp. Ther. 279(2), pp. 956-966, 1996, 2 pages  |                |
|  | P344                  | Dearden et al., "Quantitative structure-biodegradability studies: an investigation of the MITI aromatic compound data-base," in: Biodegradability Prediction, Edited by Willie J.G.M. Peijnenburg et al., NATO ASI Series. 2. Environment - Vol. 23, pp. 93-104, 1996 |                |
|  | P345                  | Caplus 127:293717, "Optical properties of segmented oligourethane with azomethine terminal fragments," National Academy of Science of Ukraine, M. V. Kurik et al., pp. 2038-2041, 1996, 2 pages   |                |
|  | P346                  | Caplus 127:34137I, "Preparation of quinoline and quinazoline derivatives inhibiting platelet-derived growth factor receptor autophosphorylation," Kazuo Kubo et al., May 15, 1997, WO 97/17329  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |    |                          |                        |
|---|----|----|--------------------------|------------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | <b>Complete if Known</b> |                        |
|   |    |    | Application Number       | 09/993,647             |
|   |    |    | Filing Date              | November 27, 2001      |
|   |    |    | First Named Inventor     | Bernd Riedl et al.     |
|   |    |    | Group Art Unit           | 1624                   |
|   |    |    | Examiner Name            | Deepak R. RAO          |
| Sheet   | 51 | of | 56                       | Attorney Docket Number |
|   |    |    |                          | BAYER-0018-A           |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | † <sup>6</sup> |
|  | P347                  | Caplus 131:58658k, "Inhibition of raf kinase using symmetrical and unsymmetrical substituted diphenyl ureas," Miller, Scott, et al. July 1, 1999, WO 99 32,436  |                |
|  | P348                  | Caplus 131:73649b, "Preparation of pyrazolyl aryl ureas and related compounds as p38 kinase inhibitors," Jacques Dumas et al., July 1, 1999, WO 99/32110  |                |
|  | P349                  | Caplus 131:87909y, "Inhibition of p38 kinase activity using substituted heterocyclic ureas," Jacques Dumas et al., July 1, 1999, WO 99/32111  |                |
|  | P349a                 | Caplus 146:265643 Abstract of Strumberg et al., "Sorafenib - A novel opportunity in oncology," Arzneimitteltherapie 25(1):2-6 (2007) abstract, 1 page   |                |
|  | P350                  | Kujundzic et al., "Synthesis of 8-methyl-1,2,3,4-tetrahydropyrido[3,4-d] pyrimidine-2,4-diones," Croat. Chem. Acta (1991) 64(4):599-606, Chemical Abstracts Vol. 116, No. 21, 25 May 1992, (pp. 741-742) No. 116:214456   |                |
|  | P351                  | Badran et al., "Novel piperazinyl-substituted pyrimidines as antihypertensive and vasodilators," Revue Roumaine de Chimie (1992), 37(2):238-288, Chemical Abstracts Vol. 117:251318   |                |
|  | P352                  | "Beilstein number" Collection, 28 pp. (1997)  |                |
|  | P353                  | "Beilstein number" Collection, 4 pp. (1997)   |                |
|  | P354                  | Derwent World Patents Index Search, pp. 20-26. (1997)   |                |
|  | P355                  | Dumas, J. "CAS Substructure," May 6, 1997, pp. 1-29   |                |
|  | P356                  | Scott, Bill, "Substructure (Patent Families)," August 11, 1997, pp. 1-19  |                |
|  | P357                  | Scott, Bill, "Substructure #2," November 25, 1997, pp. 1-3  |                |
|  | P358                  | Scott, Bill, "Substructure Search," December 2, 1997, pp. 1-49  |                |
|  | P359                  | Substructure Search, pp. 1-29. (1997)   |                |
|  | P360                  | Wild, Hanno, "Substructure #1," search, pp. 1-150, 1996   |                |
|  | P361                  | A "Notice of References Cited" from the USPTO for U.S. application 08/995,749, filing date of 12/22/97, Inhibition of P38 Kinase Using Symmetrical and Unsymmetrical Diphenyl Ureas, 2 pages  |                |
|  | P362                  | A "Notice of References Cited" from the USPTO for U.S. application 09/083,399, filing date of 5/22/98, Patent 6187799 issued 2/13/2001, Inhibition of Raf Kinase Activity Using Aryl Ureas, 1 page  |                |
|  | P363                  | A "Notice of References Cited" from the USPTO for U.S. application 09/425,228, filing date of 10/22/99, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 3 pages  |                |
|  | P364                  | A "Notice of References Cited" from the USPTO for U.S. application 09/425,229, filing date of 10/22/99, Omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, 1 page  |                |
|  | P365                  | A "Notice of References Cited" from the USPTO for U.S. application 09/458,015, filing date of 12/10/1999, Inhibition Of p38 Kinase Using Symmetrical And Unsymmetrical Diphenyl Ureas, 1 page   |                |
|  | P366                  | A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filing date of 12/27/99, Patent 7329670 issued 2/12/2008, Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas, 1 page                              |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |                          |                    |
|--|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    | Application Number       | 09/993,647         |
|  |    | Filing Date              | November 27, 2001  |
|  |    | First Named Inventor     | Bernd Riedl et al. |
|  |    | Group Art Unit           | 1624               |
|  |    | Examiner Name            | Deepak R. RAO      |
|  |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 52 | of                       | 56                 |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | † <sup>6</sup> |
|  | P367                  | A "Notice of References Cited" from the USPTO for U.S. application 09/472,232, filing date of 12/27/99, Patent 7329670 issued 2/12/2008, Inhibition of Raf Kinase Using Aryl and Heteroaryl Substituted Heterocyclic Ureas, 1 page                              |                |
|  | P368                  | A "Notice of References Cited" from the USPTO for U.S. application 09/773,604, filing date of 2/2/01, Publication No. US 2001-0034447-A1, Publication Date 10/25/01, Omega-carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page              |                |
|  | P369                  | A "Notice of References Cited" from the USPTO for U.S. application 09/773,659, filing date of 2/2/01, Publication No.: US 2001-0011135 A1, Publication Date: August 2, 2001, Omega-carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page      |                |
|  | P370                  | A "Notice of References Cited" from the USPTO for U.S. application 09/773,672, filing date of 2/2/01, Publication No.: US 2001-0016659 A1, Publication Date: August 23, 2001, Omega-carboxyaryl substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page     |                |
|  | P371                  | A "Notice of References Cited" from the USPTO for U.S. application 09/773,675, filing date of 2/2/01, Publication No.: US 2001-0011136-A1, Publication Date: August 2, 2001, Omega-Carboxyaryl Substituted Diphenyl Ureas as Raf Kinase Inhibitors, 1 page      |                |
|  | P372                  | A "Notice of References Cited" from the USPTO for U.S. application 09/776,935 filing date of 12/22/98, Inhibition Of p38 Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, 1 page  |                |
|  | P373                  | A "Notice of References Cited" from the USPTO for U.S. application 09/776,936, filing date of 12/22/98, Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas, 1 page   |                |
|  | P374                  | A "Notice of References Cited" from the USPTO for U.S. application 09/777,920, filing date of 2/7/01, Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas, 1 page   |                |
|  | P375                  | A "Notice of References Cited" from the USPTO for U.S. application 09/948,915, filing date of 9/10/01, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page  |                |
|  | P376                  | A "Notice of References Cited" from the USPTO for U.S. application 10/042,226, filing date of 01/11/2002, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, 1 page   |                |
|  | P376a                 | Co-pending application Serial No. 09/458,014, filed December 10, 1999, Dumas et al.   |                |
|  | P377                  | Abandoned application Serial No. 09/776,935 filed December 22, 1998, Dumas et al.   |                |
|  | P378                  | Co-pending application Serial No. 09/776,936 filed December 22, 1998, Miller et al.   |                |
|  | P379                  | Issued application Serial No. 09/889,227 filed July 12, 2000, Riedl et al., issued as 7351834, 4/1/2008   |                |
|  | P380                  | Co-pending application Serial No. 09/993,647 filed November 27, 2001, Riedl et al., published as 2003-0181442, 9/25/2003  |                |
|  | P381                  | Issued application Serial No. 10/060,396 filed February 1, 2002, Miller et al., patent 7517880, issued 4/14/2009, also published as 2004-0102636, 5/27/2004   |                |
|  | P382                  | Issued application Serial No. 10/071,248 filed February 11, 2002, Riedl et al., patent 7528255, issued 5/5/2009, also published as 2003-139605, 7/24/2003   |                |
|  | P383                  | Abandoned application Serial No. 10/086,417 filed March 4, 2002, Riedl et al., published as 2003-0105091, 6/5/2003  |                |
|  | P384                  | Abandoned application Serial No. 10/125,369 filed April 19, 2002, Dumas et al., published as 2003-0207914, 11/6/2003  |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |    |                          |                    |
|--|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | Application Number       | 09/993,647         |
|  |    |    | Filing Date              | November 27, 2001  |
|  |    |    | First Named Inventor     | Bernd Riedl et al. |
|  |    |    | Group Art Unit           | 1624               |
|  |    |    | Examiner Name            | Deepak R. RAO      |
|  |    |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 53 | of | 56                       |                    |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|  | P385                  | Abandoned application Serial No. 10/308,187 filed December 3, 2002, Carter et al., published as 2003-0232765, 12/18/2003  |                |
|  | P386                  | Abandoned application Serial No. 10/361,844 filed February 11, 2003, Dumas et al., published as 2004-0023961, 2/5/2004  |                |
|  | P387                  | Abandoned application Serial No. 10/361,850 filed February 11, 2003, Dumas et al., published as US 2003-0216396, 11/20/2003   |                |
|  | P388                  | Co-pending application Serial No. 10/361,859 filed February 11, 2003, Dumas et al., published as 2003-0216446, 11/20/2003   |                |
|  | P389                  | Co-Pending U.S. Patent Application No. 10/895,985 filed July 22, 2004, Boyer et al., published as US 2005-0038080, 2/17/2005  |                |
|  | P389b                 | Co-Pending U.S. Patent Application No. 11/932,548 filed October 31, 2007, Dumas et al.,   |                |
|  | P390                  | Co-Pending U.S. Patent Application No. 12/084,662 filed May 7, 2008, Sandner et al., published as 2010-0035888, 2/11/2010.  |                |
|  | P391                  | Co-Pending U.S. Patent Application No. 12/086,454 filed June 12, 2008, Weber et al.   |                |
|  | P391a                 | Co-Pending U.S. Patent Application No. 12/093,515 filed November 13, 2008, Wilhelm et al.   |                |
|  | P392                  | Co-Pending U.S. Patent Application No. 12/095,611 filed May 30, 2008, Smith et al.  |                |
|  | P393                  | Co-Pending U.S. Patent Application No. 12/158,524 filed June 20, 2008, Smith et al.   |                |
|  | P394                  | Co-Pending U.S. Patent Application No. 12/294,979 filed September 29, 2008, Wilhelm et al.  |                |
|  | P394a                 | Co-Pending U.S. Patent Application No. 12/421,690 filed April 10, 2009, Dumas et al.,   |                |
|  | P395                  | Co-Pending U.S. Patent Application No. 12/444,974 filed April 9, 2009, Grunenberget al.   |                |
|  | P396                  | Co-Pending U.S. Patent Application No. 12/514,129 filed May 8, 2009, Grunenberget al.   |                |
|  | P397                  | Co-Pending U.S. Patent Application No. 12/514,715 filed May 13, 2009, Stiehl et al.   |                |
|  | P398                  | Co-Pending U.S. Patent Application No. 12/520,618 filed June 22, 2009, Smith et al.   |                |
|  | P399                  | Co-Pending U.S. Patent Application No. 12/520,609 filed June 22, 2009, Smith et al.   |                |
|  | P400                  | Co-pending U.S. Patent Application No. 12/523,652 filed July 17, 2009, Wilhelm et al.   |                |
|  | P401                  | Co-pending U.S. Patent Application No. 12/523,697 filed July 17, 2009, Wilhelm et al.   |                |
|  | P402                  | Co-Pending U.S. Patent Application No. 12/628,735 filed December 1, 2009, Dumas et al.  |                |
|  | P402a                 | Co-Pending U.S. Patent Application No. 12/692,845 filed January 25, 2010, Dumas et al.  |                |
|  | P403                  | Co-Pending Application PCT/US09/61506, filed October 21, 2009, Carol Pena   |                |
|  | P404                  | International search report for International Application No. PCT/US98/10375 dated 9/3/98, Inhibition Of p38 Kinase Activity By Aryl Ureas, publication No. 98/52558, publication date 11/26/1998, 1 page   |                |
|  | P405                  | International search report for International Application No. PCT/US98/10376 dated 7/30/98, Raf Kinase Inhibitors, publication No. WO 98/52559, publication date 11/26/1998, 1 page   |                |
|  | P406                  | International search report for International Application No. PCT/US98/26078 dated 4/2/99, Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas, publication no. WO 99/32106, publication date 7/1/1999, 2 pages                                       |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |    |                          |                    |
|--|----|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO  |    |    | <i>Complete if Known</i> |                    |
| <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    |    | Application Number       | 09/993,647         |
|  |    |    | Filing Date              | November 27, 2001  |
|  |    |    | First Named Inventor     | Bernd Riedl et al. |
|  |    |    | Group Art Unit           | 1624               |
|  |    |    | Examiner Name            | Deepak R. RAO      |
|  |    |    | Attorney Docket Number   | BAYER-0018-A       |
| Sheet  | 54 | of | 56                       |                    |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.       | T <sup>6</sup> |
|  | P407                  | International search report for International Application No. PCT/US98/26079 dated 4/12/99, Inhibition Of p38 Kinase Activity Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. WO 99/32110, publication date 7/1/1999, 1 page                |                |
|  | P408                  | International search report for International Application No. PCT/US98/26080 dated 4/12/99, Inhibition Of p38 Kinase Using Substituted Heterocyclic Ureas, publication No. WO 99/32111, publication date 7/1/1999, 1 page   |                |
|  | P409                  | International search report for International Application No. PCT/US98/26081 dated 4/2/99, INHIBITION OF RAF KINASE USING SYMMETRICAL AND UNSYMMETRICAL SUBSTITUTED DIPHENYL UREAS, publication No. WO 99/32436, publication date 7/1/1999, 1 page                    |                |
|  | P410                  | International search report for International Application No. PCT/US98/26082 dated 5/12/99, Inhibition Of Raf Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. WO 99/32455, publication date 7/1/1999, 1 page                         |                |
|  | P411                  | International search report for International Application No. PCT/US98/27265, dated 3/2/99, Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas, publication No. WO 99/32463, publication date 7/1/99, 1 page                                 |                |
|  | P412                  | International search report for International Application No. PCT/US00/00648 dated 6/29/00, Omega-Carboxyaryl Substituted Diphenyl Ureas as RAF Kinase Inhibitors, publication No. WO 00/42012 A1, publication date 7/20/2000, 2 pages                                |                |
|  | P413                  | International search report for International Application No. PCT/US00/00768 dated 5/16/00, Omega-Carboxy Aryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, publication No. WO 00/41698 A1, publication date 7/20/2000, 1 page                                |                |
|  | P414                  | International search report for International Application No. PCT/US02/12064 dated 9/20/02, HETEROARYL UREAS CONTAINING NITROGEN HETERO-ATOMS AS p38 KINASE INHIBITORS, publication No. 02/085859, publication date 10/31/2002, 2 pages                               |                |
|  | P415                  | International search report for International Application No. PCT/US02/12066 dated 9/27/02, Inhibition Of Raf Kinase Quinolyl, Isoquinolyl Or Pyridyl Ureas, publication No. 02/085857, publication date 10/31/2002, 2 pages  |                |
|  | P416                  | Supplemental search report from the EPO for European application EP 98963809.3 dated 3/30/01, Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas, publication No. 1049664, publication date 7/1/1999, granted 3/16/2005, 4 pages |                |
|  | P417                  | Supplemental search report from the EPO for European application EP 98963810.1 dated 12/21/00, Inhibition Of Raf Kinase Using Aryl And Heteroaryl Substituted Heterocyclic Ureas, publication No. 1056725, publication date 7/1/1999, granted 6/7/2006, 4 pages       |                |
|  | P418                  | Supplemental search report from the EPO for European application EP 98965981.8 dated 12/21/00, Inhibition Of Raf Kinase Using Substituted Heterocyclic Ureas, publication No. 1047418, publication date 7/1/1999, granted 7/27/2005, 8 pages                          |                |
|  | P419                  | Supplemental search report from the EPO for European application EP 00903239.2 dated 8/7/02, Omega-Carboxyaryl Substituted Diphenyl Ureas As Raf Kinase Inhibitors, publication no. EP 1140840, published 7/20/2000, granted 3/22/2006, 6 pages                       |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|   |    |                          |                    |
|---|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br><i>(use as many sheets as necessary)</i> |    | <b>Complete if Known</b> |                    |
|   |    | Application Number       | 09/993,647         |
|   |    | Filing Date              | November 27, 2001  |
|   |    | First Named Inventor     | Bernd Riedl et al. |
|   |    | Group Art Unit           | 1624               |
|   |    | Examiner Name            | Deepak R. RAO      |
| Sheet   | 55 | of                       | 56                 |
|   |    | Attorney Docket Number   | BAYER-0018-A       |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | † <sup>6</sup> |
|  | P420                  | Supplemental search report from the EPO for European application EP 00905597.1 dated 2/7/08, Omega-Carboxyaryl Substituted Diphenyl Ureas As p38 Kinase Inhibitors, publication no. EP 1158985, 7/20/2000, 9 pages  |                |
|  | P421                  | Belgore et al., "Measurement of free and complexed soluble vascular endothelial growth factor receptor, Flt-1, in fluid samples: development and application of two new immunoassays," Clinical Science, 100: 567-575 (2001)                                    |                |
|  | P422                  | Belgore et al., "Plasma Levels of Vascular Endothelial Growth Factor (VEGF) and Its Receptor, Flt-1, in Haematological Cancers: A Comparison With Breast Cancer," American Journal of Hematology, 66:59-61 (2001)   |                |
|  | P423                  | Coskun et al., "Significance of serum vascular endothelial growth factor, insulin-like growth factor-I levels and nitric oxide activity in breast cancer patients," The Breast, 12, 104-110 (2003)  |                |
|  | P424                  | Kaya et al., "The prognostic significance of vascular endothelial growth factor levels in sera of non-small cell lung cancer patients," Respiratory Medicine, 98:632-636 (2004)   |                |
|  | P425                  | Kumar et al., "Soluble FLT-1 is Detectable in the Sera of Colorectal and Breast Cancer Patients," Anticancer Research, 22:1877-1880 (2002)  |                |
|  | P426                  | Pasieka et al., "Evaluation of the Levels of bFGF, VEGF, sICAM-1, and sVCAM-1 in Serum of Patients with Thyroid Cancer," Recent Results in Cancer Research, 162:189-194 (2003)  |                |
|  | P427                  | Pegram et al., "Combined Biological Therapy of Breast Cancer Using Monoclonal Antibodies Directed Against HER2/neu Protein and Vascular Endothelial Growth Factor," Seminars in Oncology, 29(Suppl. 11):29-37 (2002)  |                |
|  | P428                  | Poon et al., "Prognostic significance of serum vascular endothelial growth factor an endostatin in patients with hepatocellular carcinoma," British Journal of Surgery, 91:1354-1360 (2004)   |                |
|  | P429                  | Ria et al., "Serum levels of angiogenic cytokines decrease after antineoplastic radiotherapy," Cancer Letters, 216:103-107 (2004)   |                |
|  | P430                  | Secord et al., "The relationship between serum vascular endothelial growth factor, persistent disease, and survival at second-look laparotomy in ovarian cancer," Gynecologic Oncology, 94:74-79 (2004)   |                |
|  | P431                  | English abstract of JP 10-306078, 1998-11-17, Patent Abstracts of Japan, 2 pages  |                |
|  | P432                  | English abstract of JP 08-301841, 1996-11-19, Patent Abstracts of Japan, 2 pages  |                |
|  | P433                  | English abstract of JP 03-198049, 1991-08-29, Patent Abstracts of Japan, 1 page   |                |
|  | P434                  | English abstract of JP 03-144634, 1991-06-20, Patent Abstracts of Japan, 1 page   |                |
|  | P435                  | English abstract of JP 03-053247, 1991-03-07, Patent Abstracts of Japan, 1 page   |                |
|  | P436                  | English abstract of JP 02-150840, 1990-06-11, Patent Abstracts of Japan, 1 page   |                |
|  | P437                  | English abstract of JP 02-108048, 1990-04-19, Patent Abstracts of Japan, 1 page   |                |
|  | P438                  | English abstract of JP 02-105146, 1990-04-17, Patent Abstracts of Japan, 1 page   |                |
|  | P439                  | English abstract of JP 02-035450, 1990-02-06, Patent Abstracts of Japan, 1 page   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**

Please type a plus sign (+) inside this box → +

PTO/SB/08A (08-00)

Approved for use through 10/31/2002. OMB 0651-0031  
 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

|  |    |                          |                    |
|--|----|--------------------------|--------------------|
| Substitute for form 1449A/PTO<br><br><b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b><br><br>(use as many sheets as necessary) |    | <b>Complete if Known</b> |                    |
|  |    | Application Number       | 09/993,647         |
|  |    | Filing Date              | November 27, 2001  |
|  |    | First Named Inventor     | Bernd Riedl et al. |
|  |    | Group Art Unit           | 1624               |
|  |    | Examiner Name            | Deepak R. RAO      |
| Sheet  | 56 | of                       | 56                 |
|  |    | Attorney Docket Number   | BAYER-0018-A       |

| OTHER PRIOR ART -- NON PATENT LITERATURE DOCUMENTS |                       |   |                |
|--|-----------------------|---|----------------|
| Examiner Initials *                                | Cite No. <sup>1</sup> | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | T <sup>6</sup> |
|  | P440                  | English abstract of JP 01-200254, 1989-08-11, Patent Abstracts of Japan, 1 page   |                |
|  | P441                  | English abstract of JP 01-259360, 1989-10-17, Patent Abstracts of Japan, 2 pages  |                |
|  | P442                  | English abstract of JP 01-102461, 1989-04-20, Patent Abstracts of Japan, 1 page   |                |
|  | P443                  | English abstract of JP 06-120039, 1994-04-28, Patent Abstracts of Japan, 1 page   |                |
|  | P444                  | English abstract of JP 05-180862, 1993-07-23, Patent Abstracts of Japan, 1 page   |                |
|  | P445                  | English abstract of JP 05-163170, 1993-06-29, Patent Abstracts of Japan, 1 page   |                |
|  | P446                  | English abstract of JP 05-077375, 1993-03-30, Patent Abstracts of Japan, 1 page   |                |
|  | P447                  | English abstract of JP 05-076072, 1993-03-26, Patent Abstracts of Japan, 2 pages  |                |
|  | P448                  | English abstract of JP 50-149668 A and JP 56-29871 B, Derwent World Patents Index, Dialog File No. 351, Acc. No. 1488399, 3 pages, <b>1975</b>  |                |
|  | P449                  | English abstract of JP 53-086033, 1978-07-29, Patent Abstracts of Japan, 1 page   |                |
|  | P450                  | English abstract of JP 54-032468, 1979-03-09, Patent Abstracts of Japan, 1 page   |                |
|  | P451                  | English abstract of JP 55-098152, 1980-07-25, Patent Abstracts of Japan, 1 page   |                |
|  | P452                  | English abstract of JP 64-009455, 1989-01-12, Patent Abstracts of Japan, 1 page   |                |
|  | P453                  | English abstract of JP 02-023337, 1979-03-09, Patent Abstracts of Japan, 2 pages  |                |
|  | P454                  | English abstract of EPA 0379915/EP-A1, 1990-08-01, 2 pages  |                |
|  | P455                  | English abstract of DD 253997 A, 1988-02-10, 1 page   |                |
|  | P456                  | English abstract of DE511468, European Patent Office, 2 pages, <b>1930</b>  |                |
|  | P457                  | Co-Pending U.S. Patent Application No. 12/619,913, filed November 17, 2009, Ranges et al.   |                |

|                    |              |                 |            |
|--------------------|--------------|-----------------|------------|
| Examiner Signature | /Deepak Rao/ | Date Considered | 06/29/2010 |
|--------------------|--------------|-----------------|------------|

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number. <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language translation is attached.

**ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /DR/**